diff --git "a/test.csv" "b/test.csv" --- "a/test.csv" +++ "b/test.csv" @@ -1,786 +1,786 @@ ticker,disease,stage,date,catalyst,label -RLAY,Cholangiocarcinoma (CCA),Phase 1,10/12/23,"Phase 1 data from non-CCA expansion cohort presented at AACR-NCI-EORTC reported a 35% overall response rate (ORR), and nine of 26 patients experienced a partial response (PR), noted October 12, 2023.",2 -GSK,Rheumatoid Arthritis,Phase 2b,10/21/18,"Phase 2b released October 21, 2018 did not meet primary endpoint.",0 -ABBV,Episodic Migraine,Phase 3,4/21/23,"Phase 3 trial met its primary and secondary endpoints, noted April 21, 2023.",1 -CRSP,Advanced clear cell renal cell carcinoma,Phase 1,11/10/22,"Phase 1 result reported a 77% disease control rate in a heavily pretreated RCC patient population. The longest duration of stable disease achieved was observed for 7.8 months, noted November 10, 2022.",2 -RHHBY,Follicular lymphoma,Phase 3,6/10/22,"Phase 3 final analysis reported that PFS was significantly improved with Gazyva plus chemotherapy (63.4%) compared with Rituxan plus chemotherapy (55.7%), noted June 10, 2022.",2 -KMDA,COVID-19,Phase 1/2,3/31/21,"Phase 1/2 top-line data released March 31, 2020. 11/12 patients recovered.",1 -MRKR,Pancreatic cancer,Phase 1/2,7/19/19,Phase 1/2 data at AACR noted 5/9 patients with stable disease with one complete response.,1 -AGRX,Contraceptive patch,Approved,2/14/20,"FDA Approval announced February 14, 2020.",2 -REGN,Retinopathy of Prematurity (ROP),Approved,2/8/23,"FDA approval on February 8, 2023.",2 -AMRX,Attention Deficit Hyperactivity Disorder (ADHD),Approved,9/6/23,"ANDA approved September 6, 2023.",2 -INCY,Rheumatoid arthritis,Approved,6/1/18,"FDA approval announced for low dose only - June 1, 2018.",2 -ERYP,Triple-Negative Breast Cancer (TNBC),Phase 2,9/19/22,"Phase 2 data reported that no clinical benefit was demonstrated, noted September 19, 2022.",2 -ANAB,Non-squamous non-small cell lung cancer (NSCLC),Phase 2,10/5/22,"Phase 2 trial met primary endpoint, noted October 5, 2022.",1 -FGEN,Anaemia of myelodysplastic syndromes (MDS),Phase 3,10/20/23,"Phase 3 data presented at ESMO reported that treatment demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response (pCR) versus neoadjuvant chemotherapy alone, noted October 20, 2023.",2 -NCNA,Colorectal Cancer,Phase 1/2,10/13/23,"Phase 1b/2 achieved a longer progression-free survival as compared to their first-line treatment with 5-FU-based Therapy, noted October 13, 2023.",2 -ANIP,Tranxene generic,Approved,6/22/22,"Approved June 22, 2022.",2 -XFOR,Severe Congenital Neutropenia (SCN),Phase 2,8/10/23,"Phase 2 data reported that three participants receiving G-CSF and once-daily oral mavorixafor showing robust increases in ANC, maintenance of ANC levels in the normal range, and the ability to reduce G-CSF dose earlier than anticipated, noted August 10, 2023.",2 -CBAY,Primary biliary cholangitis (PBC),Phase 3,9/21/23,"Phase 3/4 study initiated, noted September 21, 2023.",1 -EBS,Anthrax Vaccine,Approved,5/17/12,"Approved May 17, 2012.",2 -DERM,"Microbial flora, papulopustular rosacea",Phase 1,6/13/23,"Phase 1 study achieved all primary objectives and no significant safety issues were noted during the study, noted June 13, 2023.",2 -ACLX,Multiple Myeloma,Phase 2,6/19/23,"Phase 2 clinical hold received by the FDA after a recent patient death, noted June 19, 2023.",1 -BGNE,Nasopharyngeal cancer (RM-NPC),Phase 3,4/19/22,"Additional Phase 3 data reported that progression-free survival was 15.5 months, noted April 19, 2022.",1 -APLT,Sorbitol Dehydrogenase Deficiency (SORD Deficiency),Phase 2,5/25/23,"Phase 2 EMA granted Orphan medicinal product designation, noted May 25, 2023.",1 -RHHBY,Autosomal Dominant Alzheimer's Disease (ADAD,Phase 3,8/2/22,"Additional Phase 3 data reported that cognitive test scores of API ADAD composite 22.9%, FCSRT 19.9% and RBANS total score 43.8%, noted August 2, 2022.",1 -REGN,Atopic dermatitis 12-17 year-olds,Approved,3/11/19,"FDA approval announced March 11, 2019.",2 -AZN,"Chronic Lymphocytic Leukemia (CLL), small lymphocytic lymphoma (SLL) and refractory mantle cell lymphoma (MCL)",Approved,8/5/22,"Approved August 5, 2022.",2 -RHHBY,Multiple sclerosis (MS),Phase 2,10/13/23,"Phase 2 showed that fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS). More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at eight week, noted October 13, 2023.",2 -MRK,Cutaneous squamous cell carcinoma (cSCC),Approved,7/6/21,"FDA approval announced July 6, 2021.",2 -FBIO,AL amyloidosis,Phase 1/2,12/11/17,Phase 1/2 data at ASH December showed 67% response rate.,2 -RHHBY,Duchenne Muscular Dystrophy,Approved,6/22/23,"FDA acelerated Approval on June 22, 2023.",2 -XFOR,Renal Cell Carcinoma (RCC),Phase 2a,9/30/19,Phase 2a data presented at ESMO 2019 - TKI therapy PFS 7.4 months; ORR 18%.,1 -CGEN,Platinum resistant ovarian cancer,Phase 1/2,6/5/23,"Phase 1/2 data presented at ASCO reported an objective response rate (ORR) of 2/9 [22%] pts; 2 pts with SD. Disease control rate [CR + PR + SD] 4/9 [44%], noted June 5, 2023.",2 -PDSB,Cervical cancer,Phase 2a,10/2/23,"Additional Phase 2a data to be reported at the American Society for Radiation Oncology (ASTRO 2023) demonstrated that patients treated with PDS0101 had greater clearance of cfDNA as compared to those treated with SOC, noted October 2, 2023.",2 +CANF,"Advanced liver cancer, hepatocellular carcinoma",Phase 2,12/20/21,"Phase 2 data reported a complete response with that patient surviving 5 years, noted December 20, 2021.",1 +PTCT,Spinal Muscular Atrophy (SMA) Type 1,Approved,8/7/20,"FDA Approval announced August 7, 2020.",2 +LGND,Chronic obstructive pulmonary disease (COPD),Phase 3,12/20/22,"ENHANCE-1 Phase 3 topline data met its primary and key secondary endpoints, noted December 20, 2022.",1 +ATXS,"Hereditary angioedema (HAE), healthy volunteers",Phase 1a,2/24/23,"Phase 1a trial data reported a half-life of 117 days, supporting dosing every three months or less, noted February 24, 2023.",1 +MRTX,Renal cell carcinoma (RCC),Phase 1/2,2/15/20,"Phase 2 updated data presented at ASCO GU 2020. 15/38 (39%) partial response rate, PFS 10.3 months - February 15, 2020.",1 +AXSM,Smoking cessation,Phase 2,4/15/19,"Phase 2 top-line data met primary endpoint - April 15, 2019.",2 +TAK,Post-transplant Hodgkin lymphoma (HL) cancer,Approved,8/17/15,"Approved August 17, 2015 under priority review.",2 +BPTS,COVID-19,Phase 2/3,5/25/23,"Phase 2/3 data reported that at 28 days the adjusted difference in the proportion of patients with hospital discharge of 11% showed a trend towards a statistically significant difference in BIO101 group versus placebo in ITT population, noted May 25, 2023.",2 +AZN,"Severe, uncontrolled asthma",Phase 3,5/10/17,"Phase 3 trial did not meet primary endpoint - May 10, 2017.",0 +STOK,Dravet syndrome,Phase 1/2,7/25/23,"Phase 1/2a OLE OLE data of STK-001 (30mg, 45mg) showed a Sustained reductions in convulsive seizure frequency and improvements in cognition and behavior, noted July 25, 2023.",2 +INCY,Triple-negative breast cancer,Phase 2,12/10/21,"Phase 2 data reported that treatment is tolerated, noted December 10, 2021.",2 +AZN,Chronic obstructive pulmonary disease (COPD),CRL,10/1/19,"CRL announced October 1, 2019.",1 +VBLT,Recurrent platinum resistant ovarian cancer,Phase 3,7/19/22,"Phase 3 trial did not meet the primary endpoint, noted July 19, 2022.",2 +SWTX,Neurofibromas,Phase 2b,2/25/21,Phase 2b interim data noted 10/20 Patients (50%) achieved an Objective Response,1 +GRTS,Non-small cell lung cancer (NSCLC),Phase 2,9/12/22,"Phase 2 data presented at ESMO demonstrated early evidence of efficacy with a 39% molecular response rate in evaluable patients, noted September 12, 2022.",2 +ABBV,Follicular lymphoma (FL),Phase 1/2,6/28/23,"Phase 1/2 FL cohort data reported an overall response rate (ORR) of 82% and that the median duration of response (DOR) was not reached, noted June 28, 2023.",2 +MRK,Non-muscle invasive bladder cancer (NMIBC),Phase 1,7/28/23,"Phase 1 dosing initiated, noted July 28, 2023.",1 +AMRX,Avastin biosimilar,Approved,4/13/22,"Approved April 13, 2022.",2 +GSK,Multiple Myeloma,Phase 3,11/7/22,"Phase 3 trial did not meet its primary endpoint, noted November 7, 2022.",2 +REGN,Ebola,Approved,10/14/20,"FDA Approval announced October 14, 2020.",2 +AZN,Thyroid cancer,Phase 3,7/26/18,"Phase 3 trial did not meet primary endpoint - noted July 26, 2018.",0 +MRK,Ebola,Approved,8/3/23,"Approval in children aged 12 months and older on August 3, 2023.",2 +ABBV,Uterine Fibroids,Approved,5/29/20,"FDA approval announced May 29, 2020.",2 +CLNN,Multiple Sclerosis,Phase 2,4/25/23,"Phase 2 topline data presentated at AAN reported that the primary BC-LCLA outcome LS-mean difference was 3.13 and 2 of 3 key secondary outcomes were significant, noted April 25, 2023.",2 +ACIU,Alzheimer’s disease,Phase 2,9/23/20,"Phase 2 top-line data did not meet endpoints - September 23, 2020.",0 +MRK,Cytomegalovirus (CMV) Infection,Approved,11/9/17,"Approval announced November 9, 2017.",2 +QNRX,Netherton Syndrome (NS),Phase 1,10/24/23,"Phase 1 data from 6 subjects demonstrated well defined efficacy signals across a number of study endpoints, noted October 24, 2023.",2 +TYRA,Achondroplasia,Phase 2,8/1/23,"FDA Orphan drug designation (ODD) granted on August 1, 2023.",1 +MRK,Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL),Approved,6/13/18,"Approval announced June 13, 2018.",2 +AMGN,Heart failure with reduced ejection fraction (HFrEF),Phase 3,4/3/22,"Phase 3 results reported that there was no change in pVO2 in patients treated with omecamtiv mecarbil versus placebo, noted April 3, 2022.",2 +SONN,Solid tumors,Phase 1,4/18/23,"Phase 1 data presented at AACR reported no dose limiting toxicities, and 5 of the first 14 patients (36%) have evidence of clinical benefit, noted April 18, 2023.",2 +CYCN,Sickle Cell disease,Phase 2,10/14/20,"Phase 2 data released October 14, 2020 - insufficient efficacy shown to support further development.",0 +ASLN,Gastric cancer,Phase 2,1/13/19,"Phase 2 trial did not meet primary endpoint - January 13, 2019.",0 +BPTS,Sarcopenia,Phase 2b,10/4/21,"Phase 2b data displayed that the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-Meter Walk Test (400MWT), the primary endpoint of the study, including in sub-populations at higher risk of mobility disability, after 6 months of treatment. Safety profile at the doses of 175 mg bid and of 350 mg bid showed no Serious Adverse Events (SAE) related to treatment, noted October 4, 2021.",2 +LGND,Osteoporosis,Approved,10/7/19,"FDA approval announced October 7, 2019.",2 +KPRX,Rheumatoid Arthritis,Phase 1b,4/25/22,"Phase 1b results demonstrated safety and tolerability of treatment as well as statistically significant improvements in conjunctival hyperemia in the 0.15% arm compared to vehicle control, noted April 25, 2022.",2 +NVS,ABSSSI,Approved,8/6/14,"Approved August 6, 2014 under priority review",2 +SNSE,Various cancers,Phase 1,11/4/23,"Phase 1 safety data reported that a total of 11 adverse events (including one serious adverse event not considered related to SNS-101) was reported in five patients, with no dose-limiting toxicities observed, noted November 4, 2023.",2 +AMGN,Osteoporosis,Approved,4/9/19,"FDA Approval announced April 9, 2019.",2 +MOLN,Solid Tumors,Phase 1,11/3/23,"Phase 1 data presented at SITC continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment, noted November 3, 202",2 +RHHBY,Ulcerative colitis,Phase 3,8/10/20,"HIBISCUS I induction study, in people without prior anti-tumor necrosis factor (anti-TNF) treatment, etrolizumab met the primary endpoint. HIBISCUS II induction study, including people without prior anti-TNF treatment, did not meet its primary endpoint.",1 +JAZZ,Dravet Syndrome and Lennox-Gastaut syndrome,Phase 3,3/14/16,"Top line Phase 3 data released March 14, 2016 met primary endpoint.",2 +FIXX,Phenylketonuria (PKU),Phase 1/2,11/6/20,"Data released November 6, 2020 noted 2/6 showed meaningful reductions in Phe.",2 +BNTX,Resected pancreatic ductal adenocarcinoma (PDAC),Phase 1,6/5/22,"Phase 1 initial preliminary data readout from 16 vaccinated patients revealed that combination was well-tolerated. Only 1 of 16 patients (6%) developed a vaccine-related Grade 3 fever and hypertension, no other Grade 3 or higher adverse events were observed. In addition, the treatment induced de-novo, neoantigen-specific T cell response in half (8/16) of these patients from undetectable levels to large fractions of all blood T cells (median 2.9%). At an early median follow-up of 18 months, patients with de-novo immune response (n=8) had a significantly longer recurrence-free survival (RFS) as compared to those without vaccine-induced immune responses (n=8) (median not reached vs. 13.4 months, HR 0.08, 95% CI 0.01-0.4, P = 0.003)., noted June 5, 2022.",2 +PHAT,Erosive esophagitis / Gastroesophageal reflux disease (GERD),Approved,11/1/23,"FDA Approved on November 1, 2023.",2 +GMAB,Multiple myeloma,Approved,5/1/20,"FDA Approval announced May 1, 2020.",2 +DCPH,Tenosynovial Giant Cell tumor,Phase 3,10/30/23,"Phase 3 study met primary endpoint with objective response rate (ORR) at week 25 of 40% compared to 0% for placebo. The study also met all key secondary endpoints at Week 25 compared to placebo, noted October 30, 2023.",1 +ALDX,Allergic conjunctivitis,Phase 3,6/15/23,"Phase 3 top-line data met primary and all secondary endpoints, noted on June 15, 2023.",1 +OBSV,Uterine fibroids,Phase 3,10/20/21,"Phase 3 data reported once daily treatment without ABT reduced uterine volume by 39% after 24 weeks. However, co-administration of hormonal ABT after 24 weeks counteracted the uterine volume reducing effects at 52 weeks, noted October 20, 2021.",1 +ASRT,Colorectal cancer,Approved,4/29/11,"Approved April 29, 2011.",2 +TMBR,Congenital Ichthyosis,Phase 3,6/20/23,"Phase 3 interim pharmacokinetic data indicated minimal systemic absorption of isotretinoin or its major metabolites in patients with moderate to severe forms of congenital ichthyosis (CI) who were treated with TMB-001 0.05% ointment, noted June 20, 2023.",2 +BIIB,Biosimilar (ranibizumab),Approved,9/20/21,"Approved September 20, 2021.",2 +ARWR,Cystic Fibrosis,Phase 1/2,7/2/21,"Phase 1/2 trial paused following a trial in rats that contained unexpected signals of local lung inflammation - July 2, 2021.",0 NVO,haemophilia B,Approved,5/31/17,"Approval announced May 31, 2017.",2 -IKNA,"Solid tumors and urothelial carcinoma, bladder cancer",Phase 1,11/10/22,"Phase 1 data presented at SITC showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma. Monotherapy activity observed; confirmed partial response with DoR of 14.9 months and ongoing, noted November 10, 2022.",2 -AZN,Amyloidosis,Phase 2,12/12/22,"Phase 2 1-year study results reported that treatment has been generally well tolerated without evidence of organ toxicity. Organ response persisted even after cessation of anti-PCD treatment, noted December 12, 2022.",2 -LXRX,Heart failure,Approved,5/26/23,"Approved May 26, 2023.",2 -MMM,Venous leg ulcers (VLU’s),Phase 2,5/12/22,"Phase 2 results reported that both primary and key secondary endpoints were met, noted May 12, 2022.",1 -CYBN,Major Depressive Disorder (MDD) and Alcohol use disorder (AUD),Phase 1/2,10/31/23,"Phase 1/2a topline data reported that the reduction in major depressive disorder (""MDD"") symptoms, defined as change from baseline in MADRS total score, was superior in participants assigned to CYB003 compared to the participants who received placebo by 14.08 points, noted October 31, 2023.",2 -JNJ,Second-line Chronic graft-versus-host disease (GVHD),Approved,8/2/17,"Approval announced August 2, 2017.",2 -IVA,Non-alcoholic steatohepatitis (NASH),Phase 2b,6/24/23,"Phase 2b additional data presented on EASL showed that lanifibranor significantly increases the levels of adiponectin and that this increase is correlated with the improvements of cardiometabolic markers, including insulin resistance, glycemic control, lipid metabolism, and systemic inflammation, noted June 24, 2023.",2 -CBIO,Hemophilia,Phase 3,11/12/21,"Program to be discontinued, Phase 3 data reported that the trial successfully treated bleeds with subcutaneous (SQ) MarzAA and has not observed any treatment-related adverse or thrombotic events, noted November 12, 2021.",2 -CLNN,Amyotrophic Lateral Sclerosis (ALS),Phase 2/3,9/25/23,"Phase 2/3 post hoc results showed significantly improved survival with a 49% decreased risk of death for the covariate risk-adjusted analyses compared to the largest U.S. clinical database of previous amyotrophic lateral sclerosis (ALS) trials (PRO-ACT), noted September 25, 2023.",2 -IMVIQ,Ovarian Cancer,Phase 1/2,6/6/22,"Results from Phase 1 and Phase 2 expansion cohort presented at ASCO reported that G3/G2 immune-related AE and injection site reactions were observed in 1/1 and 1/3 pts treated at DL1, and in 1/0 and 2/2 pts at DL2, respectively. At Phase 1, one patient with MSI-High clear cell subtype had an ongoing CR after 26 months of follow-up, 2 patients had PR and 6 SD. There were 1 PR and 3 SD on P2EC, of which 1 and 2, respectively, achieved response greater than 12 weeks, noted June 6, 2022.",2 -PRVB,Coxsackievirus B (CVB) vaccine,Phase 1,10/26/21,"Phase 1 interim data met the primary endpoint and secondary efficacy endpoint as it induced high titers of viral-neutralizing antibodies against all CVB serotypes, noted October 26, 2021.",2 -ATNXQ,Neoadjuvant breast cancer,Phase 2,12/20/22,"Phase 2 data reported that oral treatment was associated with less neuropathy and was not associated with an increase in febrile neutropenia, noted December 20, 2022.",2 -MRK,Newly Diagnosed Classical Hodgkin Lymphoma (cHL),Phase 2,12/12/22,"Phase 2 data reported that after a median follow-up of 15.5 months, 22 patients had objective response (ORR, 73% [95% CI, 54-88]; complete response, 9 [30%]; partial response, 13 [43%]), noted December 12, 2022.",1 -NVS,Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI),CRL,4/30/14,CRL April 30 2014.,1 -ENDP,"Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate",Approved,10/26/15,"Approved October 26, 2015.",2 -LGND,Acute lymphoblastic leukemia (ALL),Approved,6/30/21,"FDA approval announced June 30, 2021.",2 -CLVS,Urothelial carcinoma,Phase 2,4/12/19,"Phase 2 trial to be discontinued due to lack of efficacy - April 12, 2019.",0 -IMMP,Ulcerative Colitis,Phase 2,1/21/21,"Phase 2 trial discontinued following interim analysis - January 21, 2021.",0 -SABS,Type A and Type B influenza,Phase 2a,5/4/23,"Phase 2a first fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy in Phase 1 and 2a trials, noted May 4, 2023",2 -TVTX,Cystinuria,Approved,6/28/19,"FDA Approval announced June 28, 2019.",2 -EWTX,Duchenne Muscular Dystrophy (DMD),Approved,10/26/23,"Approved October 26, 2023.",2 -ALNA,Hyperuricemia in chronic kidney disease (CKD),Phase 2a,1/4/22,"Phase 2a initial data reported statistically significant reduction in serum uric acid (sUA) from baseline compared to placebo, noted January 4, 2022.",2 -SPRB,Classic Congenital Adrenal Hyperplasia,Phase 2,6/17/23,"Phase 2 data presented at ENDO highlighted that gonadal axis disruption is common in men with 21OHD and suggests that modulation of adrenal androgen production via CRFR1 antagonism may improve testicular function, noted June 17, 2023.",2 -PFE,BRAF-Mutant Colorectal Cancer,Approved,4/8/20,"FDA Approval announced April 8, 2020.",2 -TSVT,Acute myeloid leukemia (AML),Phase 1,6/14/23,"Phase 1 paused after recent Grade 5 (fatal) serious adverse event (SAE) and was followed by the required notification to the FDA, noted June 14, 2023.",0 -ABBV,Chronic Lymphocytic Leukemia,Phase 3,12/10/22,"Phase 3 reported that treatment reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy, noted December 10, 2022.",2 -BTAI,Agitation associated with Alzheimer’s Disease,Phase 3,6/29/23,"Phase 3 topline data reported that only 60mcg dose met primary endpoint, with a 7.5 point reduction versus 5.4 point reduction in the placebo group, noted June 29, 2023.",2 -GTHX,Neoadjuvant breast cancer,Phase 2,12/20/22,"Phase 2 data reported that oral treatment was associated with less neuropathy and was not associated with an increase in febrile neutropenia, noted December 20, 2022.",2 -INCY,Alopecia Areata,Approved,6/14/22,"Approved June 14, 2022.",2 -VTGN,Social Anxiety Disorder (SAD),Phase 3,8/7/23,"Phase 3 topline data met its primary endpoint, noted August 7, 2023.",1 -ADGI,COVID-19 (prevention),Phase 2/3,3/23/23,"Phase 2/3 study suggests clinically meaningful protection can be achieved at low neutralizing antibody titers, noted March 23, 2023.",2 -ARQT,Plaque psoriasis,Phase 3,3/25/22,"Phase 3 pooled data reported that 40% of patients treated with roflumilast cream achieved IGA success and and 48% of patients treated with roflumilast cream achieved IGA status of clear, noted March 25, 2022.",2 -HALO,Multiple myeloma,Approved,5/1/20,"FDA Approval announced May 1, 2020.",2 -ABBV,Crohn’s Disease,Approved,6/17/22,"Approved June 17, 2022.",2 -AIM,Early-stage triple negative breast cancer,Phase 1,9/11/23,"Phase 1 complete topline results confirmed treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC), noted September 11, 2023.",2 -AIMD,Sjögren's syndrome,Phase 3,11/3/22,"Phase 3 results showed increased unstimulated whole saliva and improvements in mouth dryness and seven other SS symptoms, noted November 3, 2022.",2 -FENC,"Ototoxicity in non-metastatic, solid tumors",Approved,9/20/22,"Approved September 20, 2022.",2 +AXSM,Migraine,CRL,5/2/22,"CRL announced May 2, 2022.",1 +VRTX,Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.,CRL,2/5/16,"CRL issued February 5, 2016.",1 +INCY,Non-Small-Cell Lung Cancer (NSCLC),Phase 2,5/19/21,Phase 2 data in ASCO abstract noted ORR of 65.6% for the treatment-naive expansion Cohort 7.,2 +LGND,Pneumococcal disease,Approved,7/16/21,"FDA approval announced July 16, 2021.",2 +COYA,Alzheimer’s Disease (AD),Phase 2,10/9/23,"Phase 2 enrollment completed, noted October 9, 2023.",1 +TBPH,Asthma,Phase 2,11/5/20,"Phase 2a trial did not meet primary endpoint - November 5, 2020.",0 +MNOV,Progressive multiple sclerosis (progressive MS),Phase 2b,10/28/17,"Phase 2b top-line data released October 28, 2017 at Joint ECTRIMS – ACTRIMS meeting. Primary endpoint met.",2 +IBRX,Merkel cell carcinoma (MCC),Phase 2,11/7/19,"Phase 2 data noted 2/7 responses (1 PR / 1 CR) - November 7, 2019.",1 +NVS,PIK3CA-Related Overgrowth Spectrum (PROS),Approved,4/6/22,"Approval announced April 6, 2022.",2 +GILD,Sjogren’s syndrome,Phase 2,10/24/19,Phase 2 trial did not meet primary endpoint.,0 +MEIP,Solid tumors,Phase 1,6/4/18,Phase 1 data presented at ASCO June 2018. Noted primary endpoint P=0.06.,1 +ADMP,Anaphylaxis,Approved,9/27/18,"FDA Approval announced September 27, 2018.",2 +ASRT,Adrenocortical insufficiency screening,CRL,10/21/19,"CRL announced October 21, 2019.",1 +GLMD,HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD),Phase 2,2/14/18,"Phase 2 top-line data released February 14, 2018 did not meet primary endpoint.",0 +PCRX,Lower extremity nerve blocks,Phase 3,5/26/21,"Phase 3 data released May 26, 2021. Did not demonstrate statistical significance for primary endpoint.",0 +SGEN,Cervical Cancer,Approved,9/20/21,"Approved September 20, 2021.",2 +JNJ,Metastatic castration-sensitive prostate cancer (mCSPC).,Approved,9/18/19,"FDA Approval announced September 18, 2019.",2 +SNY,Dengue,Approved,5/1/19,"FDA approval announced May 1, 2019.",2 JNJ,High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC),Phase 2b,10/24/23,"Phase 2b data presented at ESMO reported that centrally confirmed CR was achieved in 23/30 pts, noted October 24, 2023.",2 -RLMD,Major Depressive Disorder (MDD),Phase 3,9/20/23,"Phase 3 results showed that patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment, noted Septemeber 20, 2023.",2 -NKTR,1L Non-small cell lung cancer (NSCLC),Phase 2,12/13/21,"Phase 2 data reported an overall response rate (ORR) of 17%, including 2 complete responses (CR) in the highest PD-L1 status cohort, noted December 13, 2021.",1 -BIIB,Friedreich’s ataxia (FA),Approved,6/28/23,"PAS approved June 28, 2023.",2 -KNSA,COVID-19,Phase 2,12/22/20,"Phase 2 trial did not meet primary endpoint - December 22, 2020.",0 -XOMA,Hyperprolactinemia,Phase 2,4/24/17,"Phase 2 proof-of-concept results released April 24, 2017.",1 -FNCH,C. difficile Infection,Phase 2,10/24/22,"Phase 2 biomarker data presented at ACG 2022 showed that administration of treatment after standard-of-care (SOC) CDI antibiotics, there was a significant increase in microbiome diversity from baseline through week 8 and week 24, noted October 24, 2022.",2 -NRBO,Homozygous Familial Hypercholesterolemia (HoFH),Phase 2b,6/28/17,"Phase 2b data released June 28, 2017 - primary endpoint met.",2 -DVAX,COVID-19 vaccine,Phase 2/3,9/22/21,"Phase 2/3 interim analysis showed primary and secondary endpoints met. 100% efficacy against severe COVID-19 & hospitalization and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2 in SPECTRA, and 79% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant, noted September 22, 2021.",2 -MRK,Bladder cancer,Approved,8/31/21,"FDA approval announced August 31, 2021.",2 -UTHR,Pulmonary arterial hypertension (PAH),Phase 3,4/8/19,"Phase 3 data released April 8, 2019 did not meet primary endpoint.",0 -LGVN,Aging Frailty,Phase 2b,9/29/21,"Phase 2b biomarker data showed Lomecel-B had statistically significant reduction in serum levels of soluble TIE-2 in a dose-dependent fashion at Day 270 compared to placebo. The levels fell by -243.13 ± 1073.21 pg/mL compared to an increase of 356.03 ± 1018.95 pg/mL in the placebo group, noted September 29, 2021.",2 -JNJ,Multiple myeloma,Approved,8/10/23,"Approved August 10, 2023.",2 -OCUL,Dry eye disease (DED),Phase 2,10/22/21,"Phase 2 data did not show separation between the OTX-CSI treated subjects and the vehicle treated subjects for the primary endpoint of increased tear production, noted October 22, 2021.",0 -HALO,Pancreatic cancer,Phase 3,11/4/19,"Phase 3 data November 4, 2019 did not meet primary endpoint.",0 -BLUE,Sickle cell disease,PDUFA,6/21/23,"PDUFA Date assigned for December 20, 2023.",1 -FHTX,Synovial sarcoma,Phase 1,11/2/23,"Phase 1 preliminary results shared at the Connective Tissue Oncology Society Annual Meeting reported that FHD-609 treatment led to dose-dependent BRD9 degradation in tumor tissue, noted November 2, 2023.",2 -IDYA,Metastatic uveal melanoma (MUM),Phase 2,4/23/23,"Phase 2 darovasertib and crizotinib combination data reported a cORR of 45%, DCR of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patients, noted April 23, 2023.",2 -NVS,CV risk reduction,CRL,10/18/18,"CRL announced October 18, 2018.",1 -TPTX,Non-small-cell lung cancer (NSCLC) and solid tumors,Phase 1/2,4/12/22,"Phase 1/2 top-line data reported that in the ROS1-positive TKI-naïve advanced NSCLC population the cORR was 79%, with 4 patients receiving a complete response, and 52 having a partial response. With DOR ranging from 1.4+ to 35.1+ months and PFS ranging from 0+ to 40.4+ months, noted April 12, 2022.",1 -SLRX,Hematological cancers and solid tumors,Phase 1,6/12/23,"Phase 1 clinical trial data revealed that in Jeko-1 (lymphoma) cells, SP-3164 induces twice the degradation of target proteins I/A at 1/10th the dose of lenalidomide, providing further support for the development of SP-3164 in relapsed refractory non-Hodgkin lymphoma, noted June 12, 2023.",1 -INMB,Immune mediated complications from COVID-19,Phase 2,11/3/21,"Phase 2 trial discontinued, noted November 3, 2021.",0 -RYTM,Hypothalamic obesity,Phase 2,6/19/23,"Phase 2 data demonstrated a mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean BMI reduction at 16 weeks, noted June 19 2023.",2 -GSK,Anaemia in chronic kidney disease for patients on dialysis,Approved,2/1/23,"Approved February 1, 2023.",2 -IOVA,Non-small cell lung cancer (NSCLC),Phase 2,11/12/21,"Phase 2 data results showed a 21.4% overall response rate (ORR) in heavily pre-treated patients (n=28), including one complete response and five partial responses, noted November 12, 2021.",1 -GBT,Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest,Phase 2a,10/23/17,"Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.",0 -BIIB,Postpartum depression (PPD),Phase 3,10/17/22,"Additional Phase 3 data reported that a total of two participants (all in the zuranolone group) experienced four serious adverse events all of which were assessed by the investigator as unrelated to the therapy, noted October 17, 2022.",1 -RHHBY,Immunoglobulin A nephropathy (IgAN),Phase 2,11/7/22,IONIS-FB-LRx achieved a 44% mean reduction in proteinuria in patients treated for 6 months,2 -VRTX,alpha-1 antitrypsin (AAT) deficiency,Phase 2,10/14/20,Phase 2 trial and development to be discontinued due to safety.,0 -ANTX,Treatment-Refractory MAC Lung Disease,Phase 2/3,9/13/23,"Phase 2/3 enrollment completed, noted September 13, 2023.",1 -DNLI,Frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN),Phase 1/2,11/1/22,"Phase 1/2 part A interim results showed that single doses of treatment result in substantial increases in CSF progranulin levels suggesting brain delivery of DNL593 was achieved and has the potential to address progranulin deficiency, noted November 1, 2022.",2 -MTEM,Multiple Myeloma,Phase 1,4/7/23,"Partial clinical hold placed April 7, 2023.",1 -BHC,Allergic conjunctivitis,Approved,9/25/20,"FDA approval announced September 25, 2020.",2 -ARCT,COVID-19 variant vaccine,Phase 1/2,1/24/22,"Additional Phase 1/2 data reported neutralization against several variants of concern after day 15 and 29, noted January 24, 2022.",1 -LLY,Migraine prevention,Approved,9/28/18,"FDA approval announced September 27, 2018.",2 -KDNY,Chronic kidney disease,Phase 2,11/3/22,"Interim data reported that of the 20 patients enrolled, ten patients remained on study, nine patients completed 52 weeks of treatment and one patient discontinued after 13 weeks of treatment due to a headache. Treatment demonstrated mean reductions in 24-hour urine protein creatinine ratio (UPCR) of 38.1% at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment, noted November 3, 2022.",2 -FULC,Sickle Cell Disease,Phase 1,2/24/23,"IND placed on hold February 24, 2023.",1 -AMRX,Advanced prostatic cancer,Approved,11/2/22,"FDA Abbreviated New Drug Application (ANDA) approval on November 2, 2022.",2 -NRXP,COVID-19,Phase 2/3,10/14/21,"Data from ineligible subjects for the Phase 2b/3 trial recorded a 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment, noted October 14, 2021.",2 -CAPR,COVID-19,Phase 2,3/28/22,"Phase 2 met safety primary endpoint, with an overall mortality of 20% and 5 deaths in the treatment group, noted March 28, 2022.",2 -AMGN,Thyroid Eye Disease (TED),Approved,1/21/20,"FDA Approval announced January 21, 2020.",2 +DNLI,Amyotrophic lateral sclerosis (ALS),Phase 1b,4/25/23,"Phase 1b data due presented at AAN reported low variability, predictable dose-related increases in exposure, and a half-life supporting once-daily dosing, noted April 25, 2023.",2 +BGNE,Waldenström’s macroglobulinemia,Approved,9/1/21,"FDA Approval announced September 1, 2021.",2 +LNTH,Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA),Phase 3,9/12/18,Phase 3 trial met one of two co-primary endpoints.,2 +GSK,Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype,CRL,9/7/18,"CRL issued September 7, 2018.",1 +AEZS,Endometrial cancer,Phase 3,5/1/17,"Phase 3 trial did not meet primary endpoint - May 1, 2017.",0 +MRK,Hospital-acquired bacterial pneumonia (HABP),Approved,6/3/19,"FDA approval announced June 3, 2019.",2 +JNJ,Pulmonary arterial hypertension (PAH),Phase 3,4/18/23,"Phase 3 data reported that trial met its co-primary endpoint, with PVR change with M/T STCT was significantly greater versus macitentan, noted April 18, 2023.",1 +LGND,Refractory status epilepticus (RSE),Phase 2,9/26/19,"Phase 2 data met primary endpoint - September 26, 2019.",2 +BCRX,Acute uncomplicated influenza to pediatric patients,Approved,9/21/17,"Approved September 21, 2017.",2 +TBPH,COPD,Approved,11/9/18,"FDA Approval announced November 9, 2018.",2 +STTK,Ovarian Cancer,Phase 1a,6/5/23,"Phase 1a monotherapy data shared at ASCO reported that the best response was stable disease in 6/27 response evaluable (22%) pts, noted June 5, 2023.",2 +BMY,Stage IIA to IIIB non-small cell lung cancer (NSCLC),Phase 3,10/21/23,"Phase 3 data presented at ESMO reported that NIVO + chemo/NIVO improved pCR rates (25.3% vs 4.7%; odds ratio, 6.64 [95% CI, 3.40–12.97]) and MPR rates (35.4% vs 12.1%; odds ratio: 4.01 [2.48–6.49]) vs chemo/PBO, noted October 21, 2023.",2 +ABCL,COVID-19 Antibody,Approved,11/9/20,"Emergency Use Authorization (EUA) announced November 9, 2020.",2 +PFE,Metastatic Merkel cell carcinoma,Approved,3/23/17,"Priority review announced November 29, 2016. Approval announced March 23, 2017.",2 +HALO,Subcutaneous treatment for patients with primary immunodeficiency (PI),Approved,9/12/14,"Approved September 12, 2014.",2 CLLS,Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL),Phase 2,6/8/23,"Phase 2 data presented at EHA reported that treatment was well tolerated and clinical responses were achieved, noted June 8, 2023.",2 -BIIB,Mild cognitive impairment (MCI) due to Alzheimer's disease (AD),Approved,7/6/23,"Traditional approval received July 6, 2023.",2 -AZN,"Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer",Approved,8/28/17,"Expanded approval announced August 28, 2017.",2 -FMTX,Acute myeloid leukemia,Approved,12/1/22,"Approved December 1, 2022.",2 -HOTH,"Aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and systemic mastocytosis with associated hematological neoplasm (SM-AHN).",Phase 1a,9/13/23,"Preclinical Results of Novel HT-KIT Therapeutic Performed at NC State University demonstrated that gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Positive Results in AML, noted September 13, 2023.",2 -ATAI,Healthy volunteers,Phase 1,8/8/23,"Phase 1 was generally well-tolerated with no SAE reported. At the 60mg IV dose, rates of sedation and dissociation were consistent with prior studies of PCN-101 at this dose-level, noted August 8, 2023.",2 -VTYX,Ulcerative Colitis (UC),Phase 2,10/9/23,"Phase 2 top-line data results showed that at 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission, noted on October 9, 2023.",2 -ALKS,Multiple sclerosis (MS),Approved,10/30/19,"FDA Approval announced October 30, 2019.",2 -NVO,Type 2 Diabetes,Approved,3/28/22,"Approved March 28, 2022.",2 -GRTS,1L Microsatellite-Stable Colorectal Cancer (MSS-CRC),Phase 1/2,1/13/22,"Phase 1/2 data demonstrated that patients who experienced a molecular response, continue to have an OS advantage compared to those patients who did not have a molecular response. All patients alive at the time of the ESMO 2021 data presentation remain alive after an additional 22 weeks of follow-up, noted January 13, 2021.",2 -RAPT,Advanced Cancer,Phase 1/2,11/3/23,"Phase 1/2 update SITC showed a confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI). Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off, noted November 3, 2023",2 -ABBV,Forehead lines,Approved,10/3/17,"Approval (third indication) announced October 3, 2017.",2 -VBIV,Recurrent glioblastoma multiforme (rGBM),Phase 2b,9/7/23,"Phase 2b treatment in the primary GBM expected to commenced, noted September 7, 2023.",2 -REGN,Asthma,Approved,10/19/18,"FDA approval announced October 19, 2018.",2 -GSK,HIV,Approved,4/8/19,"FDA approval announced April 8, 2019.",2 -INCY,Myelofibrosis,Approved,11/16/11,"Approved November 16, 2011.",2 -ACIU,Neurodegenerative diseases (NDD),Phase 1,7/18/23,"Updated biomarker data reported that ACI-15916shows significantly improved specific binding to pathological a-syn aggregates in brain sections from different a-synucleinopathy cases, noted July 18, 2023.",2 -ZLAB,Metastatic breast cancer,Approved,9/7/21,"Final overall survival data did not demonstrate MARGENZA plus chemotherapy had a statistically significant advantage compared to trastuzumab plus chemotherapy; September 7, 2021.",0 -REGN,Chronic spontaneous urticaria (CSU),CRL,10/20/23,"CRL issued by the FDA, noted October 20, 2023.",1 -RIGL,Immune Thrombocytopenic Purpura (ITP),Approved,4/17/18,"Approved April 17, 2018.",2 -RDHL,Crohn’s disease,Phase 3,7/30/18,"Phase 3 data released July 30, 2018. Primary endpoint met but further trial required.",1 -TVTX,IgA nephropathy,Approved,2/17/23,"FDA accelerated approval on February 17, 2023.",2 -ACST,Subarachnoid hemorrhage (SAH),Phase 3,5/8/23,"PK study met all endpoints, noted May 18, 2022. Phase 3 trial to be initiated in 2H 2023. If the Phase 3 study meets the primary endpoint, an NDA filing for GTX-104 under Section 505(b)(2) is expected to follow, noted April 4, 2023. The company successfully submited GTX-104 Pivotal Phase 3 protocol IND amendment to the FDA with expectation for first patient dosed in calendar 4Q 2023, noted May 8, 2023.",2 -JAZZ,Idiopathic Hypersomnia,Approved,8/12/21,"FDA approval announced August 12, 2021.",2 -REGN,Wet AMD,CRL,8/13/18,"CRL issued August 13, 2018 - ongoing labeling discussions.",1 -AZN,Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS),Phase 3,6/24/20,"Phase 3 trial met primary endpoint - June 24, 2020",2 -MRSN,Ovarian Cancer,Phase 3,6/15/23,"A clinical hold placed due to bleeding events, noted June 15, 2023.",1 -AUTL,Relapsed or refractory diffuse large B-celllymphoma (DLBCL),Phase 2,12/7/20,"Phase 2 updated data at ASH December 7, 2020 noted objective response rate (ORR) of 65% and a CR rate of 51%.",2 -ACAD,Rett Syndrome,Approved,3/10/23,"Approved March 10, 2023.",2 -NVO,Hemophilia A,Approved,2/19/19,"FDA Approval announced February 19, 2019.",2 -CKPT,Non-small cell lung cancer (NSCLC),Phase 1/2,9/25/18,"Phase 1/2 preliminary data released September 24, 2018.",1 -CYBN,Major Depressive Disorder (MDD),Phase 1b,9/27/23,"Phase 1b data reported that 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depression, noted September 27, 2023.",1 -URGN,Overactive Bladder (OAB),Phase 2,8/27/20,"Phase 2 trial did not meet primary endpoint - August 27, 2020.",0 -CCXI,Focal Segmental Glomerulosclerosis,Phase 2,5/18/20,"Phase 2 trial did not meet primary endpoint - May 18, 2020.",0 -GLTO,Non-small cell lung cancer (NSCLC),Phase 2a,10/23/23,"Phase 2a data reported that the objective tumor responses (defined as partial responses per RECIST criteria 1.1) were observed in three of five patients (60%) who received GB1211 for at least three weeks, noted October 23, 2023",2 -CLVS,Mutant EGFR T790M-positive lung cancer,CRL,6/28/16,"CRL June 28, 2016. Phase 3 TIGER-3 also terminated.",0 -ADPT,Multiple Myeloma,Approved,8/14/23,"FDA Approved on August 14, 2023.",2 +PRTC,Solid tumors,Phase 1/2,12/12/22,"Phase 1/2 data reported no dose limiting toxicities, noted December 12, 2022.",1 +AMGN,Coronary Artery Disease (CAD),Phase 3,3/4/23,"Phase 3 data presented at the ACC.23/WCC reported that treatment significantly reduced both first and recurrent CV events, with more than double the number of total events prevented as compared with 1st events only, noted March 4, 2023.",2 +ORIC,Metastatic prostate cancer,Phase 1b,10/7/21,"Phase 1b initial results showed that the dose was well tolerated, with no substantial added toxicity. PK showed no evidence of drug-drug interaction. Within the key patient population (8), 75% of patients' tumors expressed moderate to high GR and 25% of patients' tumors expressed low GR, noted October 7, 2021.",2 +RHHBY,COVID-19 (Anti-viral antibody),Phase 2/3,9/30/21,"Phase 3 trial met primary endpoint, with 36% reduced risk of death by day 29, and 56% reduced risk in patients who were seronegative. Of 2,007 patients (REGEN-COV=1,340, placebo=667) serious adverse events occurred in 21% REGEN-COV patients and 26% placebo patients, noted September 30, 2021.",2 +ANAB,Non-squamous non-small cell lung cancer (NSCLC),Phase 2,10/5/22,"Phase 2 trial met primary endpoint, noted October 5, 2022.",1 +AZN,Lupus,Phase 3,8/2/21,"FDA approval announced August 2, 2021.",2 +NVS,HR+/HER2− metastatic breast cancer,Phase 2,12/6/22,"Phase 2 data reported that treatment doubled the median PFS vs. combination CT at 24.0 months compared to 12.3 months, noted December 6, 2022.",2 +AZN,Non-small cell lung cancer (NSCLC),Phase 2,9/17/21,"Phase 2 trial met primary endpoint of confirmed ORR of 30%, and for durvalumab plus monalizumab 36%. The 10-month PFS rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone, September 17, 2021.",2 +CYCN,Alzheimer's disease with vascular features (ADv),Phase 2a,5/11/23,"Phase 2a data was inconclusive, noted May 11, 2023.",1 JNJ,HIV,Approved,7/18/18,"FDA Approval announced July 17, 2018.",2 -MRUS,Solid Tumors,Phase 3,10/26/22,"Phase 1/2 update reported that treatment was well-tolerated, with 2 confirmed partial responses observed and 4 additional patients had >20% tumor shrinkage, noted October 26, 2022.",2 -XERS,Severe hypoglycemia,Approved,9/10/19,"FDA Approval issued September 10, 2019.",2 -SIGA,Smallpox,Approved,5/19/22,"Approved May 19, 2022.",2 -ADMA,Primary Immune Deficiency Diseases,Approved,12/13/22,FDA supplemental approval for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life.,2 -JAZZ,Small cell lung cancer (SCLC),Approved,6/15/20,"FDA Approval announced June 15, 2020.",2 -EGRX,Severe Community-Acquired Bacterial Pneumonia (SCABP),Phase 2/3,6/14/23,"FDA granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation, noted June 14, 2023. QIDP designation entitles Eagle to an additional five years of exclusivity upon NDA approval.",2 -OCUL,Glaucoma and ocular hypertension,Phase 3,5/20/19,"Phase 3 data May 20, 2019 did not meet primary endpoint.",0 -KPTI,Dedifferentiated liposarcoma,Phase 3,11/2/20,"Phase 3 trial met primary endpoint - November 2, 2020.",2 -INCY,Cancer - first-line metastatic melanoma,Phase 3,4/6/18,"Phase 3 trial did not meet primary endpoint - noted April 6, 2018.",0 -MRK,"First-line, lower-risk Myelodysplastic syndromes (MDS)",Approved,8/28/23,"Approved August 28, 2023.",2 -ONTX,2nd-line HR-MDS (high risk myelodysplastic syndromes),Phase 3,8/24/20,"Phase 3 trial did not meet primary endpoint - August 24, 2020.",0 -BIIB,Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH,Phase 3,3/30/20,Phase 3 trial stopped following DSMB recommendation. Primary endpoint unlikely to be met.,0 -INCY,Anal cancer,Phase 2,9/18/20,Phase 2 data noted objective response rate of 14% and disease control rate of 49%.,1 -EFTR,Metastatic breast cancer (mBC),Phase 2a,5/25/23,"Phase 2a data observed partial responses seen in 26% of patients, is substantially higher than we would expect for treating such heavily pretreated patients with just fulvestrant and abemaciclib, noted May 25, 2023",2 -ALXO,Myelodysplastic syndromes (MDS),Phase 1b,8/10/23,"Phase 1b data reported that the evorpacept combination did not substantially improve upon the historical activity of azacitidine alone, noted August 10, 2023.",2 -NKTR,Melanoma,Phase 3,3/14/22,"Phase 3 data did not meet the primary endpoints, noted March 14, 2022.",2 -RVNC,Moderate to severe glabellar (frown) lines,Approved,9/8/22,"Approved September 8, 2022.",2 -NVS,Pegfilgrastim biosimilar,Approved,11/5/19,"FDA Approval announced November 5, 2019.",2 -SNY,Immune thrombocytopenic purpura (ITP),Phase 2,12/7/19,Phase 2 data at ASH December 2019 noted 39% of patients achieved primary endpoint.,1 -SGEN,Frontline Hodgkin lymphoma,Approved,4/4/18,"sBLA approval announced March 20, 2018.",2 -AERI,Dry eye disease,Phase 2b,4/26/22,"Phase 2b results reported that statistically significant improvements were reported with signs and symptoms following treatment, noted April 24, 2022.",2 +KPTI,Myelofibrosis,Phase 2,12/11/21,"Additional Phase 2 results reported that of the ten patients who were on treatment for at least 24 weeks, four (40%) patients achieved SVR of ≥35% and six (60%) patients achieved SVR of ≥25%, noted December 11, 2021.",2 +RARE,Osteogenesis Imperfecta,Phase 2b,10/16/23,"Phase 2b data demonstrated that treatment with setrusumab (UX143) significantly reduced the incidence of fractures in patients with osteogenesis imperfecta (Gr) with at least six months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD), noted October 16, 2023.",2 +AZN,Chronic Kidney Disease (CKD),Phase 2b,11/3/23,"Phase 2b showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), noted November 3, 2023.",2 +SPRB,Classic Congenital Adrenal Hyperplasia,Phase 2,6/17/23,"Phase 2 data presented at ENDO highlighted that gonadal axis disruption is common in men with 21OHD and suggests that modulation of adrenal androgen production via CRFR1 antagonism may improve testicular function, noted June 17, 2023.",2 +NWBO,Glioblastoma multiforme (GBM),Phase 3,11/17/22,"Phase 3 data reported that both median survival and ""Long Tail"" of extended survival were increased in both newly diagnosed and recurrent glioblastoma, noted November 17, 2022.",1 +UTHR,Small cell lung cancer,Phase 2/3,2/3/20,"Phase 2/3 trial did not meet primary endpoint - February 3, 2020.",0 +ARQT,Plaque psoriasis,Phase 3,9/30/21,"Phase 3 data met its primary endpoint of Investigator Global Assessment Success rate at week 8 in 37.5% compared to a vehicle rate of 6.9%, noted September 30, 2021.",2 +IPHA,Non-small cell lung cancer (NSCLC),Phase 2,9/17/21,"Phase 2 trial met primary endpoint of confirmed ORR of 30%, and for durvalumab plus monalizumab 36%. The 10-month PFS rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone, September 17, 2021.",2 +RHHBY,Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC),Phase 3,9/29/19,Phase 3 updated data at ESMO noted HR 0.43. PFS 34.8 months vs 10.9 months for crizotinib.,1 +PGEN,"Myelodysplastic Syndromes, Acute Myeloid Leukemia",Phase 1b,12/13/22,"Phase 1/1b data reported a 27% objective response rate (ORR) in heavily pre-treated r/r AML patients, noted December 13, 2022.",2 +BNTX,COVID-19 Vaccine (Omicron Booster),Approved,9/11/23,"FDA booster approved on September 11, 2023.",2 +RHHBY,Chronic rhinosinusitis with nasal polyps (CRSwNP),Approved,12/1/20,"FDA approval announced December 1, 2020.",2 +LEGN,Multiple Myeloma,Phase 3,6/5/23,"Phase 3 results shared at ASCO demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26, noted June 5, 2023",2 +MBRX,Acute Myeloid Leukia (AML),Phase 1b,10/2/23,"Phase 1b portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33%, noted Octobeer 2, 2023.",2 +SLRN,Hidradenitis Suppurativa (HS),Phase 2/3,9/11/23,"Phase 2b/3 data to did not meet statistical significance at week 16, noted Septemeber 11, 2023.",2 TEVA,Rituxan (rituximab) biosimilar,Approved,11/28/18,"FDA Approval announced November 28, 2018.",2 -NVS,IgA nephropathy (IgAN),Phase 3,10/2/23,"Phase 3 data reported that met its pre-specified interim analysis primary endpoint, noted October 2, 2023.",1 -KA,Solid tumors,Phase 1/2,11/3/23,"Phase 1/2 biomarker data to be presented at SITC, noted Noember 3 2023.",2 -CHRS,Esophageal Squamous Cell Carcinoma,Phase 3,9/17/21,"Phase 3 trial met the co-primary endpoints of progression free survival (PFS) and overall survival (OS) for patients treated with the toripalimab and chemotherapy combination compared to chemotherapy alone, September 17, 2021.",2 -MOR,Psoriatic Arthritis,Approved,7/14/20,"FDA Approval announced July 14, 2020.",2 -MRK,Head and neck squamous cell carcinoma (HNSCC),Phase 3,7/20/22,"Phase 3 trial did not meet primary endpoint, noted June 20, 2022.",2 -REGN,Homozygous familial hypercholesterolemia (HoFH),Approved,4/1/21,"FDA approval announced April 1, 2021.",2 -AMGN,Hematopoietic Syndrome of Acute Radiation Syndrome,Approved,2/2/21,"FDA approval announced in earnings release - February 2, 2021.",2 -BYSI,Docetaxel-induced neutropenia in breast cancer,Phase 2/3,12/13/22,"Additional data reported that plinabulin was superior vs no-treatment for DIN and hematologic complications, noted December 13, 2022.",2 -AZN,"Severe, uncontrolled asthma",Phase 3,5/10/17,"Phase 3 trial did not meet primary endpoint - May 10, 2017.",0 -RHHBY,Hepatocellular carcinoma,Phase 3,4/17/23,"Additional Phase 3 data reported that the combination reduced the risk of cancer returning by 28%, compared with active surveillance, at a median follow-up of 17.4 months, noted April 17, 2023.",2 -TENX,Reduce the incidence of low cardiac output syndrome during cardiac surgery,Phase 3,1/31/17,"Phase 3 top line data released January 31, 2017 - primary endpoints not met.",0 -AZN,Neuromyelitis Optica Spectrum Disorder (NMOSD),CRL,9/6/23,"CRL issued on September 6, 2023.",1 -INCY,Relapsed or refractory diffuse large B cell lymphoma,Approved,7/31/20,"FDA Approval announced July 31, 2020.",2 -ABBV,Major depressive disorder (MDD),Approved,12/19/22,"Approved December 19, 2022.",2 -JAZZ,Acute Myeloid Leukemia (AML),Phase 1b,12/12/22,"Phase 1b subgroup analysis reported that complete remission (CR) was achieved by 14/17 (82%) patients with a FLT3 ITD mutation and by 5/6 (83%) patients with a FLT3 TKD mutation, noted December 12, 2022.",2 -EVAX,Metastatic Melanoma,Phase 2b,10/31/23,"Phase 2b data presented at SITC reported that a pronounced and ongoing tumor reduction was observed in a patient with progressive disease, noted October 31, 2023.",2 -ANNX,Retinal vein occlusion (RVO),Phase 2,8/11/23,"Phase 2 data reported a long duration of effect with a single dose of standard of care anti-VEGF treatment in two of five treated patients. These two patients also had some positive effects on visual acuity and the retina already during the four weeks before standard of care treatment was used, noted August 11, 2023.",2 -TEVA,Tardive dyskinesia (TD),Approved,2/17/23,"FDA Approval on February 17, 2023.",2 -REGN,Chaple,Approved,8/18/23,"Approved August 18, 2023.",2 -PTN,Dry eye disease (DED),Phase 2,12/15/20,Phase 2 trial met the primary endpoints in the moderate to severe patient population but not in the overall population including mild patients.,1 -KURA,Head and neck squamous cell carcinomas (HNSCC),Phase 2,10/21/23,"Phase 2 data presented at ESMO reported that the Tipifarnib ORR was higher in 2L setting than 3L+ setting (29% vs. 15%), noted October 21, 2023.",2 +GMAB,Metastatic cervical cancer,Phase 1/2,6/6/22,"Phase 1b/2 data reported an 41% objective response rate, noted June 6, 2022.",1 +AERI,Dry eye disease,Phase 2b,4/26/22,"Phase 2b results reported that statistically significant improvements were reported with signs and symptoms following treatment, noted April 24, 2022.",2 +FGEN,Duchenne muscular dystrophy,Phase 3,6/7/23,"Phase 3 trial did not meet its primary endpoint, noted June 7, 2023.",2 +ARDX,Constipation-predominant irritable bowel syndrome (IBS-C),Phase 3,5/12/17,"Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.",1 +PFE,Metastatic uveal melanoma (MUM),Phase 2,4/23/23,"Phase 2 darovasertib and crizotinib combination data reported a cORR of 45%, DCR of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patients, noted April 23, 2023.",2 +CYT,"Hematologic malignancies, solid tumors, triple negative breast cancer",Phase 1,6/30/23,"Phase 1 development discontinued due to dissolution, noted June 30, 2023.",0 +RLFTF,COVID-19,Phase 3,5/25/22,"Phase 3 DSMB review requested that randomization to aviptadil be stopped due to not meeting the futility guidelines, noted May 25, 2022.",2 +INCY,Treatment-naïve acute GVHD,Phase 3,1/2/20,"Phase 3 trial did not meet primary endpoint - January 2, 2020.",0 +AMYT,Acromegaly,Approved,6/26/20,"FDA approval announced June 26, 2020.",2 +AIM,Colorectal cancer,Phase 2,4/11/22,"Phase 2 initial results presented at AACR reported that the primary endpoint was met, noted April 11, 2022.",2 +REGN,Wet age-related macular degeneration (AMD),Phase 2,8/10/23,"Phase 2 two-year longer-term data demonstrated that the vast majority of aflibercept 8 mg patients with wAMD could maintain or further extend their dosing intervals. Among those who completed the two-year follow-up, noted August 10, 2023.",2 +SRNE,Acute lower back pain (LBP),Phase 2,9/14/23,"Phase 2 data reported that none of the subjects in the active group and 3 (8.1%) subjects in placebo group had AEs of special interest, with a meaningful reduction of pain over the first week, noted September 14, 2023.",2 +SNY,Hidradenitis suppurativa / atopic dermatitis,Phase 1,12/14/22,"Phase 1 data reported that a 37% mean reduction in EASI in AD and 42% of HS patients has AN Count 0/1/2, noted December 14, 2022.",2 +ZVRA,induced Vasomotor Symptoms (iVMS) associated with menopause,Phase 1,3/17/23,"Phase 2a PoC did not meet its primary endpoint of ability to decrease the frequency or severity of hot flashes in postmenopausal women. As a result, the company is pausing the program until a full dataset review, noted March 17, 2023",2 +REGN,Asthma,Approved,10/19/18,"FDA approval announced October 19, 2018.",2 +VRNA,Chronic obstructive pulmonary disease (COPD),Phase 2,10/13/21,"Phase 2 part B data noted when administered by hand-held pMDI over one week treatment provided clinically meaningful, statistically significant and dose-dependent bronchodilation, noted October 13, 2021.",2 +PFE,Biosimilar bevacizumab,Approved,6/28/19,"FDA Approval announced June 28, 2019.",2 +GSK,"Meningitis, meningococcal disease caused by serogroups A, B, C, W and Y",Phase 3,5/12/23,"Phase 3 data reported that the trial met all primary endpoints, noted May 12, 2023.",1 +MRK,House dust mite allergies,Approved,3/1/17,"Approved March 1, 2017.",2 TAK,Medullary thyroid cancer,Approved,11/29/12,"Approved November 29, 2012.",2 -MREO,Solid tumors,Phase 1/2,11/30/21,"Phase 1b/2 interim data showed that the dose was well tolerated with a favorable safety profile. One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set",2 -XERS,Endogenous Cushing’s syndrome,Approved,12/30/21,"Approved December 30, 2021.",2 -AMGN,Ph+ R/R ALL,Approved,7/11/17,"PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.",2 -FREQ,Acquired Sensorineural Hearing Loss (SNHL),Phase 2a,3/23/21,"Phase 2a trial did not show improvement versus placebo - March 23, 2021.",0 -DYAI,COVID-19 booster vaccine,Phase 1,7/24/23,"Phase 1 safety data reporter no Serious Adverse Events or Adverse Events of Special Interest have been reported to date, noted July 24, 2023",1 -JSPR,Sickle Cell Disease and Beta Thalassemia,Phase 1/2,2/16/23,"Phase 1/2 follow up data reported that two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up, noted February 16, 2023.",2 -IMGN,Acute Myeloid Leukemia (AML),Phase 1/2,12/12/21,"Phase 1b/2 data reported a objective response rate (ORR) of 48%, with a composite complete remission (CCR) rate of 30%, noted December 12, 2021.",1 -JNJ,Relapsed or refractory (R/R) multiple myeloma.,Approved,10/26/22,"Approved October 26, 2022.",2 +AXSM,Treatment resistant depression,Phase 2,8/9/21,"Phase 2 trial met primary and key secondary endpoints - August 9, 2021.",2 +ALNY,Acute hepatic porphyrias,Approved,11/20/19,"FDA approval announced November 20, 2019.",2 +BYSI,Docetaxel-induced neutropenia in breast cancer,Phase 2/3,12/13/22,"Additional data reported that plinabulin was superior vs no-treatment for DIN and hematologic complications, noted December 13, 2022.",2 +BMY,Non-Small Cell Lung Cancer (NSCLC),Phase 3,4/11/22,"Phase 3 results reported that treatment reduced the risk of disease recurrence, progression or death by 37%, noted April 11, 2022.",2 +BMY,(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC),Approved,8/1/17,"Approval announced August 1, 2017.",2 +PRAX,Essential tremor,Phase 2,8/8/23,"Phase 2 patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111). Patients withdrawing from ulixacaltamide to placebo experienced worsening in mADL11, noted August 8, 2023.",2 +BHC,Macular edema associated with uveitis,Approved,10/25/21,"Approved October 25, 2021.",2 +TXMD,Contraception,Approved,8/10/18,"FDA Approval announced August 10, 2018.",2 +AADI,PEComa​,Approved,11/23/21,"Approved November 23, 2021.",2 +OPTN,Chronic sinusitis,Phase 3,2/16/23,"Phase 3 trial met both co-primary endpoints, noted March 7, 2022. Phase 3 additional analysis reported that patients experienced a spectrum of benefits on symptoms and quality of life, as well improvement in objective measures of disease, relative to patients receiving a placebo comparator, noted July 8, 2022. Phase 3 pre-planned analysis of pooled data revealed 66% reduction in sinusitis exacerbations (flares) with treatment compared to placebo, noted July 13, 2022. sNDA submitted to FDA on February 16, 2023",2 +GRTS,Colorectal Cancer / Gastric Cancer,Phase 1/2,9/17/21,"Phase 1/2 data showed a 44% molecular response rate (4/9) and extended median overall survival >17 months, September 17, 2021.",2 +EXEL,First-line BRAF wild-type metastatic or unresectable locally advanced melanoma,Phase 3,6/20/19,"Phase 3 data did not meet primary endpoint - June 20, 2019.",0 +BPMC,Indolent and smoldering systemic mastocytosis (SM),Phase 2,2/27/23,"Phase 2 data presented at AAAAI reported a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, noted February 27, 2023.",2 +ARWR,Dyslipidemia,Phase 2b,11/7/22,"Phase 2b data presented at AHA reported that ARO-ANG3 is associated with relative reduction in liver fat fraction at Week 24, with no AEs related to LFT changes reported to date, noted November 7, 2022.",2 +MRK,Pneumococcal conjugate vaccine,Phase 3,7/27/23,"Phase 3 trial met primary endpoint, noted July 27, 2023.",1 +NVCT,Non-small cell lung cancer (NSCLC),Phase 1a,9/12/23,"Phase 1a dose escalation initiated, noted September 12, 2023.",1 +CHRS,NSCLC neoadjuvant setting,Phase 3,6/3/23,"Phase 3 Interim event-free survival (EFS) analysis presented at ASCO reported that MPR and pCR rates per BIPR were higher in the toripalimab arm, 48.5% vs 8.4% and 24.8% vs 1.0%, respectively, noted June 3, 2023.",2 +EQ,Systemic lupus erythematosus (SLE) and lupus nephritis (LN),Phase 1b,9/27/22,"Phase 1b interim data demonstrated clinically meaningful response in highly proteinuric subjects: 5 of 6 (83%) subjects achieved a complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction in urine protein creatinine ratio (UPCR) by week 28, 8 of 12 (67%) subjects achieved > 50% reduction in UPCR (6 subjects still dosing). The treatment continues to demonstrate favorable safety and tolerability through six months, noted September 27, 2022.",2 +ALPMY,Untreated locally advanced or metastatic urothelial cancer (la/mUC),Phase 3,10/23/23,"Phase 3 data presented at ESMO reported a median OS of 31.5 months (95% CI: 25.4-NR) compared to 16.1 months in the chemotherapy arm, significantly prolonged OS, reducing the risk of death by 53% compared to treatment with chemotherapy, noted October 23, 2023.",2 +VRNA,COPD,Phase 2,1/14/19,"Phase 2 trial did not meet primary endpoint - January 13, 2019.",0 +SAGE,Parkinson Disease,Phase 2a,3/15/22,"Phase 2a data reported that sustained effects and improving trends were seen out to Day 28, noted March 15, 2022.",2 +ERAS,Non-small-cell Lung Cancer,Phase 1b,6/5/23,"Deprioritized as clinical efficacy data do not support continued evaluation, noted June 5, 2023.",2 +KOD,Treatment-Naive Wet Age-Related Macular Degeneration (AMD),Phase 3,10/13/23,"Phase 3 data presented at the Retina Society meeting reported a favorable safety profile with low rates of intraocular inflammation and no cases of intraocular inflammation with vasculitis or vascular occlusion, noted October 13, 2023.",2 +AZN,COVID-19 vaccine,Phase 3,3/22/21,"Data from U.S. trial noted 76% efficacy rate - March 24, 2021.",2 +WVE,Huntington’s disease,Phase 1/2,3/29/21,Phase 1/2 data showed no statistically significant change in mutant huntingtin protein (mHTT). Development to be stopped,0 +AMGN,Rheumatoid arthritis (RA),Approved,6/6/22,"Approved June 6, 2022.",2 +KMDA,AATD - Alpha-1 Antitrypsin deficiency,Phase 2,8/30/16,"Top-line data released August 30, 2016. Primary endpoint met",2 +MNOV,COVID-19 / acute respiratory distress syndrome (ARDS),Phase 2,6/8/22,"Phase 2 trial met one co-primary endpoint with statistical significants with 71% of the treated group free from respiratory failure at Day 7, noted June 8, 2022.",2 +AMGN,Migraine,Approved,5/17/18,"Approval announced May 17, 2018.",2 +ETNB,Nonalcoholic Steatohepatitis (NASH),Phase 2b,9/21/23,"Phase 2b trial received Breakthrough Therapy Designation (BTD) granted by the FDA, noted September 21, 2023.",1 +SYRS,Solid tumors,Phase 1b,5/25/23,"Phase 1/1b data from ASCO reported that in solid tumors, data demonstrated a 100% disease control rate (DCR) with 10 mg SY-5609 monotherapy, with the PDAC patient experiencing a 10% tumor reduction, noted May 25, 2023.",2 +MRK,Solid tumors - TMB-H ≥10 mutations/megabase,Approved,6/17/20,"FDA Approval June 17, 2020.",2 +BIIB,Essential tremor,Phase 2,4/12/21,"Phase 2 trial met primary endpoint (P=0.049) - April 12, 2021. 62% of patients were down-titrated to from 60mg to 45 mg or 30 mg with the high dose not well tolerated.",2 +PFE,HIV,Approved,2/1/22,"Approved February 1, 2022.",2 +PLX,Fabry disease,Approved,5/10/23,"Approved May 10, 2023.",2 +LGND,Postpartum Depression - moderate,Approved,3/19/19,"FDA approval announced March 19, 2018.",2 +PBYI,Breast Cancer,Phase 2,6/5/23,"Phase 2 data reported an increased MYC RNA expression was observed in tumors from patients who did not derive clinical benefit from paclitaxel alone compared to those with benefit from paclitaxel alone, noted June 5, 2023.",2 +SNY,Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,8/10/18,"FDA Approval announced August 10, 2018.",2 +FGEN,Duchenne Muscular Dystrophy,Phase 3,8/29/23,"Phase 3 topline data reported that the trial did not meet its primary endpoint, noted August 29, 2023.",2 +AZN,COVID-19 vaccine (variant),Phase 2/3,2/10/22,"Phase 2/3 trial met primary endpoint, noted February 10, 2022.",1 +VIRX,Epstein-Barr Virus Associated Lymphoma,Phase 1/2,8/8/23,"Phase 1b/2 data results showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the most aggressive cancers, noted August 8, 2023.",2 +ENSC,Overdose Protection,Phase 1,5/9/23,"Phase 1 was completed with final part B data showing that a 25 mg dose of PF614-MPAR, delivered oxycodone as designed for what may be a prescribed dose of one to two capsules, noted May 9, 2023.",2 +APTX,Fibromyalgia,Phase 2b,8/12/22,"Phase 2b data reported that trial did not meet statistically significant, noted August 12, 2022.",2 +FRTX,Atopic dermatitis,Phase 1,3/7/23,"Phase 1 topline results reported that treatment was well tolerated and plasma concentrations within the potential therapeutic dose range were consistent with efficacious exposure levels established in nonclinical disease models, noted March 7, 2023.",2 +VIR,Mild to moderate COVID-19,Phase 3,3/3/21,Independent Data and Safety Monitoring Board (DSMB) recommended that enrollment to be closed - raised concerns about the magnitude of potential benefit.,0 +KZIA,Brain Metastases,Phase 1,7/6/23,"FDA awarded Fast Track Designation, noted July 6, 20223.",1 +GSK,"Covid-19 vaccine, omicron variant",Phase 1,1/30/23,"Phase 1 immunogenicity data reported that on day 29 at the 12µg dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against BA.1 of 13.3, noted January 30, 2023.",1 +TAK,Renal Cell Carcinoma (RCC),Phase 3,9/8/22,"Phase 3 data presented at ESMO reported that the median PFS was not reached for the triple combination and was 11.3 months for the combination of nivolumab and ipilimumab. Objective response rates in the PFS intent-to-treat population was 43% and 36%, respectively, noted September 8, 2022.",2 +INCY,Non-small cell lung cancer,Approved,5/6/20,"FDA Approval announced May 6, 2020.",2 +AZN,Second-line ovarian cancer,Approved,8/17/17,"Approval announced August 17, 2017.",2 +ALDX,Chronic Cough,Phase 2,6/27/23,"Phase 2 trial demonstrated statistically significant reduction in cough frequency following administration of ADX‑629 relative to placebo, noted June 27, 2023.",2 +MRK,Cutaneous squamous cell carcinoma (cSCC),Approved,7/6/21,"FDA approval announced July 6, 2021.",2 +CDXS,Phenylketonuria (PKU),Phase 1,11/8/18,"Phase 1 trial met endpoints - November 8, 2018.",2 +ASRT,Peripheral T-Cell Lymphoma cancer,Approved,7/7/14,"Approved July 7, 2014.",2 +EGRX,Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma,Approved,10/27/17,"Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.",1 +HALO,Testosterone deficiency,Approved,10/1/18,"FDA Approval announced October 1, 2018.",2 +SNY,Eosinophilic esophagitis (EoE),Approved,5/20/22,"Approved May 20, 2022.",2 +BHC,Ocular Inflammation,Approved,2/25/19,"FDA approval announced February 25, 2019.",2 +ITCI,Bipolar depression,Phase 3,7/8/19,"Phase 3 trial met primary endpoint - July 8, 2019.",2 +CYBN,Major Depressive Disorder (MDD) and Alcohol use disorder (AUD),Phase 1/2,10/31/23,"Phase 1/2a topline data reported that the reduction in major depressive disorder (""MDD"") symptoms, defined as change from baseline in MADRS total score, was superior in participants assigned to CYB003 compared to the participants who received placebo by 14.08 points, noted October 31, 2023.",2 +TAK,Dengue Vaccine,Phase 3,6/9/22,"Phase 3 data reported that treatment prevented 84% of hospitalizations and 61% of symptomatic dengue illness overall, with identified safety risks, noted June 9, 2022.",2 +BPMC,RET-fusion non-small cell lung cancer (NSCLC),Approved,9/4/20,"FDA Approval announced September 4, 2020.",2 +EDIT,Transfusion-Dependent Beta Thalassemia (TDT),Phase 1/2,6/9/23,"Phase 1/2 first patient demonstrated successful neutrophil and platelet engraftment, and, at one and a half months post-infusion, the patient's response resembles that of the first four RUBY patients, noted June 9, 2023.",2 +NVO,Hemophilia A,Approved,2/19/19,"FDA Approval announced February 19, 2019.",2 +REGN,Stage II to IV resectable cutaneous squamous cell carcinoma (CSCC),Phase 2,10/23/23,"Phase 2 data from ESMO 23 reported a 89% event-free survival rate at one year, and no disease recurrence among patients who achieved a pCR (n=40), noted October 23, 2023.",2 +AVXL,Rett syndrome,Phase 3,2/1/22,"Phase 3 data reported that trial met primary and all secondary efficacy and safety endpoints, noted February 1, 2022.",1 +MRK,Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI),Approved,7/17/19,"FDA Approval announced July 17, 2019.",2 +RHHBY,Urothelial cancer,Phase 3,1/24/20,"Phase 3 trial did not meet primary endpoint - January 24, 2020.",0 +REGN,High low-density lipoprotein (LDL) cholesterol,Approved,4/25/17,"sBLA Approval announced April 25, 2017.",2 +THRX,Gastrointestinal stromal tumors (GIST),Phase 1/2,5/25/23,"Phase 1/2 dose-escalation data demonstrated encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation, noted May 25, 2023.",2 +JNCE,Non-small cell lung cancer and bladder cancer,Phase 2,11/2/20,"Phase 2 interim analysis noted the trial will not meet pre-specified interim criteria for continuation of enrollment - November 2, 2020.",0 +BBIO,Autosomal Dominant Hypocalcemia Type 1 (ADH1),Phase 2b,6/13/22,"Phase 2b treatment data presented at ENDO resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5 of therapy and sustained at 24 weeks, and was well-tolerated without any reported serious adverse events. At week 24 of treatment, 92% (12/13) of participants had achieved normal trough blood calcium levels in the absence of extra-dietary calcium supplements and active vitamin D, and 77% (10/13) of participants had normal urinary calcium excretion",2 +VRDN,Thyroid eye disease (TED),Phase 1,8/15/22,"Phase 1 study demonstrated that treatment achieved a substantially extended half-life of 30-40 days and the feasibility of a convenient, low-volume, subcutaneous injection paradigm of 2mL 300mg, noted August 15, 2022.",2 +ABBV,Neurogenic Detrusor Overactivity,Approved,2/10/21,"FDA approval announced February 10, 2021.",2 +IONS,Cardiovascular (CV) risk reduction and hypertriglyceridemia,Phase 2b,11/24/21,"Phase 2b updated data demonstrated that in the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo, noted November 24, 2021.",2 +SNGX,Cutaneous T-Cell Lymphoma (CTCL) cancer,Phase 3,5/4/23,"Phase 3 data results confirm and extend response results, noted May 4, 2023.",1 +GRTX,Severe Oral Mucositis (SOM),CRL,8/9/23,"FDA issued a Complete Response Letter (CRL), noted August 9, 2023.",1 +BCTX,Breast cancer,Phase 1/2,2/23/23,"Additional Phase 1/2 data reported that 9 of 11 (82%) patients remain alive from 2021/2022 dosing and 7 of 11 (64%) patients showed either disease control or progression-free survival, noted February 23, 2023.",2 +PFE,Acute treatment of migraine,Approved,2/27/20,"FDA Approval announced February 27, 2020.",2 CYDY,Triple Negative Breast Cancer,Phase 1/2,11/3/21,"Phase 1/2 data reported 75% of patients with a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival, as compared to a 980% reported in August 2021. A 580% increase in 12-month Progression Free Survival was reported as well, November 3, 2021.",2 -INCY,Squamous Cell Carcinoma of the Anal Canal (SCAC),CRL,7/23/21,"CRL announced July 23, 2021",1 -OMER,Cataract surgery,Approved,6/2/14,"Approved June 2, 2014.",2 -PFE,Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults,Approved,8/17/17,"Approval announced August 17, 2017.",2 -NVIV,Complete Thoracic AIS A Spinal Cord Injury,Phase 3,3/9/23,"Pivotal trial did not meet the primary endpoint, noted March 9, 2023.",2 -GKOS,Dry Eye Disease (DED),Phase 2a,1/10/23,"Phase 2a outcomes for GLK-301 demonstrated improvement in the quality of tear film, noted January 10, 2023.",2 -VERU,Benign prostatic hyperplasia (BPH),Approved,12/13/21,"Approved December 13, 2021.",2 -FIXX,Phenylketonuria (PKU),Phase 1,7/21/23,"Phase 1 initial data reported that participant 2 has experienced a meaningful plasma Phe reduction of 49% at 17, and participant 1 had a reduction in plasma phenylalanine (Phe) levels to below the ACMG PKU treatment guideline threshold of <360 μmol/L, noted July 27, 2023.",2 -BLRX,Stem-cell mobilization for autologous transplantation,Approved,9/11/23,"FDA Approved on September 11, 2023.",2 -BPMC,Treatment-resistant EGFR-driven NSCLC,Phase 1/2,6/5/23,"Phase 1/2 initial clinical data presented at ASCO reported confirmed partial responses observed in patients whose tumors had progressed following treatment with osimertinib, note June 5, 2023.",2 -ARAV,Platinum Resistant Ovarian Cancer (PROC),Phase 3,8/2/23,"Phase 3 topline data did not meet primary endpoint of progression-free survival, noted August 2, 2023.",2 -MRTX,Non-small cell lung cancer (NSCLC) with a KRASG12C Mutation,Approved,12/13/22,"Approved December 13, 2022.",2 -AVRO,Fabry disease,Phase 2,10/19/21,"Phase 2 safety data noted that no adverse events (AEs) or serious adverse events (SAEs) were reported, October 19, 2021.",2 -CINC,Uncontrolled Hypertension (rHTN),Phase 1,11/28/22,"Phase 1 topline data reported that trial did not meet primary endpoint, noted November 28, 2022.",2 -GSK,COVID-19 vaccine,Phase 3,12/15/21,"Phase 3 data reported that the vaccine is well tolerated, with a safety profile similar to currently approved COVID-19 vaccines, noted December 15, 2021.",2 -BIIB,Acute ischemic stroke,Phase 2b,4/3/18,"Phase 2b data released February 8, 2018 - primary endpoint not met.",0 -MRK,Colorectal cancer (CRC),Approved,6/29/20,"FDA Approval announced June 29, 2020.",2 -CLVS,Cancer - ovarian second line,Approved,12/19/16,"Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.",2 -ABEO,Sanfilippo syndrome type A (MPS IIIA),Phase 1/2,2/12/21,"Phase 1/2 updated safety data released February 12, 2021. Well tolerated.",2 -REGN,Ebola,Approved,10/14/20,"FDA Approval announced October 14, 2020.",2 -AGLE,Arginase I deficiency,Phase 3,4/11/22,"Phase 3 results reported that 65% of patients treated reached or exceeded prespecified response criteria for at least one mobility assessment, with 6 exceeding for tow mobility outcomes, noted April 11, 2022.",2 -VALN,Chikungunya Virus Infection,Phase 3,8/5/21,"Phase 3 trial met primary endpoint - August 5, 2021.",2 -BYSI,Multiple Myeloma,Phase 2,8/29/22,"Phase 2 data reported that the median white blood count (WBC) on Day 0, 1 and 2 was 7.6. Six patients had fever at median of eight days post AHCT. Five patients with engraftment syndrome were treated with steroids, and there was one patient with non-engraftment-related neutropenic fever, noted August 29, 2022.",2 -ARQT,Vitiligo,Phase 2b,7/1/21,"Phase 2a trial to be terminated - noted July 1, 2021.",0 -ABBV,HCV - genotype 1,Approved,12/19/14,"Approved December 19, 2014.",2 -GMAB,Solid tumors,Phase 1/2,11/10/21,"Phase 1/2 data demonstrated biologic and early antitumor activity with a favorable safety profile in patients with advanced solid tumors. Expansion cohorts, including combination therapy with PD-1 inhibitors, are currently enrolling, noted November 10, 2021.",2 -VIR,COVID-19 antibody,Approved,5/26/21,"FDA Emergency Use Authorization filing approval announced May 26, 2021.",2 -ANIP,"Acute exacerbations of multiple sclerosis, rheumatoid arthritis, systemic lupus erythematous and ulcerative colitis",Approved,10/2/23,"1-ml vial approved October 2, 2023.",2 -BNTX,Solid tumors,Phase 1/2,11/10/21,"Phase 1/2 data demonstrated biologic and early antitumor activity with a favorable safety profile in patients with advanced solid tumors. Expansion cohorts, including combination therapy with PD-1 inhibitors, are currently enrolling, noted November 10, 2021.",2 -NKTR,Hemophilia A,Approved,11/16/15,"Approved November 16, 2015.",2 -MIRM,Alagille Syndrome (ALGS),Approved,9/29/21,"Approved September 29, 2021.",2 -OBSV,Endometriosis,Phase 3,1/10/21,Phase 3 trial discontinued due to enrollment challenges.,0 -GLSI,HER2/neu breast cancer,Phase 2b,4/19/22,"Phase 2b trial data reported that treatment safely elicited a potent immune response, as evidenced by injection site reactions that correlate to and may serve as a complement to immune response data such as DTH, noted April 19, 2022.",2 -CWBR,Cancer vaccine for merkel cell carcinoma (MCC),Phase 1b,6/5/23,"Phase 1b data presented at ASCO demonstrated to have a promising safety profile at all 3 dose schedules tested 71% of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested, noted June 5, 202",2 -NVS,Wet macular degeneration,Phase 3,8/15/23,"Phase 3 trial met its primary endpoint, noted August 15, 2023.",1 -NBIX,Negative symptoms of schizophrenia,Phase 2,3/2/21,"Phase 2 trial did not meet primary endpoint - March 2, 2021.",0 -TNXP,Major depressive disorder (MDD),Phase 2,11/1/23,"Phase 2 topline data reported that the trial did not meet its primary endpoint, noted November 1, 2023.",2 +EYPT,Diabetic macular edema,Approved,9/26/14,Approved Sept 26 2014.,2 +NRSN,Parkinson's disease,Phase 1,5/2/23,"Biomarker data reported statistically significant decreased levels of novel biomarker AGO2 observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individuals, noted May 2, 2023.",2 +LIAN,Hypertrophic cardiomyopathy (HCM),Approved,4/28/22,"Approved April 28, 2022.",2 +OVID,Adolescents with Angelman syndrome,Phase 3,12/1/20,"Phase 3 trial did not meet primary endpoint - December 1, 2020.",0 +NVCR,Gastric cancer,Phase 2,6/3/22,"Phase 2 data reported a confirmed objective response rate of 50%, with a 10.3 month duration of response and 72% one-year survival rate, noted June 3, 2022.",1 +INO,Ebola,Phase 1b,4/16/23,"Phase 1b data presented at ECCMID reported that GMTs rose significantly after boosting for each time point measured, peaking at week 2, noted April 16, 2023.",2 +ABIO,COVID-19,Phase 2b,3/31/22,"Phase 2b top-line data reported that neither doses met the primary endpoint, noted March 31, 2022.",1 +BGNE,HER2-amplified biliary tract cancers,Phase 2,6/5/23,"Phase 2 pivotal trial recruitment completed, noted April 28, 2022. Phase 2 full data presented at ASCO reported a confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months, noted June 5, 2023.",2 +BFRI,Actinic Keratosis on face & scalp,Phase 1,8/28/23,"Phase 1 data reported that treatment was generally well tolerated and all TEAEs were transient, noted August 28, 2023.",2 +LLY,Atopic dermatitis,PDUFA,7/16/21,"Noted FDA will not meet assigned July 2021 PDUFA date - July 16, 2021",0 +LQDA,Pulmonary arterial hypertension,Approved,11/8/21,"Tentative approval November 8, 2021. Final approval due in October 2022 or earlier upon resolution of on-going litigation.",2 +CHRS,Cancer,CRL,9/25/23,"CRL issued September 25, 2023.",1 +ALNY,Gout,Phase 1,12/15/22,"Phase 1 pharmacodynamic data suggest extrahepatic contributes significantly to serum urate in humans, noted December 15, 2022.",1 +SYBX,Phenylketonuria (PKU),Phase 1,7/11/23,"FDA Granted Fast Track Designation on July 11, 2023.",1 +ATAI,Cognitive Impairment Associated with Schizophrenia,Phase 2a,12/14/21,"Full Phase 2a results reported dose-related improvements on exploratory cognitive endpoints. A dose dependent response in qEEG was observed, with the greatest increases seen in 20mg and 40mg doses of RL-007, noted December 14, 2021.",2 +JAGX,Cancer related diarrhea (CRD),Phase 2,12/10/21,"Phase 2 results reported that CID occurred significantly less (23%) in the crofelemer group during cycle 1 and crofelemer patients were 1.8 times more likely than control patients to have their diarrhea resolved, noted December 10, 2021.",2 +AERI,Macular edema due to RVO (retinal vein occlusion),Phase 2,10/7/21,"Phase 2 data displayed that the implant achieved targeted 6-month duration of efficacy, with improvements in BCVA and macular edema demonstrated for at least 6 months. Adverse events were consistent with other corticosteroid treatments, noted October 7, 2021.",2 +CNTB,Atopic dermatitis (AD),Phase 2b,3/18/23,"Phase 2b data reported that baseline median Eczema Area and Severity Index (EASI) was 26.9. 54.5% of patients were considered severe, with a baseline Investigators Global Assessment (IGA) score of 4, noted March 18, 2023.",1 +AQST,Erectile dysfunction,CRL,11/16/18,"CRL issued November 16, 2018.",1 +VIGL,Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP),Phase 1,12/14/22,"Phase 1 trial achieved favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohorts. VGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action, noted December 14, 2022.",2 +SLS,Malignant pleural mesothelioma (MPM),Phase 1,6/28/23,"Phase 1 topline data reported that the median overall survival for patients who entered the study as Stage IV patients was 62.3 weeks, noted June 28, 2023.",1 +PFE,Persistent Pulmonary Hypertension (PPHN),Phase 3,6/28/19,"Phase 3 trial did not meet primary endpoint - June 28, 2019.",0 +JNJ,Psoriatic Arthritis in Pediatric Patients,Approved,8/1/22,"Approved August 1, 2022.",2 +TNGX,Solid Tumors,Phase 1/2,7/10/23,"Phase 1/2 dosing initiated, noted July 10, 2023.",1 +BGNE,Hepatocellular carcinoma (HCC),Phase 3,6/5/23,"Phase 3 additional data presented at ASCO reported that treatment demonstrated numerically longer median overall survival (OS) versus sorafenib in the biomarker subgroups of ALBI grade 1 (19.9 months vs. 16.9 months), PLR ≤141 (19.4 months vs. 14.5 months), and NLR ≤3 (20.9 months vs. 15.2 months, noted June 5, 2023.",2 +PRAX,Early-seizure-onset SCN2A developmental and epileptic encephalopathy (DEE),Phase 3,10/2/23,"Phase 3 results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients, noted October 2, 2023.",2 +AGTC,X-linked Retinitis Pigmentosa (XLRP),Phase 1/2,5/4/22,"Phase 1/2 18-month data appear to show safety and efficacy signals similar to the study's 12-month findings, including improvements to the ellipsoid zone (EZ). In patients with XLRP, the EZ, a defined region within the photoreceptor layer of the retina, degenerates over time and is eventually lost.",2 +VTGN,Premenstrual dysphoric disorder (PMDD),Phase 2a,9/12/23,"Phase 2a exploratory analysis demonstrated statistically and clinically significant improvement versus placebo, noted Septemeber 12, 2023.",2 +ICPT,Primary Biliary Cholangitis (PBC),Phase 2a,6/23/23,"Phase 2a data presented at EASL showed that the Combination was well-tolerated with lowest rates of pruritus observed in OCA 5-10 mg + bezafibrate 400 mg treatment arm, noted June 23, 2023.",2 +FGEN,Pancreatic cancer,Phase 2,1/17/17,"Phase 2 abstract released January 17, 2017.",1 +MRK,Heart Failure,Approved,1/20/21,"FDA approval announced January 20, 2021.",2 +SABS,COVID-19,Phase 3,4/26/23,"Phase 3 trial demonstrated benefit in sustained symptom resolution in study participants with COVID-19 caused by Omicron as compared to participants who received a monoclonal antibody combination, REGEN-COV. Specifically, 66% of participants treated with SAB-185 reached full symptom resolution for at least 4 consecutive days by Day 28, while only 50% of participants on REGEN-COV met this endpoint, and the median time to symptom resolution for at least 4 consecutive days was 7 days shorter for SAB-185, noted April 26, 2023.",2 +SYRS,Myelodysplastic Syndrome,Phase 2,12/5/20,"Phase 2 presentation December 5, 2020 at ASH. Overall response rate (ORR) was 67% (12/18).",2 +ARAV,Clear Cell Renal Cell Carcinoma (ccRCC),Phase 1/2,5/25/23,"Updated Phase 1b/2 data from ASCO abstract reported an objective response rate (ORR) of 50% in this population (n=12), compared to 38% (n=13) in patients with no prior VEGF-TKI, noted May 25, 2023.",1 +ADMP,Opioid overdose,Approved,10/18/21,"Approved October 18, 2021.",2 +ALPMY,Severe vasomotor symptoms (VMS) due to menopause,Phase 3,6/28/23,"Phase 3b data reported that the trial met its primary endpoint, noted June 28, 2023.",1 +PLUR,"Intermittent claudication, or IC",Phase 2,6/12/18,"Phase 2 data released June 12, 2018 - primary endpoint met.",2 +BIIB,Mild Alzheimer's disease,Phase 1b,10/25/23,"Phase 1b data presented at CTAD showed favorable trends reported for the high-dose groups on multiple measures of cognition and function, noted October 25, 2023.",2 +AZN,COVID-19,Phase 3,4/12/21,Phase 3 trial did not achieve statistical significance for the primary endpoint.,0 +FDMT,Choroideremia,Phase 1,10/25/21,"Phase 1 initial data from 6 patients enrolled in one of two dose cohorts: 3E11 vg/eye (cohort 1; n=3) and 1E12 vg/eye (cohort 2; n=3). The study showed that at the 3E11 vg/eye dose (Cohort 1), 4D-110 was well-tolerated with no dose-limiting toxicities or serious adverse events. At the 1E12 vg/eye dose, pigment dispersion (iris transillumination) was observed in 3 patients in the 1E12 vg/eye cohort ~7 to 9 months following treatment, 2 cases were asymptomatic and 1 patient reported mild glare.",1 +MRSN,Platinum-sensitive Ovarian Cancer,Phase 1,6/15/23,"A clinical hold placed due to bleeding events, noted June 15, 2023.",1 +BHC,Allergic conjunctivitis,Approved,9/25/20,"FDA approval announced September 25, 2020.",2 +ARDS,Ventilator associated pneumonia (VAP) / Staphylococcus aureus,Phase 3,6/20/23,"FDA granted Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), noted June 20, 2023. The official determination regarding using the LPAD pathway will be made after the Company's request following the filing of the biologics license application (BLA).",0 +CLVS,Ovarian Cancer - First-line maintenance treatment,PDUFA,6/26/23,Company went bankrupt in 2022 not information disclosed about the PDUFA.,1 +ATHA,Alzheimer’s disease,Phase 3,10/17/22,"Phase 3 interim analysis reported that an additional enrollment of ~150 patients will be well powered for the primary endpoint analysis, noted October 17, 2022.",1 SAGE,Insomnia,Phase 1/2,1/31/18,"Phase 1/2 trial met primary endpoint - January 31, 2018.",2 -NVAX,Covid-19,Approved,10/3/23,"EUA approved October 3, 2023.",2 -RHHBY,Relapsed or refractory Chronic Lymphocytic Leukemia (CLL),Approved,6/11/18,"Approval announced June 11, 2018.",2 -ADAP,Urothelial Cancer,Phase 1,11/8/22,"Phase 1 data reported increased ORR now 57% in urothelial cancer with one new complete response, noted November 8, 2022.",1 -ALNY,Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR,Approved,8/10/18,"FDA Approval announced August 10, 2018.",2 -TAK,Non-small cell lung cancer (NSCLC),Approved,9/15/21,"Approved September 15, 2021.",2 -MRK,Endometrial Cancer,Phase 3,7/22/21,"FDA approval announced July 22, 2021.",2 -LSTA,Solid Tumors,Phase 2a,9/12/23,"Phase 2a dosing initiated on head and neck squamous cell carcinoma cohort, noted Septemeber 12, 2023.",1 -MRK,First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer,Approved,5/10/17,"Approved May 10, 2017.",2 -MRK,NMIBC Bladder cancer,Approved,1/8/20,"FDA Approval announced January 8, 2020.",2 -AMLX,Amyotrophic Lateral Sclerosis (AML),Phase 3,2/2/23,"Phase 3 trial enrollment completed, noted February 2, 2023.",1 -RHHBY,HER2-positive breast cancer - residual invasive disease,Approved,5/6/19,"FDA approval announced May 6, 2019.",2 -IPHA,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Phase 2,10/16/23,"Phase 2 results reported that D+M 1 partial response (PR) was recorded and stable disease (SD) was observed in 11 pts (26%), noted October 16, 2023.",2 +ADCT,Hodgkin lymphoma (HL),Phase 2,6/22/21,"Phase 2 interim data presented June 22, 2021. Overall response rate (ORR) was 66.3% (67/101 patients) with a complete response rate (CRR) of 27.7% and partial response rate (PRR) of 38.6%. Median duration of response has not been reached.",0 +LGVN,Aging Frailty,Phase 2b,9/29/21,"Phase 2b biomarker data showed Lomecel-B had statistically significant reduction in serum levels of soluble TIE-2 in a dose-dependent fashion at Day 270 compared to placebo. The levels fell by -243.13 ± 1073.21 pg/mL compared to an increase of 356.03 ± 1018.95 pg/mL in the placebo group, noted September 29, 2021.",2 +HRMY,Fragile X Syndrome in Children and Adolescents,Phase 3,7/18/22,"Longterm data reported improvements in ABC-CFXS Social Avoidance in the full population, noted July 18, 2022.",2 +AMGN,Sjögren’s syndrome,Phase 2,5/31/23,"Additional Phase 2 data reported that all ESSDAI responder analyses (pre-specified and post-hoc) favored dazodalibep over placebo, with greater numerical differences for the highest levels of response and patients treated with dazodalibep experienced numerically greater improvements in ESSPRI score and fatigue compared to those who received placebo at Day 169, noted May 31, 2023.",2 +ZLAB,Ovarian cancer,Approved,4/29/20,"FDA Approval announced April 29, 2020.",2 +MRK,Merkel Cell Carcinoma,Approved,12/19/18,"FDA Approval announced December 19, 2018.",2 +NVS,CV risk reduction,CRL,10/18/18,"CRL announced October 18, 2018.",1 +NVS,Secondary progressive multiple sclerosis,Approved,3/26/19,"FDA approval announced March 26, 2019.",2 +TNXP,Post-traumatic stress disorder (PTSD),Phase 3,12/21/20,"Phase 3 primary endpoint was not met - December 21, 2020.",0 +WINT,Cardiogenic Shock in severe acute heart failure,Phase 2,9/26/22,"Phase 2 dose response data demonstrated that study met its primary endpoint of significantly improved systolic blood pressure over the first 6 hours of study drug infusion. The study also met several other secondary endpoint assessments of cardiac function, noted on September 26, 2022.",2 +SVRA,Heart failure with preserved ejection fraction (HFpEF),Phase 2,3/11/18,"Phase 2 top line data presented March 11, 2018 failed to meet primary endpoint.",0 +OCUP,Dim Light or Night Vision Disturbances (DLD),Phase 3,5/19/22,"Phase 3 topline data reported that the trial met the primary endpoint and key secondary endpoints with no serious adverse event, noted May 19, 2022.",1 +GLYC,Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer,Phase 1/2,12/12/17,Phase 3 trial to be initiated mid-2018. Phase 1/2 data released at ASH 2017 showed clinical remission (CR+CRi) was 43%. Median overall survival was 9.4 months.,1 +ZYNE,Fragile X syndrome,Phase 2/3,5/13/22,"Phase 2/3 long-term data reported that sustained improvement in ABC-CFXS Social Avoidance from baseline, noted May 13, 2022.",2 +BGNE,Cervical Cancer (CC),Phase 2,10/22/23,"Phase 2 data presented at ESMO reported that the ORR was 22.5%, with 13 complete responses; 76.8% had a durable response of ≥6 mo, noted October 22, 2023.",2 +LLY,Treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC),Approved,9/21/22,"FDA Approval on September 21, 2022.",2 +EGRX,Supraventricular tachycardia (SVT) - atrial fibrillation and atrial flutter,CRL,5/31/23,"CRL received on May 31, 2023.",1 +ALNY,Wild-type ATTR amyloidosis patients with cardiomyopathy,CRL,10/9/23,"CRL issued by the FDA on October 9, 2023. As a result of the CRL, the Company will no longer pursue an expanded indication for patisiran in the US.",0 +XAIR,Solid tumors,Phase 1,11/3/23,"Phase 1 data presented at SITC demonstrated early clinical proof of concept, noted November 3, 2023.",2 +EWTX,Duchenne Muscular Dystrophy (DMD),Approved,10/26/23,"Approved October 26, 2023.",2 +VBIV,Covid-19,Phase 1,9/27/23,"Phase 1 interim data reported a 25% reduction in GMT against Wuhan after 5 months vs. peak responses, noted September 27, 2023.",2 +SNY,Eosinophilic esophagitis (EoE) in 1-11 year olds,Phase 3,7/14/22,"Phase 3 data reported that trial met its primary endpoint, noted July 14, 2022.",1 +ALDX,Retinitis Pigmentosa,Phase 2,6/29/23,"Phase 2 top-line results presented on a webcast demonstrated statistically significant improvement in retinal function across a number of different physiological and psychophysical assessments, June 29, 2023.",2 +PFE,Pneumonia and influenza for >65 yrs,Phase 3,9/29/21,"Phase 3 top-line results showed responses to the combination were noninferior to those elicited by the vaccines when administered one month apart. The safety profile of the combination was similar as compared to when each vaccine was administered separately, noted September 29, 2021.",1 +ZYME,HER2-amplified biliary tract cancers,Phase 2,6/5/23,"Phase 2 pivotal trial recruitment completed, noted April 28, 2022. Phase 2 full data presented at ASCO reported a confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months, noted June 5, 2023.",2 +EIGR,Post-Bariatric Hypoglycemia (PBH),Phase 2,10/16/18,"Phase 2 data released October 16, 2018 - endpoints met.",2 BCRX,Acute Influenza,Approved,12/22/14,"Approved December 22, 2014.",2 -MDNA,Solid tumors,Phase 1/2,8/9/23,"Phase 1/2 sixth dose escalation cohort data and agent expansion data to showed durable anti-cancer activity observed during monotherapy dose escalation without dose-limiting toxicities. Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11, noted August 9, 2023.",2 -AYTU,Attention deficit hyperactivity disorder (ADHD),Approved,9/15/17,"Approval announced September 15, 2017.",2 -MESO,"Pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT)",Phase 3,9/21/23,"Type A meeting noted the lack of a suitable potency assay for the RYONCIL product used during the Phase 3 trial, new potency assay data to be generated, noted September 21, 2023.",2 -ABBV,Relapsed or refractory MCL mantle cell lymphoma,Approved,11/13/13,"Approved November 13, 2013.",2 -SLN,Cardiovascular diseases,Phase 1,11/1/23,"Phase 1 data showed very significant and durable reductions in lipoprotein(a) of up to 99%. Lp(a) levels remained around 90% lower than baseline at study endpoint, noted November 1, 2023.",2 -AMGN,Immune thrombocytopenia (ITP),Approved,10/18/19,"FDA Approval announced October 18, 2019.",2 -OTIC,Meniere's disease,Phase 3,8/30/17,Phase 3 data released August 30 failed to meet primary and key secondary endpoints.,0 -KALA,Post‑operative inflammation and pain following cataract surgery,Approved,8/23/18,"FDA approval announced August 23, 2018.",2 -IDYA,Non-metastatic uveal melanoma (UM),Phase 1/2,5/9/23,"Phase 2 data reported that treatment showed evidence of anti-tumor activity, noted May 9, 2023.",2 -ZLAB,Non-Small Cell Lung Cancer,Phase 1/2,12/16/21,"Updated Phase 1/2a reported that 14 patients achieved a confirmed PR for a 39% confirmed response rate and one additional patient had a PR that was pending confirmation at the time of the data cut-off. The median duration of response was >15 months and the median progression free survival was 12 months in the initial cohort of Phase 1 patients, noted December 16, 2021.",2 -CTIC,Myelofibrosis,Approved,2/28/22,"Approved February 28, 2022.",2 -LLY,Metastatic colorectal cancer,Approved,9/28/21,"Approved September 28, 2021.",2 +INCY,Anemia and Post-essential Thrombocythemia Myelofibrosis,Phase 1/2,12/12/22,"Phase 1/2 data reported predominantly grade 1/2 TEAEs and no dose-limiting toxicities (DLTs), noted December 12, 2022.",1 +BPMC,Gastrointestinal stromal tumors (GIST),Phase 3,4/28/20,"Phase 3 data did not meet primary endpoint - April 28, 2020.",0 +PBYI,Extended adjuvant treatment of early stage HER2-positive breast cancer,Phase 2,12/13/21,"Phase 2 dose escalation final findings reported that Neratinib DE + loperamide PRN during the first 2 weeks of treatment was associated with the lowest rates of grade 3 diarrhea (13.3%) and diarrhea-related discontinuations (3.3%) compared with all other anti-diarrheal strategies investigated in the trial, noted December 13, 2021.",2 +BLU,Refractory Chronic Cough,Phase 2b,2/26/23,"Phase 2b data shared at AAAAI reported that similar burdens are also reported across all three LCQ subdomains in the main vs exploratory populations, noted February 26, 2023.",1 +XERS,Post-Bariatric Hypoglycemia,Phase 2b,5/22/20,"Phase 2b outpatient data released May 22, 2020.",1 +NVS,Non-small cell lung cancer (NSCLC) - 2nd/3rd line,Phase 3,3/9/21,Phase 3 trial did not meet primary endpoint.,0 +PRAX,Major depressive disorder,Phase 2,11/9/22,"Phase 2 top-line data was not statistically significant, noted November 9, 2022.",1 +JAZZ,Small cell lung cancer (SCLC),Phase 3,12/3/20,"Phase 3 trial did not meet overall survival endpoint - December 3, 2020.",0 +IONS,Chronic hepatitis B virus (CHB),Phase 2b,6/27/22,"Phase 2b data readout reported that up to 68% of patients on NA therapy and up to 65% of patients not on NA achieved HBsAg <100 IU/mL at the end of treatment, noted June 27, 2022.",2 +PTCT,Huntington's disease,Phase 2,6/28/23,"Phase 2 trial initiated March 30, 2022. Phase 2 trial data reported that treatment was well tolerated, with no treatment related serious adverse events and no adverse events leading to discontinuation, noted June 28, 2023.",2 +INFI,Solid tumors,Phase 1,11/10/18,Further data due at SITC November 2018 noted 2/44 PRs.,1 +GLPG,Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL),Phase 1/2,12/13/22,"Phase 1/2 data reported an ORR of 86% and all responding patients achieved complete response (CR), noted December 13, 2022.",2 +SNY,Autosomal dominant polycystic kidney disease (ADPKD),Phase 2/3,6/1/21,"Phase 2/3 trial stopped due to futility - June 1, 2021.",0 +ZYNE,Autism Spectrum Disorder (ASD),Phase 2,10/8/21,"Phase 2 long term data displayed a statistically significant improvement in ABC-C Subscale scores through 38 weeks. Only 7 patients (19%) experienced an AE that was deemed to be treatment related. Of the 10 treatment-related AEs reported, 7 were application site-related (application site reaction, pruritus, and dryness) and 1 each of sleep disorder, increased appetite, and pollakiuria, noted October 8, 2021.",2 +YS,Rabies,Phase 3,9/26/23,"Phase 3 trial initiated, noted September 26, 2023.",1 +VOR,Acute myeloid leukemia (AML),Phase 1/2,6/9/23,"Phase 1/2a additional data presented at EHA showed that patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism, noted June 9, 2023.",2 +MVIR,Advanced hepatocellular carcinoma (HCC),Phase 2a,10/5/23,"Phase 2a data reported that 3 patients achieved Partial Response and 10 patients Stable Disease, providing 17% Overall Response Rate (ORR) and 72% Disease Control Rate (DCR), noted October 5, 2023.",2 +TAK,Multiple myeloma,Phase 3,11/8/19,"Phase 3 trial met primary endpoint - November 8, 2019.",2 +AZN,Non-small cell lung cancer (NSCLC),Phase 3,12/19/22,"Phase 3 trial did not meet primary endpoint, noted December 19, 2022.",2 +KNSA,Giant cell arteritis (GCA),Phase 2,10/6/20,"Phase 2 trial met endpoints - October 6, 2020.",2 +BHC,Psoriasis,Approved,4/25/19,"FDA approval announced April 25, 2019.",2 +PRAX,Major Depressive Disorder and perimenopausal depression,Phase 2a,8/16/21,"Phase 2a Part B data released August 16, 2021. Mean decreases from baseline at Day 15 of 60% in frequency of moderate-to-severe hot flashes.",2 +KA,Solid tumors,Phase 1/2,11/3/23,"Phase 1/2 biomarker data to be presented at SITC, noted Noember 3 2023.",2 +SLGL,Papulopustular rosacea,Phase 3,7/8/19,"Phase 3 top-line data met primary endpoints - July 8, 2019.",2 +ACXP,C. difficile Infection,Phase 2b,11/2/23,"Phase 2a and 2b data reported an observed Clinical Cure rate in the combined Phase 2 trials in patients with CDI was 96%, noted November 2, 2023.",2 +DMAC,Chronic Kidney Disease,Phase 2,11/4/21,"Phase 2 data presented November 4, 2021 reported statistically significant reductions (over 30% decrease) in albuminuria and early signals of potential disease modification with the APRIL and IgA1 biomarkers decreasing 35% and 22%, respectively.",2 +QLGN,Lactose intolerance,Phase 3,9/12/19,Phase 3 data failed to meet primary endpoint.,0 +MRK,MSI-H/dMMR Advanced Endometrial Carcinoma,Approved,3/21/22,"Approved March 21, 2022.",2 +LVTX,"Chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML)",Phase 1/2,6/14/23,"Phase 1/2a discontinued, noted June 14, 2023.",0 +AZN,Neurofibromatosis type 1 plexiform neurofibromas,Approved,4/13/20,"FDA Approval announced April 13, 2020.",2 +SGMO,Fabry disease,Phase 1/2,5/22/23,"FDA fast-track designation granted on May 22, 2023.",1 +ADAP,Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS),Phase 1,5/26/22,"Phase 1 data released May 26, 2022. The overall response rate was 36% in heavily pre-treated patients across both types of sarcomas (41% in synovial sarcoma and 10% for MRCLS), with a median duration of response of 52 weeks. As reported last year, the pivotal trial SPEARHEAD-1 met its primary endpoint for efficacy and the benefit:risk profile of afami-cel has been favorable with mainly low-grade cytokine release syndrome and tolerable/reversible hematologic toxicities.",2 +SEEL,Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder (ASIB in MDD),Phase 2,9/20/23,"Phase 2 Part 2 cohort data readout demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality, noted September 20, 2023.",2 +SLNO,Prader-Willi syndrome (PWS),Phase 3,9/8/21,"Phase 3 extension study data showed mean (SE) improvement in hyperphagia by a decrease in the HQ-CT total score, of -9.9 (0.77), was highly significant (p<0.0001) after receiving DCCR for 52 weeks, noted September 8, 2021.",2 +NVS,Breast cancer,Phase 3,9/9/22,"Phase 3 overall survival data reported a median OS of approximately five years, noted September 9, 2022.",1 +REGN,Chronic Spontaneous Urticaria (CSU),Phase 3,2/18/22,"Phase 3 trial did not meet the primary endpoint, noted February 18, 2022.",2 +AFMD,EGFR-expressing solid tumors,Phase 1/2,6/3/23,"Phase 1/2 interim data presented at ASCO reported that 7 out of 15 heavily pre-treated patients with tumor reductions, including 2 confirmed partial responses and 5 patients exhibiting stable disease, noted June 3, 2023.",2 +GSK,Endometrial Cancer,Approved,7/31/23,"FDA approved on July 31, 2023. Ahead of PDUFA on Sept. 23, 2023.",2 +BMY,First-line Non-small cell lung cancer (NSCLC),Approved,5/26/20,"FDA Approval announced May 26, 2020.",2 +AZN,Non-small cell lung cancer (NSCLC),Phase 3,10/23/23,"Phase 3 reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors , noted October 23, 2023.",2 +MRNS,Focal onset seizures,Phase 3,6/13/16,"Phase 3 data did not meet endpoints - June 13, 2016",0 +GSK,COVID-19 vaccine,Phase 2/3,9/22/21,"Phase 2/3 interim analysis showed primary and secondary endpoints met. 100% efficacy against severe COVID-19 & hospitalization and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2 in SPECTRA, and 79% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant, noted September 22, 2021.",2 +LLY,COVID-19 antibody,Phase 3,10/26/20,"Phase 3 trial discontinued - October 26, 2020.",0 +BLUE,Childhood cerebral adrenoleukodystrophy (CCALD),Phase 2/3,3/14/21,"Phase 2/3 updated data presented March 15, 2021. 90% of evaluable patients (27/30) alive and free of major functional disabilities at two years follow-up.",2 +OPK,Obesity and diabetes,Phase 2b,3/21/19,"Phase 2b top-line data March 21, 2019 met primary endpoint.",2 +ARDX,Hyperphosphatemia - adjunctive therapy to phosphate binders,Phase 3,9/3/19,Phase 3 trial met primary endpoint.,2 +HRTX,Post operative pain,Approved,5/13/21,"FDA approval announced May 13, 2021.",2 +RETA,Mitochondrial myopathies (MM),Phase 2,3/1/18,"Phase 2 initial data released March 1, 2018 - endpoints not met.",0 +MRK,Biliary Tract Cancer,Approved,11/1/23,"Approved November 1, 2023.",2 +MYOV,Advanced prostate cancer,Approved,12/18/20,"FDA approval announced Decmber 18, 2020.",2 +AZN,Venous thromboembolism (VTE) Prevention,Approved,6/23/17,"FDA Approval noted June 23, 2017.",2 +IMRA,Sickle cell disease,Phase 2a,12/13/21,"Phase 2a 12-month OLE data showed that dose was generally well-tolerated as a monotherapy as well as in combination with hydroxyurea. There were no clinically-significant changes in lab safety data, ECGs or vital signs, and no patients have discontinued the study due to adverse events",1 +ETON,Pediatric adrenal insufficiency (AI),Approved,9/29/20,"FDA approval announced September 29, 2020.",2 +ARVN,Metastatic castration-resistant prostate cancer (mCRPC),Phase 1/2,10/23/23,"Phase 1/2 data presented at ESMO reported a PSA50 of 41% in patients with tumors harboring any AR LBD mutation, and a PSA50 of 50% in patients with any tumor harboring an AR L702H mutation, noted October 23, 2023.",2 +QNCX,Alzheimer’s disease,Phase 2/3,11/11/21,"Phase 2/3 data reported that the 40 mg demonstrated equivalent or better efficacy compared 80 mg, as well as a superior safety profile. Benefits were shown in ADAS-Cog11, CDR-SB, MMSE, and NPI, with increasing separation from placebo throughout the study consistent with disease modification. Benefits were not seen on ADCS-ADL at either dose, noted November 11, 2021.",2 +TCON,Wet age-related macular degeneration (Wet-AMD),Phase 2,3/9/20,"Development to be discontinued - March 9, 2020.",0 +ABUS,"Hepatitis B, healthy volunteers",Phase 1,9/11/23,"Phase 1 dosing commenced, noted September 11, 2023. Phase 1 preliminary data 1H 2024.",1 +VRTX,alpha-1 antitrypsin (AAT) deficiency,Phase 2,10/14/20,Phase 2 trial and development to be discontinued due to safety.,0 +MACK,Small Cell Lung Cancer,Phase 3,8/3/22,"Phase 3 trial did not meet primary endpoint, noted August 3, 2022.",2 +MORF,Ulcerative Colitis (UC),Phase 1,10/25/22,"Phase 1 additional data showed statistically significant effects on key lymphocyte subsets, noted October 25, 2022.",2 +IMCR,Solid tumors,Phase 1,12/8/22,"Phase 1 initial data reported that one patient had a durable Partial Response (PR), with a duration of 12.7 months, one patient who had a Stable Disease (SD) converted to an unconfirmed PR after the poster data cutoff date and is still ongoing, and 5 had SD, noted December 8, 2022.",1 +IMMP,Metastatic breast cancer (MBC),Phase 2b,5/4/22,"Phase 2b biomarker data reported a statistically significant increase in innate and adaptive immune response biomarkers and six patient subgroups with improvements in Overall Survival (OS), noted May 4, 2022.",2 +TMBR,Rosacea,Phase 2b,6/25/19,"Phase 2b data June 25, 2019 met endpoints.",2 +NVS,Psoriatic arthritis,Phase 3,11/1/19,"Phase 3 data did not meet primary endpoint - October 31, 2019.",0 +MRK,"Personalized cancer vaccine, high-risk melanoma",Phase 2,10/23/23,"Phase 2 additional data presented at ESMO reported that local recurrence was more common in MRs; MNRs had more distant events. This trend was supported by stronger separation in DMFS vs RFS between MRs and MNRs, noted October 23, 2023.",2 +BIIB,C9orf72-associated Amyotrophic Lateral Sclerosis (ALS),Phase 1,3/28/22,"Phase 1 study did not meet any secondary efficacy endpoints and it did not demonstrate clinical benefit. These results do not support further development, noted March 28, 2022.",2 +EWTX,dystrophinopathies including Duchenne Muscular Dystrophy in children and adolescent boys,Phase 2,10/26/23,"Phase 2 initiated, noted October 26, 2023.",1 +RHHBY,First line unfit AML,Approved,11/21/18,"FDA approval announced November 21, 2018.",2 +ADVM,Wet age-related macular degeneration (AMD),Phase 2,9/26/23,"Phase 2 14-week data reported that has been generally well-tolerated, with 90% of subjects were still receiving corticosteroid prophylactic taper, noted September 26, 2023.",2 +BGNE,Follicular Non-Hodgkin Lymphoma,Phase 2,6/9/23,"Phase 2 data presented at EHA reported that the OS rate at 24 months was 77.3%(zanubrutinib plus obinutuzumab) and 71.4% (obinutuzumab), with median OS not reached (zanubrutinib plusobinutuzumab) and 34.6 months, noted June 9, 2023.",2 +GOSS,Pulmonary arterial hypertension (PAH),Phase 2,7/25/23,"Phase 2 OLE data reported that 9 of 11 patients continued to improve, with a mean improvement of 9 PVR dual responders of 39%, and 3 patients reached a PVR below 200 dyne*s/cm5n, noted July 25, 2023.",2 +NBRV,Cystic fibrosis (CF),Phase 1,11/28/22,"Phase 1 top-line data reported that treatment was well-tolerated, noted November 28, 2022.",2 +CYTK,Amyotrophic lateral sclerosis (ALS),Phase 3,11/21/17,"Phase 3 data released November 21, 2017 - primary endpoint not met.",0 +INCY,COVID-19 associated cytokine storm,Phase 3,12/14/20,"Phase 3 top-line did not meet primary endpoint - December 14, 2020.",0 +NVS,Relapsed/Refractory B-Cell Acute lymphoblastic leukemia,Approved,8/30/17,"PDUFA date under priority review announced March 29, 2017. Approval announced early - August 30, 2017.",2 +BPTH,Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS),Phase 2,8/1/23,"Phase 2 interim analysis reported that in cohort 1, twelve of the fourteen evaluable patients (86%) achieved complete remission (CR/CRi) and two (14%) achieved partial remission (PR), and in cohort 2 eight of the fourteen evaluable patients (57%) achieved complete remission (CR/CRi), two (14%) achieved partial remission (PR) and three (22%) achieved stable disease, noted August 1, 2023.",2 +NVS,Migraine,Approved,5/17/18,"Approval announced May 17, 2018.",2 +IOBT,Non-muscle invasive bladder cancer (NMIBC),Phase 1,7/28/23,"Phase 1 dosing initiated, noted July 28, 2023.",1 +LNTH,Chronic pain,Approved,7/19/16,Approved July 19 2016.,2 +INCY,Steroid-refractory chronic GVHD (Graft versus host disease),Approved,9/22/21,"Approved September 22, 2021.",2 +CADL,Prostate Cancer (Active Surveillance),Phase 2,9/25/21,"Phase 2 safety data displayed 2 grade 4 events, and 3 hospitalizations due to inflection (n=365). The most common AE was flu-like symptoms reported by 21% of patients, noted September 25, 2021.",1 +INCY,COVID-19,Approved,5/11/22,"FDA approval on May 11, 2022.",2 +EIGR,Pulmonary arterial hypertension (PAH),Phase 2,1/16/18,"Phase 2 trial did not meet endpoints - January 16, 2018.",0 +HARP,Metastatic castration-resistant prostate cancer,Phase 1/2,5/19/21,Phase 1/2 data in ASCO abstract noted PSA and CTC reductions and treatment duration > 24 weeks in 15/62 patients.,2 +GILD,HIV,Approved,10/18/21,"Approved for pediatric patients October 18, 2021.",2 +RLYB,Paroxysmal nocturnal hemoglobinuria (PNH); Generalized Myasthenia Gravis (gMG),Phase 1,9/3/23,"Phase 1 multiple ascending trial data reported maximum exposures of greater than 1 µM and 3 µM, respectively, and greater than 99% reductions in free C5 concentrations, noted September 3, 2023.",2 +SNY,Pemphigus,Phase 3,10/29/21,"Phase 3 trial did not meet primary or key secondary endpoints, noted October 29, 2021.",0 +BIIB,Major depressive disorder (MDD),CRL,8/4/23,"CRL issued August 4, 2023.",1 +BMY,Ulcerative Colitis,Phase 2,10/7/21,"Phase 2 trial did not meet primary or secondary endpoints, October 7, 2021.",0 +MRK,BRCAm HER2-negative breast cancer,Approved,3/11/22,"Approved March 11, 2022.",2 +NVS,Adjuvant breast cancer,Phase 3,6/2/23,"Phase 3 data presented at ASCO significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups, noted June 2, 2023.",2 +ACRX,Moderate-to-severe acute pain following a surgical procedure,Approved,11/2/18,"FDA Approval announced November 2, 2018.",2 +BIIB,Lupus,Phase 2,12/3/19,"Phase 2 data met primary endpoint - December 3, 2019.",2 +CTMX,"Solid tumors / Diffuse large B-cell lymphoma (DLBCL), squamous non-small cell lung cancer (sqNSCLC), head and neck squamous cell carcinoma, and esophageal/gastro-esophageal junction (E/GEJ) cancer",Phase 2,12/20/21,"Phase 2 initial data reported an objective response rate of 18.8% and disease control rate of 87.5% in squamous non-small cell lung cancer. In advanced head and neck squamous cell carcinoma with objective response rate of 4.0 percent and disease control rate of 56.0 percent, noted December 20, 2021.",1 +ARDS,Cystic Fibrosis,Phase 2a,3/13/23,"Phase 2a trial met primary and secondary endpoints, noted March 13, 2023.",1 +GILD,Urothelial Cancer,Approved,4/13/21,"FDA approval announced April 13, 2021.",2 +ALLO,Multiple myeloma,Phase 1/2,12/13/21,"Additional Phase 1/2 data noted a 71% overall response rate (ORR) and that 46% of patients achieved a very good partial response or better (VGPR+) including 25% complete response or stringent complete response (CR/sCR), noted December 13, 2021.",2 +GMAB,Non-Hodgkin Lymphoma (NHL),Phase 1/2,12/14/21,"Phase 1/2 data reported that 25% of patients reported Grade 4 Neutropenia, with a 73% CMR and a 27% PMR, noted December 14, 2021.",1 +HCM,Non-small cell lung cancer (NSCLC),Phase 2,4/19/23,"Phase 2 poster reported that the median PFS with vs without clearance was 11.0 vs 4.1 months in pts with IHC90+ or FISH10+ tumors, noted April 19, 2023.",1 +INVA,Chronic obstructive pulmonary disease (COPD),Approved,9/18/17,"Approval announced September 18, 2017.",2 +NVS,Multiple sclerosis (MS),Approved,8/25/23,"Approved August 25, 2023.",2 +NVS,Solid tumors in adult and pediatric patients,Approved,6/22/22,"Approved June 22, 2022.",2 +VBIV,Hepatitis B vaccine,Phase 3,9/21/22,"Additional Phase 3 data reported that treatment may be effective only in low level HBsAg carriers with a low tolerizing effect of HBsAg, noted September 21, 2022.",2 +DNLI,Frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN),Phase 1/2,11/1/22,"Phase 1/2 part A interim results showed that single doses of treatment result in substantial increases in CSF progranulin levels suggesting brain delivery of DNL593 was achieved and has the potential to address progranulin deficiency, noted November 1, 2022.",2 +MRK,Cancer - first-line metastatic melanoma,Phase 3,4/6/18,"Phase 3 trial did not meet primary endpoint - noted April 6, 2018.",0 +LLY,Type 2 diabetes,Approved,2/21/20,"FDA Approval announced February 21, 2020.",2 +RCKT,Pyruvate Kinase Deficiency (PKD),Phase 1,5/19/23,"Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023.",2 +STOK,Dravet syndrome,Phase 1/2,7/25/23,"Additional Phase 1/2s safety data showed that it has been generally well-tolerated among 74 patients treated with single and multiple doses of 10mg to 70mg, noted July 25, 2023.",2 +RDHL,Gastroenteritis,Phase 3,6/14/17,"Phase 3 top-line data released June 14, 2017 - primary endpoint met.",2 +KOD,Diabetic Macular Edema (DME),Phase 3,10/13/23,"Phase 3 data presented at the Retina Society meeting reported that 1/2 of patients achieved 6-month dosing at the primary endpoint, noted October 13, 2023.",2 +IMMP,Non-small cell lung cancer; Head and neck cancer,Phase 2,11/3/23,"Additional biomarker results shared at SITC showed statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes, noted November 3, 2023.",2 +AZN,Chronic obstructive pulmonary disease (COPD),Approved,7/24/20,"FDA approval announced July 24, 2020.",2 +LRMR,Friedreich’s ataxia (FA),Phase 2,7/25/23,"FDA Phase 2 clearance for dose exploration trial and OLE trial, Initiation of open-label extension trial with 25 mg daily dosing expected in 1Q 2024, noted July 25, 2023. Phase 2 50mg cohort topline data expected 1H 2024. Phase 2 interim data expected 4Q 2024.",1 +ABBV,Upper Limb Spasticity,Approved,7/29/21,"FDA approval announced July 29, 2021.",2 +AZN,Ovarian cancer,Phase 3,3/12/20,Phase 3 trial did not meet primary endpoint.,0 +GSK,RSV vaccine,Approved,5/3/23,"FDA Approved on May 3, 2023.",2 +VRCA,Genital warts,Phase 2,11/10/20,"Phase 2 primary endpoint met - November 10, 2020.",2 KYMR,Cutaneous T-cell lymphoma (CTCL),Phase 1,9/18/23,"FDA granted Fast Track Designation in ongoing Phase 1 trial, noted September 18, 2023.",1 -ASRT,Neutropenia,Approved,9/9/22,"Approved September 9, 2022.",2 -WINT,COVID-19 / Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS),Phase 2,3/22/22,"Phase 2 data reported that treatment was safe and well tolerated with fast administration and considered feasible, noted March 22, 2022.",2 -ITCI,Schizophrenia,Approved,12/23/19,"FDA Approval announced December 23, 2019.",2 -KNTE,Solid Tumors,Phase 1,9/18/23,https://www.biopharmcatalyst.com/company/KNTE/news/159347,1 -INCY,Vitiligo,Phase 2,10/11/23,"Phase 2 trial initiated March 2021. Phase 2b study results shared at EADV reported that the total body depigmentation improvement from baseline as measured by the Total Vitiligo Area Scoring Index (T-VASI) at Week 52 for povorcitinib 15-to-75 mg, 45 mg, 75 mg and placebo-to-75 mg were 40.7%, 42.7%, 41.3% and 18.1%, respectively, noted October 11, 2023.",2 -ATHX,Acute Respiratory Distress Syndrome,Phase 1/2,2/2/22,"Phase 1/2 data reported a median 18.5 ventilator-free days compared to 6.5 days for placebo. 25% of the treatment group reported mortality compared to 40% in placebo, noted February 2, 2022.",2 -FSTX,Advanced malignancies,Phase 1,12/6/22,"Phase 1 interim data reported one complete response, 6 stable disease (SD), and 16 progressive disease, noted December 6, 2022.",1 -RHHBY,Hepatocellular carcinoma,Approved,5/29/20,"FDA Approval announced May 29, 2020.",2 -TBPH,Ulcerative Colitis,Phase 2b,8/23/21,"Phase 2b data did not meet primary endpoint - August 23, 2021.",0 -ZLDPF,Post bariatric surgery hypoglycemia,Phase 2,3/30/20,"Phase 2 data released March 30, 2020.",1 -RVNC,Cervical Dystonia,Approved,8/14/23,"Approved on August 14, 2023.",2 -SONN,Solid tumors,Phase 1,4/18/23,"Phase 1 data presented at AACR reported no dose limiting toxicities, and 5 of the first 14 patients (36%) have evidence of clinical benefit, noted April 18, 2023.",2 -HGEN,Chronic myelomonocytic leukemia (CMML),Phase 2,4/14/23,"Phase 2 preliminary study results reported that 6 subjects demonstrated clinical benefit, with ten grade 3/4 Serious Adverse Events, noted April 14, 2023.",2 -ZLAB,Non-small cell lung cancer (NSCLC) with a KRASG12C Mutation,Approved,12/13/22,"Approved December 13, 2022.",2 -AXLA,Non-alcoholic steatohepatitis (NASH) / non-alcoholic fatty liver disease (NAFLD),Phase 2b,9/29/22,"Additional Phase 2b data reported statistically significant improvements in the liver stiffness measurement (LSM) compared to placebo in the high dose arm for all subjects, noted September 29, 2022.",2 -JNJ,BRCA-positive mCRPC,Approved,8/11/23,"Approved August 11, 2023.",2 -BTAI,Adjunctive Treatment for Major Depressive Disorder (MDD) for At-Home Use,Phase 1b,5/16/23,"Phase 1b data topline data showed that BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically, noted May 16, 2023.",2 -BLCO,Dry Eye Disease Associated With Meibomian Gland Dysfunction,Approved,6/29/23,"Approved on May 18, 2023.",2 -BIIB,Alzheimer’s disease,Approved,6/7/21,"FDA approval announced June 7, 2021.",2 -REGN,Genetic hearing loss,Phase 1/2,10/26/23,"Phase 1/2 data reported that one patient experienced improvements in auditory responses through week 6 compared to baseline, noted October 26, 2023.",2 -EYEN,Mydriasis (office-based pupil dilation),Approved,11/2/23,"FDA supplemental approval on November 1, 2023.",2 -INO,HPV-associated squamous cell carcinoma of the head & neck (SCCHN),Phase 1,11/10/17,"Presentation at SITC Meeting - November 10, 2017.",2 -SNDX,Ovarian cancer,Phase 1/2,3/7/19,"Phase 2 top-line data March 7, 2019 failed to meet endpoints.",0 -REGN,Nonproliferative Diabetic Retinopathy,Approved,5/13/19,"FDA Approval announced May 13, 2019.",2 -RIGL,COVID-19,Phase 2,8/13/21,"Announced August 12, 2021 that data are insufficient for FDA emergency use authorization (EUA).",0 -SNPX,Alzheimer's disease,Phase 2b,9/9/23,"Phase 2b data presented at IBRO reported that nearly all pre-specified secondary endpoints were achieved with statistical significance in the server cohort, noted September 9, 2023.",2 -INCY,Treatment-naïve acute GVHD,Phase 3,1/2/20,"Phase 3 trial did not meet primary endpoint - January 2, 2020.",0 -OLMA,"HR+, HER2- Breast Cancer",Phase 1/2,10/22/23,"Phase 1/2 monotherapy data presented at ESMO reported that the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52%, noted October 22, 2023.",2 -TNGX,Solid Tumors,Phase 1,7/24/23,"IND cleared by FDA, noted April 3, 2023. Phase 1/2 dosing initiated, noted July 24, 2023.",1 -SAVA,Alzheimer’s disease,Phase 2b,9/22/21,"Phase 2b open label data showed ADAS-Cog11 scores improved an average of 3.2 points from baseline, 68% (n=50) improved on ADAS-Cog at 12 months, an average of 6.8 points. 20% declined less than 5 points on ADAS-Cog at 12 months, an average of 2.5 points, noted September 22, 2021.",2 RHHBY,Diabetic Macular Edema,Approved,1/28/22,"FDA Approval announced January 28, 2022.",2 -VERA,IgA nephropathy (IgAN),Phase 2a,11/5/22,"Phase 2a final data presented at the American Society of Nephrology Kidney Week reported that atacicept reduced immune complex levels in patients with IgA nephropathy (IgAN), noted November 5, 2022.",2 -BIVI,Alzheimer's disease,Phase 2,12/5/22,"Additional Phase 2 data reported that 18 of 22 patients with abnormal baseline scans showed improvement in one or more brain regions as seen from advanced functional MRI studies, noted December 5, 2022.",2 -AZN,Breast cancer,Approved,1/12/18,"Approval announced January 12, 2018.",2 -NBRV,Moderate to severe Community Acquired Bacterial Pneumonia (CABP),Approved,8/19/19,"FDA approval announced August 19, 2019.",2 -TAK,Frontline CD30-positive mature T-cell lymphomas - cancer,Approved,11/16/18,"FDA Approval announced November 16, 2018.",2 -JAZZ,Excessive sleepiness associated with obstructive sleep apnea,Phase 3,3/20/17,"Phase 3 data released March 20, 2017 - primary endpoints met.",2 -ZYNE,Developmental and Epileptic Encephalopathies (DEE),Phase 2,9/18/19,"Phase 2 top-line data released September 18, 2019. 10/46 reported a serious adverse event (SAE).",0 -NBIX,Classic congenital adrenal hyperplasia (CAH),Phase 2,6/13/22,"Phase 2 data reported that median percent reductions ranged from -57.1% to -76.2% and a greater than 50% reduction from baseline for ACTH, 17-OHP, and androstenedione (males and females), testosterone (females), and androstenedione/testosterone ratio (males) was achieved by 63%, 75%, 50%, 60%, and 67% of participants, respectively, noted June 13, 2022.",2 -LLY,Obesity,Phase 2,6/26/23,"Phase 2 24-week data met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5%. In a secondary endpoint, retatrutide showed a mean weight reduction up to 24.2% at 48 weeks, noted June 26, 2023.",2 -GSK,HIV,Approved,11/21/17,"Approval announced November 21, 2017.",2 -NVS,Chronic spontaneous urticaria (CSU),Phase 2,10/27/21,"Phase 2 trial met primary endpoint, noted October 27, 2021.",2 -AKBA,ARDS in subjects with COVID-19 and hypoxemia,Phase 2,8/4/22,"Phase 2 trial data reported that at Day 14, the proportions of subjects who had a 6, 7 or 8 on the NIAID-OS were 13.3% for vadadustat versus 16.9% for placebo, missing its primary endpoint, noted August 4, 2022.",1 -ABBV,Atopic Dermatitis,Approved,1/14/22,"Approved January 14, 2022.",2 -LIAN,Demodex Blepharitis,Approved,7/25/23,"FDA approved on July 25, 2023.",2 -CHRS,Nasopharyngeal carcinoma (NPC),Approved,10/27/23,"FDA Approval on October 27, 202",2 -MIST,Paroxysmal supraventricular tachycardia (PSVT),Phase 3,11/7/22,"Phase 3 additional data reported that median time to conversion was 17 minutes for patients treated with etripamil, three times faster than placebo, noted November 7, 2022.",2 -NRIX,Solid tumors,Phase 1a,11/10/22,"Phase 1a biomarker and safety reported dose-responsive target engagement and a mean half-life of 6 to 8 hours at doses ranging from 5 mg to 50 mg, noted November 10, 2022.",1 +RHHBY,Multiple sclerosis (MS),Phase 2,10/13/23,"Phase 2 showed that fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS). More than 90% relative reduction in new/enlarging T2 lesions and new T1 gadolinium-enhancing (Gd+) lesions with fenebrutinib beginning at eight week, noted October 13, 2023.",2 +CRNX,Congenital adrenal hyperplasia and Cushing’s disease,Phase 1,5/25/22,"Data from MAD cohort results showed serum cortisol below normal levels and a marked reduction in 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations, noted May 25, 2022.",2 +ZLAB,Generalized Myasthenia Gravis (gMG),Approved,6/20/23,"FDA Approved on June 20, 2023.",2 +CALT,Alport Syndrome,Phase 2,9/27/23,"Phase 2 to be intiated in 4Q 2023. FDA granted Orphan Drug Designation, noted September 27, 2023.",1 +REGN,Fibrodysplasia ossificans progressiva (FOP),Phase 2,1/9/20,Phase 2 trial did not meet primary endpoint p=0.07. Patient-reported flare-ups were reduced by 50% (nominal p=0.03).,0 +AKBA,Iron deficiency anemia in non-dialysis dependent CKD patients,Approved,11/7/17,"sNDA FDA Approval announced November 7, 2017.",2 +ZLAB,Ovarian cancer,Phase 3,6/1/23,"Phase 3 data reported a complete and partial responses, both confirmed, were observed in 12 (25.5%) and 15 (31.9%) niraparib-treated patients and 3 (11.5%) and 5 (19.2%) placebo-treated patients, respectively, leading to a confirmed ORR of 57.4% with niraparib and 30.8% with placebo, noted June 1, 2023.Phase 3 data reported a complete and partial responses, both confirmed, were observed in 12 (25.5%) and 15 (31.9%) niraparib-treated patients and 3 (11.5%) and 5 (19.2%) placebo-treated patients, respectively, leading to a confirmed ORR of 57.4% with niraparib and 30.8% with placebo, noted June 1, 2023.",2 +PFE,Atopic dermatitis in adolescents,Approved,2/10/23,"Approved February 10, 2023.",2 +AGEN,"Solid tumors, melanoma",Phase 1,6/3/23,"Phase 1 data at ASCO reported an overall response rate (ORR) was 11% (n=2); 37% had SD (n=7) resulting in a disease control rate (DCR) (CR, PR or SD) of 47%, noted June 3, 2023.",1 +SCLX,Acute lower back pain (LBP),Phase 2,9/14/23,"Phase 2 data reported that none of the subjects in the active group and 3 (8.1%) subjects in placebo group had AEs of special interest, with a meaningful reduction of pain over the first week, noted September 14, 2023.",2 +ZLAB,Non-small cell lung cancer (NSCLC),Phase 3,10/16/23,"Phase 3 data from ESMO abstract reported that quality of life data showed no statistically significant difference between patients who received TTFields therapy together with standard systemic therapies, noted October 16, 2023.",2 +KNSA,Pericarditis,Approved,3/18/21,"FDA approval announced March 18, 2021.",2 +ALGS,HBeAg-positive chronic hepatitis B (CHB),Phase 1b,6/21/23,"Additional Phase 1b data presented at EASL demonstrated multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks, noted June 21, 2023.",2 +TNXP,fibromyalgia-type Long COVID,Phase 2,9/5/23,"Phase 2 topline data did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at Week 14, noted September 5, 2023.",2 +REGN,Homozygous familial hypercholesterolemia (HoFH) in children,Approved,3/22/23,"Approved March 22, 2023.",2 +TPST,Solid Tumors,Phase 1,5/25/23,"Phase 1 monotherapy and combination data from abstract reported a disease control rate (DCR) by RECIST v1.1 was 44% for patients on monotherapy TPST-1495 and 40.9% for patients on TPST-1495 with pembrolizumab, noted May 25, 2023.",1 +DCPH,Gastrointestinal Stromal Tumors (GIST) - second-line,Phase 3,6/1/23,"Phase 3 data reported that the mPFS (90% CI) by IRR was 6.44 (2.89, 8.31) months and ORR was 21.1%, noted June 1, 2023.",1 +IMMP,Solid tumors,Phase 1,10/24/23,"Phase 1 additional efficacy and tolerability data reported at ESMO showed strong 71.4% Overall Response Rate, 90.5% Disease Control Rate, 10.1-month median Progression Free Survival (PFS), and median Overall Survival (OS) that has not been reached, despite 81% of patients having low or negative PD-L1 expression, noted October 24, 2023.",2 +BIIB,Parkinson's disease,Phase 2,2/3/21,"Phase 2 trial did not meet primary endpoint - February 3, 2021.",0 +RHHBY,1L Extensive-Stage Small Cell Lung Cancer,Phase 3,6/7/22,"Phase 3 results noted that the combination did not provide benefit in patients with untreated ES-SCLC, noted June 7, 2022.",2 +INCY,Graft versus host disease,Approved,5/24/19,"FDA approval announced May 24, 2019.",2 +MREO,Solid tumors,Phase 1/2,11/30/21,"Phase 1b/2 interim data showed that the dose was well tolerated with a favorable safety profile. One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set",2 +BMY,Beta-thalassemia,Approved,11/8/19,"FDA Approval announced November 8, 2019.",2 AZN,Head & neck cancer,Phase 3,2/5/21,"Phase 3 trial did not meet the primary endpoint - February 5, 2021.",0 -AUTL,Pediatric Acute lymphoblastic leukemia (ALL),Phase 1,9/5/23,"Phase 1 data presented at the Blood journal showed that of 10 responding patients, 5 had emergence of MRD (2) or frank relapse (3) with CD19 and CD22 expressing disease associated with loss of CAR T-cell persistence. Importantly, there were no cases of relapse due to antigen-negative escape, with a median follow-up of 8.7 months. Overall survival was 75% at 6 and 12 months. Six and 12-month event free survival (EFS) were 75% and 60% respectively, noted September 5, 2023.",2 -OCGN,COVID-19 (within U.S.),Phase 2/3,1/9/23,"Phase 2/3 Immuno-bridging and Broadening study met both co-primary endpoints, noted January 9, 2023.",1 -ZLAB,Gastric and gastro-esophageal junction cancer,Phase 3,7/14/23,"Trial in China initiated, noted July 14, 2023.",1 -CARA,Pruritus in patients with Atopic dermatitis,Phase 2,3/28/22,"Phase 2 presentation at AAD reported that within a sub-study treatment altered expression of multiple individual pruritus- and AD-related genes, noted March 28, 2022.",2 -ZURA,Primary Sjogren's Syndrome,Phase 2,1/27/22,"Phase 2 study withdrawn noted January 27, 2022.",1 -DNLI,Healthy Volunteers,Phase 1,10/6/21,"Phase 1 data noted that treatment was well tolerated for up to 14 days of dosing, with robust distribution in the central nervous system (CNS) and predictable dose-related increases in exposure with a PK profile supporting once daily dosing, noted October 6, 2021.",2 -AZN,Pancreatic cancer,Approved,12/30/19,"FDA Approval announced December 30, 2019.",2 -ARWR,"Familial chylomicronemia syndrome (FCS), Hypertriglyceridemia",Phase 1/2,11/15/21,"Phase 1/2 date reported APOC3 was reduced by 98% in FCS patients and 96% in MCM patients. Both groups showed similar maximum median reductions in TG of 91% and 90%, respectively, noted November 15, 2021.",2 -CYTH,Niemann-Pick Disease Type C,Phase 1,10/18/22,"Phase 1 data showed that treatment overcomes the NPC1 defect by removing trapped cholesterol from cells both systemically and in the central nervous system (CNS), noted October 18, 2022.",2 -AVIR,COVID-19,Phase 2,4/25/23,"Fast Track Designation granted on April 25, 2023.",1 -ADMP,Emergency treatment of anaphylaxis,Approved,6/15/17,"CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.",2 -LLY,Primary Sjogren's Syndrome,Phase 2,1/27/22,"Phase 2 study withdrawn noted January 27, 2022.",1 -IPSEY,Fibrodysplasia ossificans progressiva (FOP),Approved,8/16/23,"FDA Approved on August 16, 2023.",2 -SNSE,Various cancers,Phase 1,11/4/23,"Phase 1 safety data reported that a total of 11 adverse events (including one serious adverse event not considered related to SNS-101) was reported in five patients, with no dose-limiting toxicities observed, noted November 4, 2023.",2 -INTS,Advanced Soft Tissue Sarcoma,Phase 2,9/7/23,"Orphan Drug Designation granted by the FDA noted Septemeber 7, 2023.",1 -TRVI,Prurigo Nodularis (PN),Phase 2/3,10/13/23,"Phase 2/3 long-term data also supports the continued effectiveness of Haduvio in reducing itch over 52 weeks for the participants who remained in the study, noted October 13, 2023.",2 -GSK,Systemic lupus erythematosus (SLE),Approved,7/21/17,"Approval announced July 21, 2017.",2 -PTPI,Erectile Dysfunction,Approved,4/27/12,"Approved April 27, 2012.",2 -BCLI,Progressive Multiple Sclerosis (MS),Phase 2,3/24/21,"Phase 2 top-line data released March 24, 2021 - safety primary endpoint met.",2 -MRK,Cancer - first-line metastatic melanoma,Phase 3,4/6/18,"Phase 3 trial did not meet primary endpoint - noted April 6, 2018.",0 -RDHL,COVID-19 (outpatients),Phase 2/3,1/3/23,"Phase 2 trial met primary endpoint, noted January 3, 2023.",1 -ATRA,Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT),Phase 3,11/4/21,"Phase 3 data reported a 50% objective response rate (ORR), noted November 4, 2021.",1 -FULC,COVID-19,Phase 3,3/4/21,"Phase 3 trial to be discontinued - March 4, 2021.",0 -ACAD,Parkinson‚Äôs disease psychosis (PDP),Approved,4/29/16,"Approved April 29, 2016.",2 -KPRX,Later-stage Retinitis Pigmentosa,Phase 2,4/27/23,"Phase 2 interim results presented at ARVO reported patient-reported improvement in the ability to perceive a contrast between light and dark at days seven 14 and 29, noted April 27, 2023.",2 -JNJ,Plaque psoriasis,Approved,2/27/19,"Approval announced February 27, 2019.",2 -BGNE,Gastric / Gastroesophageal Junction Cancer,Phase 2,6/5/23,"Phase 2 data shared at ASCO reported that the median overall survival (OS) was 19.5 months and median progression-free survival (PFS) was 11.3 months, noted June 5, 2023.",1 -NBIX,Tourette syndrome - juvenile,Phase 2b,12/12/18,"Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.",0 -VIRX,Epstein Barr Virus-associated cancers,Phase 2,10/4/23,"Phase 2 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study demonstrated median duration of response extended to 17.3 months, noted October 4, 2023.",2 -BHVN,Focal Epilepsy,Phase 1,9/5/23,"Examination of EEG in healthy subjects administered single doses confirmed central nervous system (CNS) activity consistent with effects observed with other antiseizure medications, noted September 5, 2023.",2 -HCM,Solid Tumors,Phase 2,5/25/23,"Additional data from ASCO reported that among evaluable radioactive iodine-refractory differentiated thyroid cancer patients, median PFS was 10.9 months and median OS was not reached, and in endometrial cancer patients, the median PFS was 5.4 months and 12-month OS rate was 71.0%, noted May 25, 2023.",2 -BMY,Non-small cell lung cancer (NSCLC),Approved,3/4/22,"Approved March 4, 2022.",2 -ASMB,Hepatitis B,Phase 1b,12/19/22,"Phase 1b data reported that in the cohort of 50 mg, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNA, noted December 19, 2022.",2 -GSK,Shingles,Approved,10/20/17,"Approval announced October 20, 2017.",2 -AYTU,Attention deficit hyperactivity disorder (ADHD),Approved,6/19/17,"Approval announced June 19, 2017.",2 -SRPT,Duchenne muscular dystrophy,Phase 3,10/14/22,"Phase 3 results presented at the World Muscle Society reported that mean dystrophin levels significantly increased from baseline after 48 weeks of casimersen treatment, noted October 14, 2022.",2 -PPBT,Squamous cell carcinoma of the head & neck (SCCHN),Phase 1/2,10/3/23,"Phase 1/2 data showed that 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial response, noted October 3, 2023.",2 -MRK,"Stage IB, II or IIIA non-small cell lung cancer (NSCLC)",Approved,1/27/23,"Approved January 27, 2023.",2 -GRCL,Relapsed/refractory multiple myeloma (RRMM),Phase 1,9/10/23,"Phase 1 updated data at EHA demonstrated 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk RRMM population, noted June 10, 2023.",2 -GSK,Multiple Myeloma,Phase 3,11/7/22,"Phase 3 trial did not meet its primary endpoint, noted November 7, 2022.",2 -BHVN,Amyotrophic lateral sclerosis (ALS),CRL,7/19/19,"CRL issued July 19, 2019.",1 -AMRX,Metastatic non-squamous non-small cell lung cancer,Approved,6/14/23,"FDA 505(b)(2) Approval on June 14, 2023.",2 -JNJ,Diabetic Kidney Disease,Approved,9/30/19,"FDA Approval announced September 30, 2019.",2 -AZN,Non-squamous non-small cell lung cancer (NSCLC),Phase 2,9/11/22,"Phase 2 data to be presented at ESMO demonstrated continued durable activity across patient subtypes, noted September 11, 2022.",2 -FATE,Relapsed/refractory Multiple Myeloma,Phase 1,12/12/22,"Phase 1 data presented at ASH reported that one patient in Regimen A achieved a partial response, and one patient achieving a minor response in regimen B, noted December 12, 2022.",2 -ABBV,Multiple myeloma,Phase 3,12/13/21,"Phase 3 overall survival results reported that there were 78 (40%) deaths in the treatment arm versus 36 (37%). Median OS was not reached in the treatment or placebo arm among all patients, noted December 13, 2021.",0 -PRTA,Psoriatic Arthritis,Phase 1b,9/28/17,"Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development.",0 -ADGI,COVID-19 (treatment),Phase 2/3,9/29/21,"Phase 2/3 new data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads, noted September 29, 2021.",2 -BIOR,Ulcerative Colitis (UC),Phase 1a,9/25/23,"IND submitted to FDA, noted September 25, 2023.",1 -SRNE,Acute lower back pain (LBP),Phase 2,9/14/23,"Phase 2 data reported that none of the subjects in the active group and 3 (8.1%) subjects in placebo group had AEs of special interest, with a meaningful reduction of pain over the first week, noted September 14, 2023.",2 -MEIP,High-risk Myelodysplastic Syndrome (MDS),Phase 2,5/31/18,"Phase 2 commencement of dosing announced June 14, 2017 - analysis from first stage released May 31, 2018 - trial to expand enrollment.",1 -RHHBY,Diffuse Large B-Cell Lymphoma,Approved,4/19/23,"FDA Approved on April 19, 2023.",2 -CRVS,Peripheral T-cell lymphoma (PTCL),Phase 1b,6/15/23,"Phase 1/1b antitumor response data presented at the ICML demonstrated the potential of ITK inhibition to provide a novel immunotherapy mechanism of action for cancer therapy, noted June 15, 2023. Company plans to meet with FDA during 3Q 2023 to discuss Phase 3 design.",2 -GILD,Acute Myeloid Leukemia (AML),Phase 1/2,8/21/23,"Partial hold on enrollment by FDA, noted August 21, 2023.",1 -AZN,Asthma,Phase 2a,6/21/23,"Phase 2a AstraZeneca communicated to Pieris its decision to discontinue and cease dosing in the ongoing clinical studies, the decision was based on lung findings from a non-clinical 13-week GLP toxicology study, which are not a concern for the active clinical studies but do not support long-term use and progression to later-stage development, noted June 21, 2023.",0 -ABBV,Migraine,Approved,12/23/19,"FDA Approval announced December 23, 2019.",2 -EBS,Chikungunya virus,Phase 2,11/22/19,"Phase 2 interim analysis noted 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) within seven days after vaccination - November 22, 2019.",2 -REGN,Coronavirus COVID-19,Phase 3,9/1/20,"Phase 3 global trial did not meet primary endpoint - September 1, 2020.",0 -LABP,Ulcerative Colitis,Phase 2,10/4/21,"Phase 2 data displayed clinical remission in 36.1% of the 880 mg group and 35.5% of the 440 mg group during the blinded maintenance phase. Both dose cohorts had 10% of patients report an AE of ulcerative colitis worsening, noted October 4, 2021.",2 -COLL,Pain,Approved,10/25/15,"Approved October 26, 2015.",2 -NVO,Type 2 diabetes,Phase 3,10/3/22,"Phase 3a trial met primary endpoint, noted October 3, 2022.",1 +HALO,Rheumatoid arthritis (RA),Approved,10/14/13,"Approved Oct 14, 2013.",2 +AZN,Eosinophilic Esophagitis,Phase 3,10/25/22,"Phase 3 data reported that trial did not meet one of the two dual-primary endpoints, noted October 25, 2022.",2 +COLL,Opioid dependence,Approved,6/6/14,"Approved June 6, 2014.",2 +RVNC,Upper limb spasticity,Phase 2,2/22/21,"Phase 2 top-line data released February 22, 2021. One of two co-primary endpoints met (one missed due to reduced enrollment).",2 +REGN,Non-small cell lung cancer (NSCLC),Approved,2/22/21,"FDA approval announced February 22, 2021.",2 +ABBV,Rheumatoid arthritis,Approved,8/16/19,"FDA Approval announced August 16, 2019.",2 +ACOR,OFF episodes of Parkinson’s disease (PD),Approved,12/24/18,"FDA Approval announced December 22, 2018.",2 +AZN,Asthma and comorbid nasal polyps,Phase 3,9/5/21,"Phase 3 data showed an 86% reduction in the annualized asthma exacerbation rate (AAER) September 5, 2021.",2 +KYMR,Hidradenitis suppurativa / atopic dermatitis,Phase 1,12/14/22,"Phase 1 data reported that a 37% mean reduction in EASI in AD and 42% of HS patients has AN Count 0/1/2, noted December 14, 2022.",2 NKTR,Opioid-induced constipation (OIC),Approved,9/16/14,"Approved September 16, 2014.",2 -CBAY,Primary biliary cholangitis (PBC),Phase 3,9/7/23,"Phase 3 registration trial achieved the primary and all key secondary endpoints, noted on September 7, 2023.",2 -UTHR,Pulmonary Arterial Hypertension,Phase 2,7/10/17,"Phase 2 data released July 10, 2017. Primary endpoint met. Secondary missed.",1 -NVS,"Non-small cell lung cancer (NSCLC), adjuvant",Phase 3,8/15/22,"Phase 3 trial did not meet the primary endpoint, noted August 15, 2022.",2 -CGTX,Geographic Atrophy Secondary to Dry Age-related Macular Degeneration (AMD),Phase 1,7/11/23,"Phase 2 trial dosing initiated, noted July 11, 2023.",1 -MESO,ARDS due to COVID-19,Phase 3,4/29/21,"Remestemcel-L reduced mortality through day 60 by 46% in the pre-specified group below age 65, but not in patients 65 or older.",2 -GMDA,Follicular and diffuse large B cell lymphomas,Phase 1,10/17/23,"Phase 1 data showed promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma, noted October 16, 2023.",2 +RIGL,Immune Thrombocytopenic Purpura (ITP),Approved,4/17/18,"Approved April 17, 2018.",2 +RHHBY,Duchenne muscular dystrophy,Phase 3,10/30/23,"Phase 3 trial results showed that participants treated with ELEVIDYS (delandistrogene moxeparvovec-rokl) showed an increase on the North Star Ambulatory Assessment, a measure of motor function, compared to placebo-treated patients at 52 weeks, although the primary endpoint was not met, noted October 30, 2023.",2 +TEVA,Tardive dyskinesia (TD),Approved,2/17/23,"FDA Approval on February 17, 2023.",2 +MRK,Ovarian Cancer,Phase 1/2,6/6/22,"Results from Phase 1 and Phase 2 expansion cohort presented at ASCO reported that G3/G2 immune-related AE and injection site reactions were observed in 1/1 and 1/3 pts treated at DL1, and in 1/0 and 2/2 pts at DL2, respectively. At Phase 1, one patient with MSI-High clear cell subtype had an ongoing CR after 26 months of follow-up, 2 patients had PR and 6 SD. There were 1 PR and 3 SD on P2EC, of which 1 and 2, respectively, achieved response greater than 12 weeks, noted June 6, 2022.",2 +HCM,Primary immune thrombocytopenia (ITP),Phase 3,8/21/23,"Phase 3 trial met is primary endpoint, noted August 21, 2023.",1 +ALPMY,Nonmetastatic Prostate Cancer (nmCSPC),Phase 3,5/1/23,"Additional Phase 3 data reported that treatment reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, noted May 1, 202",2 +RHHBY,Diffuse Large B-Cell Lymphoma,BLA Filing,3/10/23,"Advisory committee meeting voted 11 to 2 in favor of approval, noted March 10, 2023.",2 +ANIP,Menopause symptoms,Approved,9/12/23,"Approved September 12, 2023.",2 +VERA,IgA Nephropathy,Phase 2b,6/17/23,"Phase 2b 36-week presented at ERA 2023 showed that atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population. Phase 3 initiated on June, noted June 17, 2023.",2 +XFOR,Severe Congenital Neutropenia (SCN),Phase 2,8/10/23,"Phase 2 data reported that three participants receiving G-CSF and once-daily oral mavorixafor showing robust increases in ANC, maintenance of ANC levels in the normal range, and the ability to reduce G-CSF dose earlier than anticipated, noted August 10, 2023.",2 +IONS,Hereditary Angioedema (HAE),Phase 2,2/21/23,"Phase 2 open-label study data reinforce the treatment's potential to be a best-in-class prophylactic treatment for patients living with hereditary angioedema, noted February 21, 2023.",2 +ADVM,Diabetic macular edema (DME),Phase 2,10/9/21,"Phase 2 data from trial (June 22, 2021, cutoff date, n=34) at ASRS demonstrated that dose and disease state appear to have an impact in determining the therapeutic window which balances efficacy and safety. Dose-dependent inflammation observed may be in part related to the study population which included patients with severe vascular and renal disease. Further drug development will focus on wet AMD and low doses (2 x 10^11 vg/eye and lower) - noted October 9, 2021",1 +CANF,Pancreatic Cancer,Phase 1a,6/13/23,"Preclinical studies demonstrated robust effect reached 90% inhibition of pancreatic cancer growth, IND underway, noted June 13, 2023.",2 +BIIB,Alzheimer’s disease,Phase 3,9/13/19,Phase 3 trial discontinued due to unfavorable risk-benefit ratio.,0 +GSK,Meningococcal disease,Approved,10/17/22,"Approved October 17, 2022.",2 +VSTM,Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma,Approved,9/24/18,"FDA Approval announced September 24, 2018.",2 +KROS,Pulmonary arterial hypertension (PAH) and disorders associated with bone loss,Phase 2,5/22/23,"Phase 2 biomarker reported that treatment led to changes in serum proteins involved in structural remodeling pathways and inflammation consistent with that seen in preclinical studies, noted May 22, 2023.",2 +SUPN,ADHD,Approved,4/2/21,"FDA approval announced April 2, 2021.",2 +ZLDPF,Severe hypoglycemia in diabetes,Approved,3/22/21,"FDA approval announced March 22, 2021.",2 +LEGN,Multiple myeloma,Approved,2/28/22,"Approved February 28, 2022.",2 +PFE,Respiratory syncytial virus (RSV) vaccine,Approved,6/1/23,"Approved June 1, 2023.",2 +ZLAB,Gastrointestinal Stromal Tumors (GIST) - second-line,Phase 3,6/1/23,"Phase 3 data reported that the mPFS (90% CI) by IRR was 6.44 (2.89, 8.31) months and ORR was 21.1%, noted June 1, 2023.",1 +ATOS,Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer,Phase 2,6/12/23,"Phase 2 enrollment of Pharmacokinetic Run-In cohort completed, noted June 12, 2023.",1 +RVMD,"Pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer.",Phase 1,9/19/23,"Phase 1 dosing initiated, noted Septemeber 19, 2023.",1 +ABBV,Crohn's disease,Phase 3,10/16/23,"Phase 3 data reported that the trial met all primary and secondary endpoints, noted October 16, 2023.",1 +BPMC,Advanced Systemic mastocytosis (SM),Phase 1,12/12/22,"Phase 1 data reported that 17 (25%) patients had disease progression, including 7 who progressed to acute myeloid leukemia. Median OS was NR in all AdvSM, ASM, and MCL, and was 46.9 months, noted December 12, 2022.",1 +JSPR,Sickle Cell Disease and Beta Thalassemia,Phase 1/2,2/16/23,"Phase 1/2 follow up data reported that two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up, noted February 16, 2023.",2 +ZLDPF,Post bariatric surgery hypoglycemia,Phase 2,3/30/20,"Phase 2 data released March 30, 2020.",1 +MTEM,Solid tumors,Phase 1,11/2/23,"Phase 1 dosing initiated, noted November 2, 2023.",1 +RETA,Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH,Phase 3,3/30/20,Phase 3 trial stopped following DSMB recommendation. Primary endpoint unlikely to be met.,0 +IONS,ATTR Amyloidosis,Phase 3,3/27/23,"Phase 3 66-week data reported that trial met all three primary endpoints, noted March 27, 2023.",1 +GLPG,Ulcerative Colitis,Phase 2,7/14/21,"Phase 2 data released July 14, 2021. No differentiation from placebo.",0 +AMGN,Immune Thrombocytopenia (Pediatric),Approved,12/14/18,"FDA approval announced December 14, 2018.",2 +IVA,Psoriasis,Phase 2b,10/31/22,"Development stopped noted October 31, 2022.",0 +LIFE,COVID-19,Phase 2,1/4/21,"Phase 2 data released January 4, 2021. Primary safety endpoint met. Median time to recovery of 5.5 days compared to 6 days in the placebo group.",2 +TRDA,Duchenne Muscular Dystrophy (DMD),Phase 1,9/21/23,"Phase 1 trial initiated, noted September 21, 2023.",1 +AMLX,Amyotrophic lateral sclerosis (ALS),Approved,9/29/22,"Approved September 29, 2022.",2 +BMY,Urothelial Carcinoma,Approved,8/20/21,"FDA approval announced August 20, 2021.",2 +PBYI,Extended adjuvant HER2-positive early stage breast cancer,Approved,7/17/17,"Approval announced July 17, 2017.",2 +MRK,Pulmonary arterial hypertension (PAH),Phase 2,5/19/21,"Phase 2 update at the American Thoracic Society 2021 International Conference May 19, 2021. Generally well tolerated, improvements in resting and exercise hemodynamics at week 24 shown.",2 +CKPT,Non-small cell lung cancer (NSCLC),Phase 1/2,9/25/18,"Phase 1/2 preliminary data released September 24, 2018.",1 +NTLA,Hereditary angioedema (HAE),Phase 1/2,6/11/23,"Phase 1/2 updated safety and efficacy data to be presented at EAACI showed that after a single dose of investigational CRISPR-based therapy, patients living with hereditary angioedema experienced durable elimination of their attacks, noted June 11, 2023.",2 +ALKS,Recurrent or metastatic head and neck squamous cell carcinoma,Phase 2,11/13/21,"Phase 2 data showed that combination therapy was generally well tolerated (n=14), 8 had no prior response to dosing and 6 had previous best response of SD or PR. Mean (SD±) age was 62±12; AE were consistent with those observed with intravenous studies. Peripheral immune cell expansion profiles are comparable to that observed with the same regimen.",2 +CALC,Wet age-related macular degeneration,Phase 2b,11/15/21,"Additional Phase 2b data reported that the anatomical control was similar to aflibercept over 18 months with BCVA maintained in extension study, noted November 15, 2021.",1 +AMRX,Parkinson's disease,CRL,7/3/23,"CRL issued by the FDA on July 3, 2023.",1 +CORT,Cushing's Syndrome,Approved,2/17/12,"Approved February 17, 2012.",2 +GSK,Asthma,Approved,9/9/20,"FDA approval announced September 9, 2020.",2 +RHHBY,Neovascular age related macular degeneration (nAMD),Phase 3,1/25/21,"Phase 3 trial met primary endpoint - January 25, 2021.",2 +VNDA,Motion sickness,Phase 3,5/25/23,"Phase 3 data reported that the 170 mg and 85 mg tradipitant doses were shown to be superior to placebo in preventing vomiting with only 18.3% and 19.5% of participants experiencing vomiting on tradipitant 170 mg and 85 mg respectively, as compared to 44.3% of participants on placebo, noted May 25, 2023.",2 SNY,Atopic dermatitis,Approved,3/28/17,"Approved under priority review - March 28, 2017.",2 -LEGN,Molluscum Contagiosum,Phase 3,9/23/21,"Phase 3 safety data showed TEAEs reported in greater than 5% of subjects in the SB206 treated groups were all at the application site (pain, erythema, pruritis, exfoliation, and dermatitis) with the high majority of these TEAEs being mild or moderate by severity, noted September 23, 2021.",2 -YMAB,Neuroblastoma,Approved,11/25/20,"FDA approval announced November 25, 2020.",2 -OTIC,Acute otitis externa,Approved,3/2/18,"Approval announced March 2, 2018.",2 -VTRS,Trastuzumab biosimilar,Approved,12/1/17,"Approval announced December 1, 2017.",2 -RHHBY,First line unfit AML,Approved,11/21/18,"FDA approval announced November 21, 2018.",2 -JAZZ,Multiple sclerosis (MS)-related spasticity,Phase 3,6/28/22,"Phase 3 trial did not meet the primary endpoint, noted June 28, 2022.",2 -EWTX,Becker muscular dystrophy (BMD),Phase 1b,6/26/23,"Phase 1b 12-month study supported the hypothesis that a reduction in contraction-induced muscle damage in muscular dystrophies, associated with administration, has the potential to preserve and improve muscle function while preventing disease progression in dystrophinopathies, noted June 26, 2023.",2 -AXGN,Severed peripheral nerves,Phase 3,5/4/22,"Phase 3 trial met primary endpoint, noted May 4, 2022.",1 -VINC,Hematologic malignancies,Phase 1,9/14/23,"IND cleared August 22, 2023. Phase 1 study dosing commenced, noted on September 14, 2023.",1 -NVS,Post-acute myocardial infarction,Phase 3,10/26/21,"Phase 3 did not meet primary endpoint, trial will not continue to regulatory submission, noted October 26, 2021.",0 -KURA,Head and Neck Squamous Cell Carcinoma,Phase 1/2,10/26/22,"Phase 1/2 data reported that one patient experienced experienced an 81% reduction in target lesions after one cycle, noted October 26, 2022.",2 -VCNX,Resectable Stage III melanoma,Phase 1,11/10/22,"Phase 1 data presented at SITC showed that 100% of patients who received the triple combination were recurrence free at 24 months. This contrasted with recurrence free survival of less than 40% in patients who received the dual combination of pepinemab and nivolumab or pepinemab and ipilimumab, noted November 10, 2022.",2 -NKTR,Bronchiectasis,Phase 3,4/5/17,"Phase 3 second trial did not meet endpoint - April 5, 2017.",0 -BNTX,COVID-19 Vaccine (Omicron Booster),Approved,9/11/23,"FDA booster approved on September 11, 2023.",2 -GALT,Non-alcoholic steatohepatitis (NASH) with cirrhosis,Phase 2/3,10/3/23,"4th DSMB concluded that NAVIGATE can continue as designed, without modifications, noted October 3, 2023.",1 -HOOK,HPV16+ Squamous cell head and neck cancers (HNSCC),Phase 1,11/3/23,"Phase 1 biomarker results demonstrated a robust increase in tumor-specific CD8+ T cells in all evaluable patients with HPV16+ head and neck cancers, noted November 3, 2023. Randomized trial planned for 2024.",2 -RYTM,"POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders",Phase 2,9/22/21,"Phase 2 data showed across all SRC1 deficiency patients, the mean overall weight loss among adults was -4.0%, and the mean overall BMI-Z score reduction among patients younger than 18 years was -0.21. Across all SH2B1 deficiency patients, the mean overall weight loss among adults was -3.1%, and the mean overall BMI-Z score reduction among patients younger than 18 years was -0.15, noted September 22, 2021.",2 -MRNA,Respiratory syncytial virus (RSV) vaccine,BLA Filing,7/5/23,"BLA rolling submission, noted July 5, 2023.",1 -CYCN,Sickle Cell disease,Phase 2,10/14/20,"Phase 2 data released October 14, 2020 - insufficient efficacy shown to support further development.",0 -SRPT,Duchenne muscular dystrophy (DMD),Phase 1b,10/11/21,"Phase 1b open label interim results from the first 11 participants in Cohort 1 (ambulatory boys aged 4-7 years) provided evidence of robust expression of micro-dystrophin and no new safety signals were identified, September 24, 2021. Functional results from study cohort 1 (n=11, ages 4-7) found participants improved 3.0 points on NSAA six months after treatment - noted October 11, 2021.",2 -SCYX,"Recurrent Vulvovaginal candidiasis (rVVC), Vaginal yeast infections",Approved,12/1/22,"FDA Approved on December 1, 2022.",2 -GILD,Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia,Phase 1/2,6/5/23,"Additional Phase 1/2 data presented at ASCO reported that median (95% CI) OS was 14.2 mo (3.2-26.0) for pts with prior blina and NR (18.6-NE) for pts without prior blina; Grade ≥3 TRAEs occurred in 80% and 97% of pts, respectively, noted June 5, 2023.",2 -CPRX,Pediatric Lambert-Eaton myasthenic syndrome (LEMS),Approved,9/29/22,"sNDA approved September 29, 2022.",2 -CHRS,Psoriasis,Approved,12/20/21,"Approved December 20, 2021.",2 -BGNE,Squamous non-small cell lung cancer (NSCLC),Phase 3,1/21/20,Phase 3 trial met primary endpoint of PFS at interim analyses.,2 -SGEN,Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma,Approved,11/9/17,"Approval announced November 9, 2017.",2 -ADVM,Wet age-related macular degeneration (AMD),Phase 2,9/26/23,"Phase 2 14-week data reported that has been generally well-tolerated, with 90% of subjects were still receiving corticosteroid prophylactic taper, noted September 26, 2023.",2 -REGN,Fibrodysplasia ossificans progressiva (FOP),Phase 2,1/9/20,Phase 2 trial did not meet primary endpoint p=0.07. Patient-reported flare-ups were reduced by 50% (nominal p=0.03).,0 -GSK,HIV,Approved,8/6/20,"FDA approval announced August 6, 2020.",2 -JNJ,Plaque psoriasis,Phase 2b,7/5/23,"Phase 2b trial met all primary and secondary efficacy endpoints, noted July 5, 2023.",1 -RANI,Neuroendocrine tumors (NETs) and acromegaly,Phase 1,11/1/23,"Program discontinued, noted November 1, 2023.",0 -HRMY,22q11.2 Deletion Syndrome,Phase 2,4/13/23,"Additional Phase 2 data reported a statistically significant improvements in PARS-R, total score and all 5 subscales of ADAMS and all 5 subscales of ABC-C, noted April 13, 2023.",2 -RHHBY,Influenza,Approved,10/24/18,"FDA Approval announced October 24, 2018.",2 -ACRS,Seborrheic keratosis (SK),Approved,12/15/17,"Approval announced December 15, 2017.",2 -ZLAB,Generalized Myasthenia Gravis (gMG),Approved,6/20/23,"FDA Approved on June 20, 2023.",2 -IPSEY,Alagille syndrome (ALGS),Approved,6/13/23,"FDA Approved on June 13, 2023.",2 -VNDA,Pneumonia associated with COVID-19,Phase 3,8/18/20,"Phase 3 data August 18, 2020 noted statistically significant improvement by Day 7. However, improvement was not statistically significant at Day 28.",1 -VTRS,Neulasta biosimilar,Approved,6/4/18,"Approval announced June 4, 2018.",2 -CLNN,Multiple Sclerosis,Phase 2,4/25/23,"Phase 2 topline data presentated at AAN reported that the primary BC-LCLA outcome LS-mean difference was 3.13 and 2 of 3 key secondary outcomes were significant, noted April 25, 2023.",2 -AFMD,Hodgkin Lymphoma - Cancer,Phase 1b,2/1/18,"Phase 1b preliminary data released February 1, 2018 - Objective response rate (ORR) of 89% (8/9), 4/9 CRs and 4/9 PRs. 3-month data due mid-2018.",2 -RNAZ,Metastatic solid tumors,Phase 1a,10/24/23,"Phase 0 preliminary data showed that radioactivity consistent with accumulation of TTX-MC138 was detected by noninvasive imaging in the regions of the metastatic lesions previously identified by fluorodeoxyglucose (FDG)/positron emission tomography (PET) (FDG/PET), noted October 24, 2023.",2 -SAGE,Parkinson Disease,Phase 2a,3/15/22,"Phase 2a data reported that sustained effects and improving trends were seen out to Day 28, noted March 15, 2022.",2 -ABBV,Parkinson's disease,CRL,3/22/23,"CRL issued by FDA on March 22, 2023.",1 -BGNE,Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma,Phase 3,10/21/23,"Phase 3 data presented at ESMO reported that OS in the TIS arm was significantly improved compared with the PBO arm in the ITT population (median OS: 15.0 mo vs 12.9 mo, respectively; HR=0.80 [95% CI: 0.70, 0.92]; 1-sided P=0.0011), noted October 21, 2023.",2 -BHVN,Generalized anxiety disorder (GAD),Phase 3,2/10/20,Phase 3 trial did not meet primary endpoint.,0 -BIIB,Alzheimer’s disease,Phase 3,3/21/19,Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion.,0 -NVS,HR + Metastatic breast cancer (MBC),Phase 3,8/23/18,"Phase 3 trial met primary endpoint - August 23, 2018 with data to be presented at an upcoming medical congress.",2 -BMY,"Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers",Phase 1/2,11/9/19,"Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate.",1 -EDIT,Transfusion-Dependent Beta Thalassemia (TDT),Phase 1/2,6/9/23,"Phase 1/2 first patient demonstrated successful neutrophil and platelet engraftment, and, at one and a half months post-infusion, the patient's response resembles that of the first four RUBY patients, noted June 9, 2023.",2 -KOD,Retinal vein occlusion (RVO),Phase 3,10/13/23,"Phase 3 one year primary data from the Retina Society meeting reported that Tarcocimab treated patients had a ~30% higher chance of not requiring any additional doses versus aflibercep, noted October 13, 2023.",2 -NBIX,Huntington's disease,Approved,8/18/23,"Approved August 18, 2023.",2 -ACXP,C. difficile Infection,Phase 2b,11/2/23,"Phase 2a and 2b data reported an observed Clinical Cure rate in the combined Phase 2 trials in patients with CDI was 96%, noted November 2, 2023.",2 -ELDN,Amyotrophic Lateral Sclerosis,Phase 2a,5/31/22,"Phase 2a topline data showed that treatment met the primary endpoints of safety and tolerability. Adverse events were equally distributed across dose levels, noted May 31, 2022.",2 -GMAB,B-cell Lymphoma (DLBCL),Approved,5/22/23,"Approved May 19, 2023.",2 -JAZZ,Tuberous Sclerosis Complex,Approved,8/3/20,"FDA approval announced August 3, 2020.",2 -FUSN,Solid tumors,Phase 1,6/26/23,"Phase 1 pre-administration data reported a favorable gain in tumor lesion uptake versus normal tissue, noted June 14, 2022.",2 -PFE,Bladder cancer,Approved,6/30/20,"FDA approval announced June 30, 2020.",2 -AZN,Non-small cell lung cancer (NSCLC),Phase 2,9/17/21,"Phase 2 trial met primary endpoint of confirmed ORR of 30%, and for durvalumab plus monalizumab 36%. The 10-month PFS rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone, September 17, 2021.",2 -AMGN,Metastatic castrate-resistant prostate cancer (mCRPC),Phase 1b,10/31/23,"Phase 1b initial data reported that efficacy was greater at higher doses (doses ≥0.75 mg target dose) where PSA50 was 59% (n=44) and RECIST objective response rate was 41% (n=37). The safety profile was clinically manageable, with CRS that was generally low grade and primarily in cycle 1, noted October 31, 2023.",1 -GILD,Non-small cell lung cancer (NSCLC),Phase 2,6/5/23,"Phase 2 presentation at ASCO reported one complete response in the monotherapy and in the DZ combo, noted June 5, 2023.",2 -VRTX,Sickle cell disease,Phase 1/2,6/13/22,"Data presented at EHA reported that all 31 patients with severe SCD were free of VOCs after exa-cel infusion through duration of follow-up, with follow-up ranging from 2.0 to 32.3 months, noted June 13, 2022.",2 -TOVX,Head and Neck Squamous Cell Carcinoma,Phase 1,10/23/23,"Phase 1 data shared at ESMO 23 showed enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies, noted October 23, 2023.",2 -LIAN,Obstructive hypertrophic cardiomyopathy (oHCM),Phase 3,8/28/23,"Phase 3 data presented at ESC reported that treatment demonstrated improvement in Valsalva LVOT peak gradient, LVOT obstruction, clinical symptoms, health status, cardiac biomarkers, and cardiac structure in Chinese oHCM patients, noted August 28, 2023.",2 -NERV,Major Depressive Disorder,Phase 2b,5/13/19,"Phase 2b data May 13, 2019 noted p-value was 0.083.",1 -ABBV,Functional Constipation in pediatric patients aged 6-17,Approved,6/12/23,"FDA Approved on June 12, 2023.",2 -AZN,Third-line ovarian cancer,Phase 3,12/20/18,"Phase 3 data released December 20, 2018 met primary and secondary endpoints.",2 -ZLAB,Gastric cancer,Phase 1/2,6/1/23,"Phase 1/2 data reported that the most common treatment-related adverse events (TRAEs) were gastrointestinal disorders, including nausea (11/19, 57.9%), vomiting (6/19, 31.6%), and abdominal pain (3/19, 15.8%), with no Grade ≥ 4 TRAEs were reported, noted June 1, 2023.",2 -EBS,Anthrax,PDUFA,3/25/15,"Approved March 25, 2015.",2 -EGRX,"Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer",Approved,12/24/15,"Approved December 24, 2015.",2 -STOK,Dravet Syndrome,Phase 1/2,7/25/23,"Phase 1/2 data presented showed that patients treated with 2 or 3 initial doses experienced substantial and sustained reductions in convulsive seizure frequency; Median reductions at 3 months after last dose of 80% and 89% at 6 months after last dose, compared to baseline, noted July 25, 2023.",2 -MRNA,"Personalized cancer vaccine, high-risk melanoma",Phase 2,10/23/23,"Phase 2 additional data presented at ESMO reported that local recurrence was more common in MRs; MNRs had more distant events. This trend was supported by stronger separation in DMFS vs RFS between MRs and MNRs, noted October 23, 2023.",2 -FREQ,Sensorineural hearing loss progression (SNHL),Phase 1b,2/13/23,"Phase 1b dosing completed, development to be discontinued, noted February 13, 2023.",0 -MDGL,Non-Alcoholic Fatty Liver Disease,Phase 3,6/27/22,"Phase 3 52-week primary data analysis reported the treatment was safe and well tolerated and provided significant reductions in liver fat, noted June 27, 2022.",2 HOTH,EGFRI-induced skin toxicity,Phase 2a,6/14/23,"Received written approval from the Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001, noted June 14, 2024.",2 -CYCC,Advanced cancers,Phase 1/2,10/26/22,"Phase 1/2 dose escalation data reported that of the 18 patients evaluable for response, two out of three T cell lymphoma patients treated achieved partial response and 11 out of 15 patients with various solid tumors achieved stable disease, noted October 26, 2022.",2 -PFE,"Influenza and COVID-19, Omicron BA.4/BA.5-adapted bivalent",Phase 1/2,10/26/23,"Phase 1/2 data demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains, noted October 26, 2023.",2 -CRBP,Cystic Fibrosis,Phase 2b,10/6/20,"Phase 2b trial did not meet primary endpoint - October 6, 2020.",0 -ICPT,Primary Biliary Cholangitis (PBC),Phase 2a,6/23/23,"Phase 2a data presented at EASL showed that the Combination was well-tolerated with lowest rates of pruritus observed in OCA 5-10 mg + bezafibrate 400 mg treatment arm, noted June 23, 2023.",2 -XERS,Exercise-Induced Hypoglycemia,Phase 2b,6/15/20,"Phase 2b trial met primary endpoints - June 15, 2020.",2 -AMLX,Amyotrophic lateral sclerosis (ALS),Approved,9/29/22,"Approved September 29, 2022.",2 -CMPS,Treatment Resistant Depression (TRD),Phase 2b,5/26/23,"Phase 2b more than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological support, noted May 26, 2023.",2 -NVS,Rheumatoid Arthritis,Approved,10/31/18,"FDA approval announced October 31, 2018.",2 -ZVRA,ADHD,Approved,3/2/21,"FDA approval announced March 2, 2021.",2 -AYLA,Desmoid tumors,Phase 2/3,10/23/23,"Phase 2 data presented at ESMO showed that 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population, AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity, noted October 23, 2023.",2 -LLY,Chronic low back pain,Phase 3,2/19/19,"Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.",1 -PFE,Migraine,Approved,3/10/23,"Approved March 10, 2023.",2 -EXAI,High adenosine signature cancers,Phase 1,4/19/23,"Phase 1 objectives were achieved in a healthy volunteer study, confirming pharmacokinetics, pharmacodynamics, safety, and tolerability, allowing selection of a starting dose for the ongoing IGNITE Phase 1/2 study ​​in combination with a PD-1 inhibitor in patients with RCC and NSCLC, noted April 19, 2023",2 -BHC,Psoriasis,Approved,2/15/17,"Approved February 15, 2017.",2 +AZN,Gastric cancer,Phase 2,9/17/21,"Phase 2 trial data showed confirmed overall response rate (ORR) of 38% as assessed by independent central review (ICR). Three (3.8%) complete responses (CR) and 27 (34.2%) partial responses (PR) were observed in patients treated with ENHERTU, September 17, 2021.",2 +YMAB,CNS/Leptomeningeal Metastases from Neuroblastoma,CRL,12/1/22,"CRL issued by FDA on December 1, 2022.",1 +ENTA,Non-alcoholic steatohepatitis (NASH),Phase 2b,10/4/21,"Phase 2b interim analysis showed 1.0 mg as the optimal dose. The monontherapy has been discontinued and priority is placed on the combinations, noted October 4, 2021.",1 +EIGR,Hepatitis delta virus (HDV),Phase 2,11/12/19,"Phase 2 data presented at AASLD November 12, 2019 - Median HDV RNA decline was 3.4 log IU/mL (IQR: 2.9-4.5, p<0.0001).",2 +KURA,Head and Neck Squamous Cell Carcinoma,Phase 1/2,10/26/22,"Phase 1/2 data reported that one patient experienced experienced an 81% reduction in target lesions after one cycle, noted October 26, 2022.",2 +ZNTL,Ovarian cancer,Phase 1b,6/5/23,"Phase 1b dose escalation data presented at ASCO reported that confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7% and mPFS of 10.4 months in combination with carboplatin, noted June 5, 2023.",2 +JAZZ,Spasticity due multiple sclerosis,Phase 2,2/7/17,"Phase 2 trial did not meet primary endpoint - noted February 7, 2017.",0 +MOR,Membranous nephropathy (MN),Phase 1/2,11/4/21,"Phase 1b/2a data reported that creatinine ratio (UPCR) results at 6 months of treatment showed a decrease in 6 of 10 patients, with 4 patients having a decrease of >=50% from baseline. The first patient who reached the 12-month time point showed a complete immunologic response and a partial clinical response, noted November 4, 2021.",1 MDGL,Heterozygous familial hypercholesterolemia (HeFH),Phase 2a,4/3/18,"Phase 2 top-line data released February 8, 2018 - primary endpoint met.",2 -GTHX,Urothelial carcinoma,Phase 2,8/2/23,"Phase 2 PFS data reported that PFS was similar between patients receiving trilaciclib prior to gemcitabine/platinum + avelumab and patients receiving gemcitabine/platinum + avelumab alone (median PFS=6.0 months and 6.1 months), noted August 2, 2023.",1 -OBSV,In Vitro Fertilization (IVF),Phase 3,2/26/18,"Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3.",2 -RIGL,Warm Autoimmune hemolytic anemia (WAIHA),Phase 3,12/12/22,"Phase 3 data presented at ASH reported that the ORR was 48%, noted December 12, 2022.",2 -TNGX,Solid Tumors,Phase 1/2,7/10/23,"Phase 1/2 dosing initiated, noted July 10, 2023.",1 -ZYME,Solid Tumors,Phase 1,4/18/23,"Additional data reported that anti-tumor activity was observed in breast cancer and gastric cancer PDXs representing a range of HER2 expression, noted April 18, 2023.",2 -FUSN,Solid tumors,Phase 1,6/26/23,"Phase 1 multi-dose safety and imaging data presented at SNMMI with Cold/Hot dosing regimen demonstrated potential to improve therapeutic index and safety profile, noted June 26, 2023.",2 -ALPN,"Lupus nephritis, IgA nephropathy",Phase 1/2,11/2/23,"Phase 1b/2a data presented at ASN reported that treatment reduced UPCR by greater than 50% in IgA nephropathy, noted November 2, 2023.",2 -GALT,Melanoma,Phase 1b,9/20/18,"Phase 1b data released September 20, 2019. ORR 50%.",1 -IPSEY,Pancreatic cancer,Phase 3,11/9/22,"Phase 3 data met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated. Key secondary efficacy outcomes of progression-free survival (PFS) also showed significant improvement over the comparator arm, noted November 9, 2022.",2 -KZR,Lupus nephritis (LN),Phase 2,11/3/22,"Phase 2 complete results reported that zetomipzomib added to stable background therapy reduced proteinuria by 50% or greater (ORR) in 11 of 17 patients (64.7%) reaching end of treatment at Week 25, noted November 3, 2022.",2 -BPMC,RET-mutant medullary thyroid cancer,Approved,12/1/20,"FDA approval announced December 1, 2020.",2 -HALO,Subcutaneous treatment for patients with primary immunodeficiency (PI),Approved,9/12/14,"Approved September 12, 2014.",2 -EOLS,Glabellar lines,Approved,2/1/19,"FDA Approval announced February 1, 2019.",2 -CCXI,Associated vasculitis (AAV),Approved,10/8/21,"FDA approval announced October 8, 2021.",2 -IPHA,COVID-19,Phase 2,7/6/21,"Phase 2 trial did not meet primary endpoints - July 6, 2021.",0 -MRNA,COVID-19 vaccine - pediatric,Phase 2/3,3/23/22,"Phase 2/3 data from children 6 months to under 6 years met primary endpoint, noted March 23, 2022.",1 -IMVIQ,Metastatic Bladder and Micro-Satellite Instability High (MSI-H) Solid Tumors,Phase 2,9/30/19,Phase 2 data at ESMO 2019 noted 2/23 PRs.,1 -MRNA,Seasonal influenza,Phase 3,9/13/23,"Phase 3 trial met all co-primary endpoints, noted September 13, 2023.",1 -MREO,Severe alpha-1 antitrypsin deficiency (AATD),Phase 2,5/9/22,Phase 2 study demonstrated to be statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose groups throughout the 12-week dosing period.,2 -BIIB,Amyotrophic lateral sclerosis (SOD1-ALS),Approved,4/25/23,"FDA granted accelerated approval on April 25, 2023.",2 -AZN,Advanced ER-positive Breast Cancer,Phase 2,12/8/22,"Phase 2 presentation at SABCS reported that treatment had a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at both 75mg and 150mg dose levels, noted December 8, 2022.",2 -PFE,C. difficile Infection,Phase 3,3/1/22,"Phase 3 trial did not meet primary endpoint, noted March 1, 2022.",2 -ABBV,Diffuse large B-cell lymphoma (DLBCL),Phase 3,7/11/18,"Phase 3 trial did not meet primary endpoint - noted July 11, 2018.",0 -BMRN,(MPS IVA) Morquio A Syndrome,Approved,2/14/14,"Approved February 14, 2014.",2 -ABBV,Chronic migraine,Approved,9/28/21,"Approved September 28, 2021.",2 -IFRX,COVID-19,Phase 3,4/4/23,"FDA granted an Emergency Use Authorization (EUA), noted April 4, 2023.",1 -REGN,Respiratory syncytial virus (RSV),Phase 3,8/14/17,"Phase 3 data released August 14, 2017 - primary endpoint not met.",0 -GSK,Multiple myeloma,Approved,8/5/20,"FDA approval granted August 5, 2020.",2 -FRTX,Axillary Hyperhidrosis,Phase 3,10/7/21,"Phase 3 study demonstrated that dosing was generally well-tolerated, the proportion of subjects achieving at least a 2-point improvement in the HDSM-Ax1 score from baseline to EOT2 was 63.9% (n=180). Additionally the change in GSP3 from baseline to EOT was -145.9mg. Overall, 82% of patients who were randomized to the dose in the study completed the full six weeks of treatment. Nine (5.0%) subjects who received the dose discontinued due to a TEAE. No treatment-related Serious Adverse Events (SAEs) were reported, noted October 7, 2021.",2 -OYST,Dry eye disease,Phase 2,1/12/20,"Phase 2 top-line data met primary endpoint - January 12, 2020.",2 -KRYS,Alpha-1 antitrypsin deficiency (AATD),Phase 1a,9/5/23,"FDA granted Orphan Drug Designation, noted September 5, 2023.",1 -AXSM,Agitation in patients with Alzheimer’s disease (AD),Phase 3,10/24/23,"Phase 3 results shared at the CTAD demonstrated rapid and sustained clinical response in patients with ADA during the open-label AXS-05 treatment. During the placebo-controlled randomized withdrawal phase, AXS-05 statistically significantly delayed the time to relapse of agitation symptoms as compared to placebo, noted October 24, 2023.",2 -RLMD,Major depressive disorder (MDD),Phase 3,2/23/22,"Phase 3 top-line results showed that all three doses (25 mg, 75 mg, and 150 mg, the therapeutic, supratherapeutic and maximum tolerated doses, respectively) tested in recreational drug users, demonstrated a substantial (30+ points) and statistically significant difference vs. intravenous ketamine 0.5 mg/kg over 40 minutes, and were statistically equivalent to placebo, noted February 23, 2022.",2 -TBPH,Asthma,Approved,4/30/15,"Approved April 30, 2015.",2 -GILD,Triple-negative breast cancer,Approved,4/22/20,"FDA Approval announced April 22, 2020.",2 -AZN,Early Alzheimer's disease,Phase 3,6/11/18,Announced discontinuation of trial due to futility.,0 +FBRX,Atopic Dermatitis,Phase 2,9/2/21,"Phase 2 failed to meet primary endpoint September 02, 2021.",2 +AKBA,Hyperphosphatemia,Approved,9/5/14,"Approved Sept 5, 2014.",2 +VSTM,KRAS mutant non-small cell lung cancer (NSCLC),Phase 1/2,10/16/23,"Phase 1/2 initial data reported that the confirmed objective response rate (ORR) was 25% (3/12) across efficacy-evaluable patients and seen in both KRAS G12C inhibitor resistant (14.3%; 1/7) and naïve (40%; 2/5) patients, noted October 16, 2023.",2 +MESO,Heart failure,Phase 3,12/6/21,Phase 3 results showed greatest treatment benefit in major adverse cardiovascular events (MACE) of cardiovascular mortality or irreversible morbidity (non-fatal heart attack or stroke) in patients with diabetes and/or myocardial ischemia (72% of total treated population),2 +EVLO,Mild to moderate psoriasis,Phase 2,3/28/22,"Phase 2 data reported that treatment was well tolerated, and the primary endpoint analysis showed that treatment was superior to placebo with 80-90% probability across each cohort, noted March 28, 2022.",2 +PTGX,Crohn's disease,Phase 2,11/3/21,"Phase 2 trial and candidate development has been stopped, noted November 3, 2021.",0 +ABBV,Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy,Approved,2/12/14,"Approved February 12, 2014.",2 +ARQT,Plaque psoriasis,Phase 3,3/25/22,"Phase 3 pooled data reported that 40% of patients treated with roflumilast cream achieved IGA success and and 48% of patients treated with roflumilast cream achieved IGA status of clear, noted March 25, 2022.",2 +ARWR,AATD-associated liver disease,Phase 2,6/27/22,"Phase 2 data showed noted a Fibrosis regression observed in 58% (7/12) of patients receiving 200 mg, a median reduction of 83% of Z-AAT accumulation in the liver and a reduction of 69% in histologic globule burden",2 +NVS,Metastatic castration-resistant prostate cancer (mCRPC),Phase 3,10/23/23,"Phase 3 trial met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival, noted October 23, 2023.",1 +HALO,Amyloidosis,Approved,1/15/21,"FDA approval announced January 15, 2021.",2 +CBIO,Hemophilia B,Phase 2b,6/15/20,"Phase 2b data noted after 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of >12% in all participants, with FIX levels of up to 27% and a half-life of 2.5 to 5.1 days with no bleeds.",2 +BIVI,Alzheimer's disease,Phase 2,12/5/22,"Phase 2 final data reported that improvements in QDRS scores were statistically significantly correlated with improvements on the ADCOMS assessment, noted December 2, 2022.",2 +CCCC,Synovial sarcoma,Phase 1,11/1/23,"Phase 1 deprioritized due to insufficient single agent efficacy, despite high levels of BRD9 degradation, noted November 1, 2023.",0 +TBPH,Neurogenic Orthostatic Hypotension (nOH),Phase 3,9/15/21,"Phase 3 study did not meet its primary endpoint September 15, 2021.",0 +CRSP,Advanced clear cell renal cell carcinoma,Phase 1,11/10/22,"Phase 1 result reported a 77% disease control rate in a heavily pretreated RCC patient population. The longest duration of stable disease achieved was observed for 7.8 months, noted November 10, 2022.",2 +HOWL,Solid Tumors,Phase 1b,11/3/23,"Phase 1/1b preliminary data provided compelling early evidence of dose-dependent biomarker and antitumor activity in patients, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg), noted November 3, 2023.",1 +REGN,Melanoma,Phase 1,5/25/23,"Additional Phase 1 data from ASCO reported an ORR of 63% (25 of 40 patients), including 6 complete responses (CR) and 19 partial responses (PR) in the initial cohort, with a ORR of 63% in the confirmatory cohort, and 56% in the Prior neo/adjuvant systemic therapy cohort, noted May 25, 2023.",1 +REGN,Transthyretin amyloidosis (ATTR),Phase 1,11/2/23,"Phase 1 updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of follow-up, noted November 2, 2023.",2 +SELB,Tophaceous gout,Phase 2,9/30/20,"Phase 2 top-line data released September 30, 2020. Numerically higher response rate on the primary endpoint during months 3 and 6 combined, but did not meet the primary endpoint of statistical superiority.",0 +BMY,Plaque psoriasis,Phase 3,11/3/20,"Phase 3 trial met both co-primary endpoints - November 3, 2020.",2 +AZN,Non-small Cell Lung Carcinoma,Approved,12/21/20,"FDA approval announced December 21, 2020.",2 +GMDA,Severe aplastic anemia,Phase 2,12/6/20,Phase 2 data presented at ASH 2020 - sustained early engraftment shown.,2 +AZN,Heart failure,Approved,5/5/20,"FDA Approval announced May 5, 2020.",2 +BMY,First-line Small cell lung cancer (SCLC),Phase 3,11/26/18,"Phase 3 trial did not meet primary endpoint - November 26, 2018.",0 +PFE,Endometriosis-associated pain,Approved,8/5/22,"Approved August 5, 2022.",2 +MDWD,Basal Cell Carcinoma (BCC),Phase 1/2,7/10/23,"Phase 1/2 data reported that treatment was safe and well-tolerated with eleven out of fifteen patients achieved complete clearance of their BCCs, noted July 10, 2023.",2 +RVMD,Advanced Solid Tumors,Phase 1b,10/22/23,"Phase 1/1b data shared at ESMO reported that the objective response rate was 38 percent, with one patient achieving a complete response (CR) as a best response and 14 patients achieving a partial response, noted October 22, 2023.",2 +EBS,Anthrax Vaccine,Approved,5/17/12,"Approved May 17, 2012.",2 SUPN,ADHD,Phase 3,12/22/20,"Phase 3 trial met primary endpoint - December 22, 2020.",2 -SUPN,Attention Deficit Hyperactivity Disorder (ADHD),Phase 3,2/25/20,Phase 3 trial did not meet primary endpoint.,0 -AGIO,Pyruvate kinase deficiency,Approved,2/17/22,"Approved February 17, 2022.",2 -CING,Healthy volunteers in fed and fasted states,Phase 1,2/23/23,"Phase 1 data demonstrated that CTx-1301 can be taken with or without food, noted February 23, 2023.",2 -TBPH,COPD,Approved,11/9/18,"FDA Approval announced November 9, 2018.",2 -ABBV,Uterine Fibroids,Approved,5/29/20,"FDA approval announced May 29, 2020.",2 -BDRX,Diffuse Midline Glioma (DMG),Phase 1,7/6/23,"Phase 1 trial reported a median overall survival (OS) of 26.1 month, noted July 6, 2023.",1 -AMGN,Multiple Myeloma,Approved,10/1/18,"FDA approval announced October 1, 2018.",2 +AZN,Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD),Approved,6/27/19,"FDA Approval announced June 27, 2019.",2 +ASMB,Hepatitis B,Phase 1b,12/19/22,"Phase 1b data reported that in the cohort of 50 mg, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNA, noted December 19, 2022.",2 +AQST,Parkinson’s Disease with motor fluctuations,Approved,5/21/20,"FDA approval announced May 21, 2020.",2 +PFE,Pneumococcal conjugate vaccine (18 yrs +),Approved,6/8/21,https://www.businesswire.com/news/home/20210608006149/en/,1 +ACRS,Seborrheic keratosis (SK),Approved,12/15/17,"Approval announced December 15, 2017.",2 +SNY,Non-small cell lung cancer (NSCLC),Phase 3,4/27/20,"Phase 3 trial stopped early due to significant improvement in overall survival - April 27, 2020.",2 +AMGN,Cardiovascular disease,Approved,9/24/21,"Approved for pediatric patients 10 years and older September 24, 2021.",2 +ABBV,Systemic Lupus Erythematosus (SLE),Phase 2,5/31/23,"Phase 2 data reported that trial met primary endpoint, noted May 31, 2023.",1 +MRK,Clostridium difficile infections (CDI),Approved,1/27/20,"FDA Approval announced January 27, 2020.",2 +NVS,Paroxysmal nocturnal hemoglobinuria (PNH),Phase 3,12/13/22,"Phase 3 data reported that trial met both primary endpoints, noted December 13, 2022.",1 +SNDX,"HR+, HER2- breast cancer",Phase 3,5/21/20,"Phase 3 did not meet overall survival primary endpoint - May 21, 2020.",0 +AZN,Hepatocellular carcinoma (HCC),Approved,10/24/22,"Approved October 24, 2022.",2 +PTPI,Erectile Dysfunction,Approved,4/27/12,"Approved April 27, 2012.",2 +LLY,Medullary thyroid cancer (MTC),Phase 3,10/21/23,"Phase 3 data presented at ESMO reported that selpercatinib demonstrated superior PFS vs control in the ITT-pembro (HR: 0.465, 95% CI: 0.309, 0.699; p-value: 0.0002) and ITT populations (HR: 0.482, 95% CI: 0.331, 0.700; p-value: 0.0001), noted October 21, 2023.",2 +FGEN,Anaemia in Chronic Kidney Disease,CRL,8/11/21,"CRL announced August 11, 2021.",1 +BNTX,Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine,Approved,12/8/22,"EUA granted for children under 5 December 8, 2022.",1 +VBIV,Hepatitis B,Phase 2,9/6/23,"Phase 2a/2b top-line data showed increased HBsAg loss rate at the end of treatment and 12 weeks follow up, noted September 6, 2023.",2 +FWBI,COVID-19-related gastrointestinal (GI) infections,Phase 2,4/29/22,"Phase 2 top-line data reported that trial did not meet its primary endpoint, noted April 29, 2022.",2 +QTRX,Superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS),Approved,4/25/23,"Approved April 25, 2023.",2 +HRMY,Fragile X syndrome,Phase 2/3,5/13/22,"Phase 2/3 long-term data reported that sustained improvement in ABC-CFXS Social Avoidance from baseline, noted May 13, 2022.",2 +INDP,Advanced/metastatic solid tumors,Phase 1,10/31/23,"Phase 1 data abstract to be presented at SITC on November 4, 2023 noted that each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, noted October 31, 2024.",2 +TCON,Angiosarcoma cancer,Phase 3,4/12/19,"Phase 3 interim analysis April 12, 2019 noted trial to be terminated due to futility.",0 +MRK,Squamous non-small cell lung cancer (sNSCLC),Approved,10/30/18,"FDA approval announced October 30, 2018.",2 +AZN,Third-line ovarian cancer,Phase 3,12/20/18,"Phase 3 data released December 20, 2018 met primary and secondary endpoints.",2 +MRK,HIV,Approved,9/20/19,"FDA Approval for sNDA announced September 20, 2019.",2 +GMDA,Follicular and diffuse large B cell lymphomas,Phase 1,10/17/23,"Phase 1 data showed promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma, noted October 16, 2023.",2 +GRTS,COVID-19 vaccine,Phase 1,10/11/23,"Phase 1 data reported that all doses were well tolerated in both HIV-negative participants and PLWH irrespective of SARS-CoV-2 serostatus at baseline, noted October 11, 2023.",2 +SNY,Multiple sclerosis,Phase 2,2/6/20,"Phase 2 data met primary endpoint - February 6, 2020. Data to be presented at upcoming meeting.",2 +MREO,Osteogenesis Imperfecta,Phase 2,10/14/23,"Additional Phase 2 data reported that the annualized fracture rate across all 24 patients in the Phase 2 portion of the study was reduced by 67%, noted October 14, 2023.",2 +ATXS,Duchenne muscular dystrophy (DMD),Phase 3,10/26/20,"Phase 3 trial did not meet primary endpoint - October 26, 2020.",0 +GILD,Refractory Large B-cell Lymphoma,Phase 1,6/5/23,"Phase 1 data presented at ASCO showed that Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population. The treatment resulted in a 27.4% Reduction in Risk of Death, Corresponding to a 38% Relative Improvement in OS, Despite 57% of Patients Subsequently Receiving Cell Therapy Off Protocol, noted June 5, 2023",2 +ADPT,Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),Approved,5/19/23,"Approved May 19, 2023.",2 +BMY,Relapsed/refractory multiple myeloma,Approved,11/6/18,"FDA approval announced November 6, 2018.",2 +EBS,Opioid overdose,Approved,3/29/23,"Approved March 29, 2023.",2 +PTN,Dry eye disease (DED),Phase 2,12/15/20,Phase 2 trial met the primary endpoints in the moderate to severe patient population but not in the overall population including mild patients.,1 +ELDN,Amyotrophic Lateral Sclerosis,Phase 2a,5/31/22,"Phase 2a topline data showed that treatment met the primary endpoints of safety and tolerability. Adverse events were equally distributed across dose levels, noted May 31, 2022.",2 +ZLAB,Non-small-cell lung cancer (NSCLC) and solid tumors,Phase 1/2,4/12/22,"Phase 1/2 top-line data reported that in the ROS1-positive TKI-naïve advanced NSCLC population the cORR was 79%, with 4 patients receiving a complete response, and 52 having a partial response. With DOR ranging from 1.4+ to 35.1+ months and PFS ranging from 0+ to 40.4+ months, noted April 12, 2022.",1 +IMAB,COVID-19,Phase 2,8/11/21,"Phase 2 interim analysis released August 11, 2021. Mechanical ventilation free (MVF) rate (83.6% vs 76.7%) by day 30, lower mortality rate (4.9% vs 13.3%) compared to placebo.",2 +AGIO,Thalassemia,Phase 2,12/12/22,"Phase 2 data reported durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoiesis were observed for up to 72 weeks of treatment in both α- and β-thalassemia patients, noted December 12, 2022.",2 +ACHL,Non-Small Cell Lung Cancer (NSCLC),Phase 1/2,12/6/22,"Phase 1/2a data reported 1 partial response (PR), and 6 stable disease with overall durable clinical benefit at 12 weeks in 71% of evaluable patients, noted December 6, 2022.",2 +DVAX,COVID-19 vaccine,Phase 3,3/2/23,"Phase 3 data reported that the fold decline of neutralizing antibodies over six months after a second vaccination with VLA2001 was similar to the active comparator, and less pronounced than for other licensed COVID-19 vaccines, noted March 2, 2023.",1 +JNJ,COVID-19 vaccine (single dose),Phase 3,9/21/21,"Phase 3 data showed 75 percent overall efficacy against severe/critical COVID-19, across all ages and countries. 74 percent efficacy in the U.S. against severe/critical COVID-19; 89 percent against hospitalization; 83 percent against COVID-19-related death, September 21, 2021.",2 +BMY,Urothelial cancer,Phase 2,4/14/22,"Phase 2 trial did not meet the efficacy threshold in its final ORR analysis, noted April 14, 2022.",2 +LCTX,Geographic atrophy (GA),Phase 1/2,10/5/23,"Phase 1/2 results presented at EURETINA Congress reported that 5 patients had an average of 4.4 letter BCVA gain by 3 months and 12.8 letter BCVA gain by 1 year compared to baseline, noted October 5, 2023.",2 +HALO,Chronic inflammatory demyelinating polyneuropathy (CIDP),Phase 2,7/17/23,"Phase 2 trial met primary endpoints, noted July 17, 2023.",1 +GILD,Refractory Large B-cell Lymphoma (R-LBCL),Phase 2,6/6/22,"Phase 2 data presented at ASCO reported a CR rate of 65% and ORR of 88%. With a median follow-up of 17 mo, 65% of the patients had ongoing response, with 57% ongoing in CR, noted June 6, 2022.",2 +MRK,Pneumococcal Conjugate Vaccine,Phase 3,7/27/23,"Phase 3 trial met primary endpoints, noted July 27, 2023.",1 +TYME,Pancreatic Cancer,Phase 2/3,1/26/22,"Phase 2/3 additional data reported that overall survival for SM-88 as a monotherapy was lower compared to standard of care chemotherapies, noted January 26, 2022.",1 +BMY,Esophageal squamous cell carcinoma (ESCC),Approved,5/27/22,"Approved May 27, 2022.",2 +INVA,Increase blood pressure in adults with septic or other distributive shock,Approved,12/21/17,"Approval announced December 21, 2017.",2 +ASND,Growth hormone deficiency in children,Approved,8/25/21,"FDA approval announced August 25, 2021.",2 +VRCA,Common warts,Phase 2,6/26/19,"Phase 2 data noted 51% of patients noted complete clearance of warts - June 26, 2019.",1 +INBX,Alpha-1 Antitrypsin Deficiency (AATD),Phase 1,11/2/22,"Phase 1 data presented at ACoP noted that treatment demonstrated the potential to achieve and maintain normal levels of functional AAT. The 120 mg/kg Q4W regimen is predicted to achieve average trough values >21.1 µM, noted November 2, 2022.",2 +ADXS,Desmoid tumors,Phase 2/3,10/23/23,"Phase 2 data presented at ESMO showed that 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population, AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity, noted October 23, 2023.",2 +VRTX,Acute Pain following bunionectomy or abdominoplasty surgery,Phase 2,3/31/22,"Phase 2 trial met primary endpoint, noted March 31, 2022.",1 +ORTX,Metachromatic leukodystrophy (MLD),Phase 3,8/31/23,"Announced long-term results from 39 patients that demonstrated that administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 12 years of follow-up (median 6.76 years), noted August 31, 2023.",2 +PFE,BRAF mutant melanoma cancer,Approved,6/27/18,"Approval announced June 27, 2018.",2 +SUPN,Epilepsy,Approved,8/19/13,"Approved Aug 19, 2013.",2 +EFTR,relapsed/refractory Acute Myeloid Leukemia (AML),Phase 1,10/24/23,"Phase 1 initiated, noted October 24, 2023.",1 XBIO,Anemia in patients with chronic kidney disease (CKD),Phase 3,12/9/20,Phase 3 data using PolyXen technology reported by partner - non-inferior to Aranesp (darbepoetin alfa) - Russia trial.,2 -AMGN,KRAS G12C-mutated solid tumors,Phase 1b,10/7/21,"Phase 1b results displayed that patients with CRC who were KRASG12C inhibitor naïve, 9% achieved PR (1 of 11), and 82% achieved disease control (9 of 11). In patients who were previously treated with a KRASG12C inhibitor, 14% achieved PR (1 of 7), and 86% achieved disease control (6 of 7). In patients with NSCLC who were KRASG12C inhibitor naïve, 20% achieved PR (3 of 15) and 87% achieved disease control (13 of 15). In patients who were previously treated with a KRASG12C inhibitor, 67% achieved disease control (2 of 3), noted October 7, 2021.",2 -ACRX,Post-operative pain following open abdominal surgery and hip or knee replacement surgery,Phase 3,8/1/17,"Phase 2 data released August 1, 2017.",1 -BLRX,Solid tumors,Phase 1/2,1/24/22,"Phase 1/2a enrollment completed January 24, 2022.",1 -EDSA,"COVID-19, Acute Respiratory Distress Syndrome (ARDS)",Phase 2/3,10/19/21,"Phase 2/3 additional results demonstrated the DSMB noted another mortality benefit in 136 hospitalized COVID-19 patients receiving supplemental oxygen (28-day mortality rate of 8.2% (5/61) in the EB05 + SOC arm versus 12.0% (9/75) in the placebo + SOC arm, Hazard Ratio (HR): 1.52 placebo vs. EB05, n=136). Phase 3 portion of the study to focus on critically ill population, noted October 19, 2021.",1 -SGEN,Hodgkin lymphoma and Anaplastic large cell lymphoma,Approved,8/19/11,"Approval announced August 19, 2011.",2 -SNY,Cutaneous squamous cell carcinoma,Approved,9/28/18,"FDA Approval announced September 28, 2018.",2 -AMGN,Multiple Myeloma,Approved,1/5/18,"sBLA approval announced January 5, 2017.",2 -SNSE,Squamous Cell Carcinoma of the Head and Neck,Phase 1/2,8/4/21,"Development has been discontinued - noted August 4, 2021.",0 -BMY,Resectable Stage III melanoma,Phase 1,11/10/22,"Phase 1 data presented at SITC showed that 100% of patients who received the triple combination were recurrence free at 24 months. This contrasted with recurrence free survival of less than 40% in patients who received the dual combination of pepinemab and nivolumab or pepinemab and ipilimumab, noted November 10, 2022.",2 -SYBX,Homocystinuria (HCU),Phase 1,3/12/23,"Phase 1 data presented at SIMD reported that no serious adverse events or deaths related to SYNB1618 or SYNB1934, noted March 19, 2023.",2 -IRON,Myelofibrosis (MF) patients with anemia,Phase 1/2,11/2/23,"Phase 1b/2 data from abstracts reported dose-dependent reductions in serum hepcidin-25 and increases in serum iron levels, noted November 2, 2023.",2 -MESO,Steroid-refractory acute graft versus host disease (aGVHD) in children,CRL,8/3/23,"Additional CRL announced August 3, 2023.",1 -MOR,Ulcerative colitis,Phase 2b,10/24/22,"Phase 2b study data reported that treatment led to a mean of 52.1 percent of IV TREMFYA week 12 clinical nonresponders to achieve clinical response at week 24, noted October 24, 2022.",2 -SLNO,Prader-Willi syndrome (PWS),Phase 3,9/8/21,"Phase 3 extension study data showed mean (SE) improvement in hyperphagia by a decrease in the HQ-CT total score, of -9.9 (0.77), was highly significant (p<0.0001) after receiving DCCR for 52 weeks, noted September 8, 2021.",2 -PRAX,Healthy volunteers,Phase 1,12/4/22,"Phase 1 data reported that there were no clinically significant safety findings in vital signs, clinical laboratory results, physical exams, ECGs, or C-SSRS. TEAEs were mostly mild or moderate, noted December 4, 2022.",1 +JAZZ,Sickle Cell Disease-Related Acute Chest Syndrome,Phase 2,12/12/22,"Phase 2 data reported that among patients who underwent Day 30 CXR or CTA, 87.5% and 92%, respectfully, showed improvement or resolution of pulmonary consolidation, noted December 12, 2022.",2 +ANIP,Absence seizures that are refractory to other drugs,Approved,5/15/23,"ANDA approved May 15, 2023.",2 +MRK,Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma,Phase 3,12/14/17,"Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.",0 +JNJ,Multiple sclerosis,Approved,4/16/15,Approved April 16 2015.,2 +SRPT,Duchenne muscular dystrophy,Approved,2/25/21,"FDA approval announced February 25, 2021.",2 +ZYME,HER2-positive breast cancer,Phase 1/2,5/26/22,"Phase 1b/2 data released in abstract reported that the cORR was 90.5% and the six-month progression-free survival rate was 95.2%, noted May 26, 2022.",1 +ZYNE,Osteoarthritis,Phase 2,8/14/17,"Phase 2 data released August 14, 2017 - primary endpoint not met. However, company still intends to initiate Phase 3 trial pending discussions with FDA.",0 +TARS,Lyme disease,Phase 1,12/15/22,"Phase 1 data data showed that treatment was well tolerated and safety data supports progression to Phase 2a (Carpo), noted December 15, 2022.",2 +AFMD,"EGFR-expressing tumors, Non-small cell lung cancer, and Squamous cell carcinoma of the head and neck",Phase 1,8/3/23,"Phase 1 dose-escalation update reported that AFM24 showed meaningful clinical activity in heavily pretreated patients with EGFRmut NSCLC (ORR [13%], DCR [47%]) with significant tumor reductions, including two confirmed PRs and five patients exhibiting stable disease, noted August 3, 2023.",2 +GILD,Ulcerative colitis,Phase 2/3,5/20/20,"Phase 2b/3 data released May 20, 2020. 200mg dose met primary endpoint. 100mg did not meet clinical remission endpoint.",1 +ABBV,Second-line Chronic graft-versus-host disease (GVHD),Approved,8/2/17,"Approval announced August 2, 2017.",2 +RDHL,H. pylori,Approved,9/18/23,https://www.biopharmcatalyst.com/company/RDHL/news/159168,1 +FHTX,Acute myeloid leukemia (AML),Phase 1,6/5/23,"Phase 1 is to be commenced in 3Q 2023, clinical hold lifted by FDA, noted June 5, 2023.",1 +NVCR,Ovarian cancer,Phase 3,8/28/23,"Phase 3 trial did not meet its primary endpoint in the final analysis, noted August 28, 2023.",2 MOLN,COVID-19,Phase 2/3,1/10/22,"Phase 2b/3 part A met primary endpoint, noted January 10, 2022.",1 -TBPH,Gastroparesis,Phase 2b,8/2/17,"Phase 2b data released August 2, 2017. Primary endpoint not met.",0 -MRK,Human Papilloma virus vaccine,Approved,10/9/18,"Approval announced October 5, 2018.",2 -CLDX,Eosinophilic esophagitis (EoE),Phase 2,7/6/23,"Phase 2 dosing initiated, noted July 6, 2023.",1 -LLY,COVID-19 antibody,Approved,2/11/22,"EUA granted by FDA February 11, 2022.",1 -DRRX,Post-operative pain relief,CRL,2/12/14,"CRL issued February 12, 2014.",1 -REGN,Eosinophilic esophagitis (EoE),Approved,5/20/22,"Approved May 20, 2022.",2 -JNJ,Ulcerative colitis,Approved,10/21/19,"FDA Approval announced October 21, 2019.",2 -CNTX,"ER+, HER2-, ESR1-mutated Breast Cancer",Approved,1/31/23,"Approved January 31, 2023.",2 -AMGN,Plaque psoriasis,Approved,12/20/21,"Approved December 20, 2021.",2 -XLO,Solid Tumors,Phase 1,5/25/23,"Phase 1 preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer, favorable preliminary safety profile for XTX101 observed at the recommended Phase 2 dose of 150 mg once every six weeks, noted May 25, 2023.",2 -ZLAB,Non-small cell lung cancer (NSCLC),Phase 3,10/16/23,"Phase 3 data from ESMO abstract reported that quality of life data showed no statistically significant difference between patients who received TTFields therapy together with standard systemic therapies, noted October 16, 2023.",2 -PFE,Juvenile idiopathic arthritis (JIA),Phase 3,9/28/20,"FDA approval announced September 28, 2020.",2 -MRK,"Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)",Approved,10/16/23,"Approved on October 16, 2023.",2 -JAZZ,Rett syndrome,Phase 3,11/12/20,"Phase 3 trial stopped due to COVID-19 - November 12, 2020.",0 -ABBV,Multiple Myeloma,Phase 1/2,12/13/21,"Phase 1/2 safety and preliminary efficacy data reported that treatment of patients with t(11;14) RRMM using VenDd and those with RRMM with VenDvd demonstrated a tolerable safety profile and an overall response rate (ORR) of 95.8% and 91.7%, respectively, noted December 13, 2021.",2 -INCY,Non-small cell lung cancer,Approved,5/6/20,"FDA Approval announced May 6, 2020.",2 -INVA,Chronic obstructive pulmonary disease (COPD),Approved,9/18/17,"Approval announced September 18, 2017.",2 -TFFP,Invasive Pulmonary Aspergillosis (IPA),Phase 2,11/1/22,"Phase 2 trial data showed that second patient treated to clinically benefit from administration in compassionate use program, noted November 1, 2022.",2 -LLY,Patients evaluated for Alzheimer's Disease,Approved,5/28/20,"FDA Approval announced May 28, 2020.",2 -PSTX,Multiple myeloma,Phase 2,12/13/21,"Phase 2 results showed that dosage was well tolerated and demonstrated strong anti-tumor activity in advanced, late line R/R MM patients, with an overall response rate (ORR) of 78%, a VGPR/sCR rate of 43% and 100% overall survival at the time of the data cutoff, noted December 13, 2021.",2 -SAGE,Major depressive disorder (MDD),CRL,8/4/23,"CRL issued August 4, 2023.",1 -BTAI,Agitation associated with bipolar I or II disorder or schizophrenia,Phase 3,5/25/23,"Phase 3 part 1 topline data clinically meaningful efficacy results were observed with half (60mcg) of the lowest approved dose of IGALMI. In addition, greater than 50% PEC response rate was achieved, with responder rate dose-proportionally consistent with those observed in SERENITY I and II trials. Although the primary efficacy endpoint was not statistically significant at 2 hours (p=0.077), BXCL501 separated from placebo at 4 hours (p=0.049), noted May 25, 2023.",2 -ABEO,Sanfilippo syndrome type B (MPS IIIB),Phase 1/2,2/12/21,"Phase 1/2 updated data announced February 12, 2021.",1 -MCRB,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)",Phase 1b,5/9/23,"Phase 1 initial safety and PK data from cohort 1 showed the successful engraftment of SER-155 bacterial strains and a substantial reduction in the cumulative incidence of pathogen domination, a biomarker associated with the risk of serious enteric infections and bloodstream infections, as well as GvHD, noted on May 9, 2023",2 -SPRO,Complicated urinary tract infections (cUTI),CRL,6/27/22,"CRL announced June 27, 2022.",1 -VRTX,Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.,CRL,2/5/16,"CRL issued February 5, 2016.",1 -ABBV,Maintenance Treatment of Schizophrenia,Approved,11/13/17,"Approval announced November 13, 2017.",2 -LGND,Relapsed Multiple Myeloma,Approved,1/17/18,"sNDA approved January 17, 2018.",2 -REGN,Chronic Spontaneous Urticaria (CSU),Phase 3,2/18/22,"Phase 3 trial did not meet the primary endpoint, noted February 18, 2022.",2 -GILD,Covid-19,Approved,7/14/23,"Approved July 14, 2023.",2 -AGTC,Achromatopsia,Phase 1/2,6/24/21,"Phase 1/2 12-month data presented June 24, 2021. Company noted at this time point consistent evidence not shown of biologic activity, patient-reported anecdotes continue to be encouraging.",2 -NERV,Major Depressive Disorder,Phase 2b,12/18/19,"Phase 2b data failed to meet endpoints - December 18, 2019. Development to be discontinued in MDD.",0 -NVS,Relapsing Multiple Sclerosis,Phase 3,4/20/23,"Phase 3 5-year data reported that more than 80% of patients remained free of six-month CDW, noted April 20, 2023.",1 -GLYC,Vaso-occlusive crisis of sickle cell disease,Phase 3,8/2/19,"Phase 3 data failed to meet endpoints - August 2, 2019.",0 -PFE,Serious Bacterial Infection,Phase 3,6/1/23,"Phase 3 data reported that 5/12 (41.7%) of the ATM-AVI ± MTZ patients with infections due to confirmed MBL-producing Gram-negative bacteria were cured at TOC versus 0/3 (0%) of those on best available therapy (BAT), noted June 1, 2023.",1 -PBYI,Third-line HER2-positive metastatic breast cancer,Approved,2/26/20,"FDA Approval announced February 26, 2020.",2 +ABEO,Sanfilippo syndrome type A (MPS IIIA),Phase 1/2,2/12/21,"Phase 1/2 updated safety data released February 12, 2021. Well tolerated.",2 +ETON,Allergic conjunctivitis,Approved,9/25/20,"FDA approval announced September 25, 2020.",2 +ASND,Achondroplasia,Phase 2,11/14/22,"Phase 2 top-line data reported that trial met primary endpoint, noted November 14, 2022.",1 +HALO,Testosterone replacement therapy (TRT),Approved,3/29/22,"Approved March 29, 2022.",2 +PFE,Oral Protease Inhibitor for COVID-19,Approved,5/25/23,"FDA approved on May 25, 2023.",2 +JNJ,Multiple Myeloma,Phase 3,6/5/23,"Phase 3 results shared at ASCO demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26, noted June 5, 2023",2 +RHHBY,Acute Myeloid Leukemia (AML),Approved,10/16/20,"FDA approval announced October 16, 2020.",2 +CNCE,Alopecia areata,Phase 3,11/21/22,"Additional data reported that for patients with an absolute Severity of Alopecia Tool (SALT) score less than 95 at baseline, 43% and 57% of the 8 mg twice-daily and 12 mg twice-daily deuruxolitinib dose groups, respectively, achieved a SALT score of 20 or less at Week 24, noted November 21, 2022.",2 +EYPT,Wet age-related macular degeneration (AMD),Phase 2,7/27/23,"Phase 2 trial continued to demonstrate that EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs, noted July 27, 2023.",2 +PALI,Reduction in adhesions following abdominal and pelvic surgery,Phase 2,8/9/23,"Phase 2 study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery, noted August 9, 2023.",2 +REGN,COVID-19 (Anti-viral antibody),Phase 2/3,9/30/21,"Phase 3 trial met primary endpoint, with 36% reduced risk of death by day 29, and 56% reduced risk in patients who were seronegative. Of 2,007 patients (REGEN-COV=1,340, placebo=667) serious adverse events occurred in 21% REGEN-COV patients and 26% placebo patients, noted September 30, 2021.",2 +MAIA,Non-small cell lung cancer (NSCLC),Phase 2,10/31/23,"Phase 2 preliminary efficacy data reported a 100% Disease Control Rate (DCR), noted October 31, 2023.",1 +LPCN,Testosterone replacement therapy (TRT),Approved,3/29/22,"Approved March 29, 2022.",2 +EQRX,1L metastatic non-small cell lung cancer (NSCLC),Phase 3,5/26/22,"Phase 3 data reported that the median OS was 25.4 months versus 16.9 months in placebo, noted May 26, 2022.",1 +LXRX,Heart failure,Approved,5/26/23,"Approved May 26, 2023.",2 +RCKT,Fanconi Anemia (FA),Phase 2,12/12/22,"Phase 2 data reported that A seventh patient has displayed evidence of progressively increasing genetic correction as demonstrated by peripheral blood and BM vector copy numbers (VCNs), noted December 12, 2022.",2 +IMUX,Relapsing-remitting multiple sclerosis (RMS),Phase 2,10/13/23,"Phase 2 data presented at ECTRIMS reported that VidoCa was associated with a Nfl reduction from baseline up to W6 of -3% for the pooled 30 and 45mg VidoCa group compared to +2.5% for placebo, and up to W24 of -19% and +7%, respectively, noted October 13, 2023.",2 +ATAI,Treatment Resistant Depression,Phase 1,10/2/23,"Phase 1 data reported that treatment was well-tolerated with a favorable safety profile, and dose-dependent increases in exposure were observed, noted October 02, 2023.",2 +NVCR,Liver cancer,Phase 2,7/1/21,"Phase 2 final data reported July 1, 2021. Objective response rate for the intent-to-treat population was 9.5%.",0 +EXEL,Metastatic renal cell cancer (RCC),Approved,4/25/16,"Approved April 25, 2016.",2 +SLRX,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML),Phase 1/2,12/12/22,"Phase 1/2 data presented at ASH reported an ORR of 50% among eight myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), noted December 12, 2022.",2 +BMRN,Phenylketonuria (PKU),Phase 1/2,9/6/21,"Phase 1/2 clinical hold announced September 6, 2021.",0 +BIIB,CKD Patients at Risk of Rapid Progression,Phase 2,5/10/23,"Program discontinued, noted May 10, 2023.",0 +TEVA,Cluster headache,Phase 3,6/15/18,"Phase 3 trial to be terminated due to lack of efficacy - noted June 15, 2018.",0 +CYTK,Chronic obstructive pulmonary disease (COPD),Phase 2,10/5/18,"Phase 2 data did not meet endpoints - October 5, 2018.",0 +AZN,Paroxysmal nocturnal hemoglobinuria (PNH),Approved,12/21/18,"FDA approval announced December 21, 2018.",2 +NRIX,"B-cell malignancies, chronic lymphocytic leukemia (CLL)",Phase 1b,11/2/23,"Phase 1b data from ASH abstract reported that 9 PRs/PR with rebound lymphocytosis; additionally, 11 patients had SD at the time of data cut-off and 4 had PD, noted November 2, 2023.",1 +ADGI,COVID-19 (prevention),Phase 2/3,3/23/23,"Phase 2/3 study suggests clinically meaningful protection can be achieved at low neutralizing antibody titers, noted March 23, 2023.",2 +RVMD,Solid Tumors,Phase 1,10/13/23,"Phase 1 preliminary data shared at AACR-NCI-EORTC reported a median time to response of 1.3 months, and median time on treatment of 3.5 months in NSCLC, with a median time to response of 1.4 months, and median time on treatment of 2.4 months in CRC, noted October 13, 2023.",2 +BTAI,Opioid Withdrawal Symptoms,Phase 1/2,3/31/21,"Phase 1b/2 top-line data released March 31, 2021. Primary endpoint met. Retention secondary endpoint not met.",1 +RNAZ,Metastatic solid tumors,Phase 1a,10/24/23,"Phase 0 preliminary data showed that radioactivity consistent with accumulation of TTX-MC138 was detected by noninvasive imaging in the regions of the metastatic lesions previously identified by fluorodeoxyglucose (FDG)/positron emission tomography (PET) (FDG/PET), noted October 24, 2023.",2 +MGTX,Xerostomia,Phase 1,10/24/23,"Phase 1 OLE data presented at ESGCT showed that dosing was safe and well-tolerated at all dose levels, with no treatment-related serious adverse events or dose limiting toxicity, noted October 24, 2023.",2 +OCUP,Diabetic Retinopathy (DR) / Macular Edema (DME),Phase 2,8/28/23,"Phase 2 data reported that APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy, noted August 28, 2023.",2 +DERM,Papulopustular Rosacea,Phase 3,7/11/23,"Phase 3 topline data achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues, noted July 11, 2023.",2 +LUMO,Pediatric Growth Hormone Deficiency (PGHD),Phase 2,6/21/23,"Phase 2 new data shared at KOL shows durable response after 12 months, noted June 21, 2023.",2 +SAGE,Postpartum depression (PPD),Phase 3,10/17/22,"Additional Phase 3 data reported that a total of two participants (all in the zuranolone group) experienced four serious adverse events all of which were assessed by the investigator as unrelated to the therapy, noted October 17, 2022.",1 +REGN,Cutaneous squamous cell carcinoma,Approved,9/28/18,"FDA Approval announced September 28, 2018.",2 +SNY,Non-small cell lung cancer (NSCLC),Phase 3,9/19/21,"Phase 3 data presented at ESMO September 19, 2021 showed trial met primary and all secondary endpoints, with an objective response rate of 43%.",2 +OBSV,Improving IVF outcomes,Phase 3,11/6/19,"Phase 3 trial did not meet primary endpoint - November 10, 2019.",0 +BMY,Melanoma,Approved,12/20/17,"Approval announced December 20, 2017.",2 +IMGN,Ovarian cancer,Phase 3,11/30/21,"Phase 3 data reported that trial met primary endpoint with a confirmed objective response rate of 32.4% and median duration of response at 5.9 months, noted November 30, 2021.",2 +FRTX,Axillary hyperhidrosis,Phase 3,10/7/21,"Phase 3 study demonstrated that dosing was generally well-tolerated, the proportion of subjects achieving at least a 2-point improvement in the HDSM-Ax1 score from baseline to EOT2 was 49.3% (n=173). Additionally the change in GSP3 from baseline to EOT was -129.5mg. Overall, 82% of patients who were randomized to the dose in the study completed the full six weeks of treatment. Five (2.9%) subjects who received the dose discontinued due to a TEAE. No treatment-related Serious Adverse Events (SAEs) were reported. Noted October 7, 2021.",2 +NVS,Melanoma with BRAF V600E or V600K mutations,Approved,4/30/18,"Approval announced April 30, 2018.",2 +VCEL,Severe burns,CRL,6/29/21,"CRL announced June 29, 2021.",1 +IVA,Nonalcoholic fatty liver disease (NAFLD),Phase 2,6/13/23,"Phase 2 data of 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty liver disease (NAFLD), noted June 13, 2023.",2 +EPIX,Castrate resistant prostate cancer,Phase 1,10/31/22,"Phase 1 trial enrollment suspending October 31, 2022",0 +LBPS,Asthma,Phase 1/2,5/17/22,"Phase 1/2 data reported that 83.3% of subjects receiving treatment had improved ACQ-6 scores compared to 56.3% of those receiving placebo, noted May 17, 2022.",2 +OPTN,Nasal polyps,Approved,9/17/17,"Approval announced September 18, 2017 (prior to IPO).",2 +VBLT,Recurrent glioblastoma (rGBM) cancer,Phase 3,3/8/18,"Phase 3 top-line data released March 8, 2018 - primary endpoint not met.",0 +RHHBY,Duchenne Muscular Dystrophy,Approved,6/22/23,"FDA acelerated Approval on June 22, 2023.",2 +JNJ,Coronary Artery Disease or Peripheral Artery Disease,Phase 3,2/8/17,"Phase 3 trial stopped early due to positive efficacy - February 8, 2017.",2 +RHHBY,Huntington's Disease,Phase 3,3/22/21,Phase 3 trial to be discontinued following review of data by an Independent Data Monitoring Committee.,0 +CBAY,Primary biliary cholangitis (PBC),Phase 3,9/21/23,"Phase 3/4 study initiated, noted September 21, 2023.",1 +PFE,BRAF-Mutant Colorectal Cancer,Approved,4/8/20,"FDA Approval announced April 8, 2020.",2 +TSVT,Acute myeloid leukemia (AML),Phase 1,6/14/23,"Phase 1 paused after recent Grade 5 (fatal) serious adverse event (SAE) and was followed by the required notification to the FDA, noted June 14, 2023.",0 +SAGE,Postpartum Depression,Approved,8/4/23,"Approved August 4, 2023.",2 +VTGN,Major depressive disorder (MDD),Phase 1,6/21/23,"Phase 1 study results showed that dosing was well-tolerated and demonstrated a favorable safety and tolerability profile across single and multiple dose intranasal administrations, noted June 21, 2023.",2 +GRTX,Esophagitis,Phase 2,10/27/22,"Phase 2 Open-Label data reported that 14 of 29 evaluable patients (48.3%) experienced acute esophagitis at week 6, noted October 27, 2022.",2 +XNCR,Systemic Lupus Erythematosus (SLE),Phase 2,10/8/18,"Phase 2 top-line data released October 5, 2018. Primary endpoint not met.",0 +AVXL,Parkinson’s Disease Dementia (PDD),Phase 2,3/30/23,"Phase 2 study data met primary and key secondary endpoints, noted March 30, 2023.",1 +TENX,Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF),Phase 2,6/2/20,"Phase 2 top-line data released June 2, 2020. Primary endpoint (Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise) not met. Various secondary endpoints met.",1 +SRPT,Duchenne muscular dystrophy,Phase 3,10/14/22,"Phase 3 results presented at the World Muscle Society reported that mean dystrophin levels significantly increased from baseline after 48 weeks of casimersen treatment, noted October 14, 2022.",2 RNA,Myotonic dystrophy type 1 (DM1),Phase 1/2,9/9/23,"Phase 1/2 topline data analysis presented at the Myotonic Dystrophy Foundation Annual Conference reported directional improvements in myotonia (vHOT) as early as 6 weeks after dosing with a sustained effect at Month 6, noted September 9, 2023.",2 -NVS,Solid tumors in adult and pediatric patients,Approved,6/22/22,"Approved June 22, 2022.",2 -ARGX,Acute myeloid leukemia (AML),Phase 2,1/8/21,"Phase 2 interim data released January 8, 2021. Complete remission (CR) rate 27% (14/52) and composite complete remission (CRc), including CRs with incomplete hematologic recovery 40% (21/52).",1 -ABBV,Ulcerative Colitis,Approved,3/16/22,"Approved March 16, 2022.",2 -BNTX,"Influenza and COVID-19, Omicron BA.4/BA.5-adapted bivalent",Phase 1/2,10/26/23,"Phase 1/2 data demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains, noted October 26, 2023.",2 -PFE,Atopic dermatitis in adolescents,Approved,2/10/23,"Approved February 10, 2023.",2 -ROIV,Atopic Dermatitis,Phase 3,3/15/23,"Phase 3 study met primary of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) and all secondary endpoints, noted March 15, 2023.",1 -MIRM,Progressive Familial Intrahepatic Cholestasis (PFIC),Phase 3,10/24/22,"Phase 3 top-line data reported that trial met primary endpoint, noted October 24, 2022.",1 -IKT,Parkinson’s disease,Phase 2,10/16/23,"Phase 2 update showed that at the end of study timepoint, participants administered the 200 mg dose had a combined Part 2 and Part 3 score that was lower by an average of -8.7 points. By contrast, the combined placebo score increased by an average of +1.7 points, a -10.4 point spread between actively treated versus placebo participants, noted October 16, 2023.",2 -NVS,Relapsing multiple sclerosis,Approved,8/20/20,"FDA approval announced August 20, 2020.",2 -JAGX,Chemotherapy-induced diarrhea (CID) in dogs,Approved,12/21/21,"FDA conditionally approved on December 21, 2021.",2 -MBRX,Soft tissue sarcoma lung metastases,Phase 1/2,7/28/22,"Preliminary Phase 1b data reported that treatment demonstrated clinical activity, defined as stable disease or better, noted July 28, 2022.",2 -BMY,Small cell lung cancer (SCLC),Approved,8/17/18,"FDA approval announced August 17, 2018.",2 -AZN,Castration-Resistant Prostate Cancer,Approved,5/19/20,"FDA Approval announced May 19, 2020.",2 -MGTX,X-linked retinitis pigmentosa (XLRP),Phase 1/2,10/1/22,"Full Phase 1/2 data presented at AAO reported an improvement in mean retinal sensitivity in the treated eye compared to untreated eyes in the randomized concurrent control arm, noted October 1, 2022.",2 -RFL,Acute myeloid leukemia (AML),Phase 3,10/28/21,"Phase 3 trial to be stopped due to lack of efficacy based on recommendation from independent data monitoring committee, noted October 28, 2021.",0 -PRAX,Essential tremor,Phase 2,8/8/23,"Phase 2 patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111). Patients withdrawing from ulixacaltamide to placebo experienced worsening in mADL11, noted August 8, 2023.",2 -MIST,Paroxysmal supraventricular tachycardia (PSVT),Phase 3,11/15/21,"Phase 3 top-line data showed that the nasal dose significantly decreased heart rate during supraventricular tachycardia (SVT) episodes and independent of conversion to sinus rhythm (SR). Heart rate changes occurred within 5 minutes and were sustained for 60 minutes, noted November 15, 2021.",2 -BBIO,Achondroplasia,Phase 2,6/20/23,"Phase 2 cohort 5 data reported at ENDO showed that at the Cohort 5 dose level resulted in a significant and robust increase in AHV compared to BL, with a change of +3.38cm/year, noted June 20, 2023.",2 -BMRN,Batten Disease,Approved,4/27/17,"PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.",2 -BPMC,Gastrointestinal stromal tumors (GIST),Phase 3,4/28/20,"Phase 3 data did not meet primary endpoint - April 28, 2020.",0 +MTNB,Cryptococcal meningitis,Phase 1/2,10/21/22,"Phase 1/2 cohort 4 data reported that CSF yeast clearance rate exceeded the prespecified primary endpoint, with an interim survival currently 90%, while the survival rate at Week 2 was 95%, noted October 21, 2022.",1 +BMY,Hypertrophic cardiomyopathy (HCM),Approved,4/28/22,"Approved April 28, 2022.",2 +MRK,Small cell lung cancer (SCLC),Phase 3,1/6/20,Phase 3 data met PFS primary endpoint; overall survival primary endpoint not met,0 +IVVD,COVID-19 Prevention,Phase 3,9/11/23,"Phase 3 dosing initiated, noted September 11, 2023.",1 +LLY,Axial Spondyloarthritis,Approved,8/26/19,"FDA Approval announced August 26, 2019.",2 +FULC,COVID-19,Phase 3,3/4/21,"Phase 3 trial to be discontinued - March 4, 2021.",0 +ALPMY,"Claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma",Phase 3,10/21/23,"Phase 3 data presented at ESMO reported that median PFS was 11.0 vs 8.9 mo and median OS was 18.2 vs 15.6 mo, noted October 21, 2023.",2 +GILD,Metastatic urothelial cancer (mUC),Phase 2,2/17/23,"Phase 2 data demonstrated the efficacy of 13.5 Months overall survival in patients, noted February 17, 2023.",2 +ABBV,Functional Constipation in pediatric patients aged 6-17,Approved,6/12/23,"FDA Approved on June 12, 2023.",2 +RHHBY,Non-Hogkin Lymphona,Phase 1/2,12/11/21,"Phase 1b/2 results reported an objective response rate (ORR) of 65% with a median duration of response (DOR) not reached (observed DOR: 0.1+ to 15.3+ months). At data cut-off, one patient had achieved a CR after an initial CR that had lasted for 15 months, noted December 11, 2021.",2 +NVO,Type 1 and type 2 diabetes,Phase 3,9/29/17,"Approved September 29, 2017.",2 +NBTX,Non-small cell lung cancer (NSCLC),Phase 1/2,7/19/23,"Phase 1/2 dosing initiated, noted July 19, 2023.",1 +DNLI,Healthy Volunteers,Phase 1,10/6/21,"Phase 1 data noted that treatment was well tolerated for up to 14 days of dosing, with robust distribution in the central nervous system (CNS) and predictable dose-related increases in exposure with a PK profile supporting once daily dosing, noted October 6, 2021.",2 +PRFX,Bunionectomy,Phase 3,6/8/23,"Phase 3 clinical trial Company's supplier of the API (active pharmaceutical ingredient) has received a deficiency notice from the FDA related to its Drug Master File (DMF). As a result, the second part of the Phase 3 trial is expected to commence once the supplier has provided the required information to the FDA and the deficiency notice has been resolved, noted June 8, 2023.",1 +PRQR,Autosomal dominant retinitis pigmentosa (adRP),Phase 1/2,11/18/21,"Phase 1/2 data reported 3 cases of cataract worsening, with maximum benefit in BCVA observed after 5 weeks and declined thereafter. A mean BCVA benefit of +1.4 letters was reported across all subjects. In doses 75 - 300µg, the mean BCVA benefit was +5 letters, maximum benefit observed was +7 letters, noted November 18, 2021.",2 +AVTX,Non-Eosinophilic Asthma (NEA),Phase 2,6/26/23,"Phase 2 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, noted June 26, 2023.",2 +IMCR,Uveal melanoma,Approved,1/26/22,"Approved January 26, 2022.",2 +JNJ,Multiple myeloma,Approved,5/1/20,"FDA Approval announced May 1, 2020.",2 +GSK,Chronic rhinosinusitis with nasal polyps,Approved,7/29/21,"FDA approval announced July 29, 2021.",2 +BMY,Mesothelioma,Approved,10/2/20,"FDA approval announced October 2, 2020.",2 +IPSEY,Pancreatic cancer,Phase 3,11/9/22,"Phase 3 data met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated. Key secondary efficacy outcomes of progression-free survival (PFS) also showed significant improvement over the comparator arm, noted November 9, 2022.",2 +ENTA,Primary biliary cholangitis (PBC),Phase 2,5/6/20,"Phase 2 top-line data did not meet primary endpoint - May 6, 2020.",0 +IOBT,Advanced melanoma,Phase 3,6/14/23,"Phase 3 trial protocol calls for an interim analysis of overall response rate (ORR) one year after 225 patients have been randomized. Additionally the number of patients to be enrolled has been increased to 380 patients, which could potentially accelerate the time to reach the primary endpoint of progression free survival, noted June 14, 2023.",2 +VALN,Chikungunya Vaccine for adolecents,Phase 3,8/28/23,"Phase 3 trial data reported that VLA1553 was generally safe and well tolerated in adolescents aged 12 to 17 years, regardless of previous CHIKV infection, noted August 28, 2023.",2 +GLPG,"B-cell malignancies, Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)",Phase 1/2,6/9/23,"Phase 1/2 data presented at EHA showed that based on current results (n=7). For all 7 pts, GLPG5201 was successfully manufactured at the PoC and administered as a fresh product, with a median vein-to-vein time of 7 days. Rapid complete responses have been observed with a 100% ORR in a heavily pre-treated pt population. Ph 1 recruitment is ongoing to establish a recommended dose for Phase 2, noted June 9, 2023.",2 +FWBI,Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency,Phase 2,8/18/21,"Phase 2 top line data released August 18, 2021. Clinically meaningful improvements in the primary efficacy endpoint noted.",2 +XERS,Hypoglycemia-Associated Autonomic Failure,Phase 2,11/21/19,"Phase 2 data showed no statistically significant differences between the treatment arms. Program to be discontinued - November 21, 2019.",0 +MRK,Classical Hodgkin lymphoma,Approved,10/15/20,"FDA Approval announced October 15, 2020.",2 +ABBV,Episodic Migraine,Phase 3,4/21/23,"Phase 3 trial met its primary and secondary endpoints, noted April 21, 2023.",1 +PFE,Bosimilar to Humira (adalimumab),Approved,11/18/19,"FDA Approval announced November 18, 2019.",2 +ALKS,Major depressive disorder,CRL,2/1/19,"CRL announced February 1, 2019.",1 +ANIP,Tranxene generic,Approved,6/22/22,"Approved June 22, 2022.",2 +TPTX,RET-altered NSCLC,Phase 1/2,4/5/21,"Phase 1/2 interim data noted 3/14 partial responses - April 5, 2021.",1 +ORTX,Mucopolysaccharidosis type I (MPS-I),Phase 1,10/26/23,"PoC data presented at ESGCT resulted in improvement 62.5% of patients or stabilization 37.5% of patients of corneal clouding at the time of last follow-up ranging from 3.14-4.58 years compared to baseline measured prior to administration with OTL-203, noted October 26, 2023.",2 +AMGN,Scalp Psoriasis,Approved,4/30/20,FDA approval announced April 2020.,2 +GTHX,Metastatic colorectal cancer (mCRC),Phase 3,2/13/23,"Phase 3 topline data reported that achieved its co-primary endpoints related to severe neutropenia but failed to achieve a significant response in overall response rate (ORR) and preliminary measures of survival, noted February 13, 2023.",2 ZLAB,Immune thrombocytopenia (ITP),Phase 3,5/5/22,"Phase 3 top-line data reported that trial met primary endpoint, noted May 5, 2022.",1 -HGEN,COVID-19,Phase 2/3,7/13/22,"Phase 2/3 top-line data showed that trial did not achieve statistical significance on the primary endpoint. The data also showed a non-significant trend toward a reduction in mortality in the overall patient population, noted July 13, 2022.",2 -PLXP,Mild infections of diabetic foot ulcers,Phase 3,10/25/16,"Phase 3 top-line data did not meet endpoints - October 25, 2016 - TICKER CHANGED FROM DPRX FOLLOWING MERGER",0 +URGN,Overactive Bladder (OAB),Phase 2,8/27/20,"Phase 2 trial did not meet primary endpoint - August 27, 2020.",0 +GRCL,Relapsed/refractory multiple myeloma (RRMM),Phase 1,9/10/23,"Phase 1 updated data at EHA demonstrated 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk RRMM population, noted June 10, 2023.",2 +ABIO,Chronic Heart Failure,Phase 2b,5/27/18,"Oral presentation of data May 27, 2018.",1 +ALVO,Inflammatory conditions,CRL,10/12/23,"CRL received October 12, 2023.",1 +LLY,Ulcerative Colitis (Maintenance data),Phase 3,5/8/23,"Additional Phase 3 data reported that bowel urgency remission directly accounted for a 44.8% and 32.5% improvement in IBDQ total score, respectively; 22.7% and 39.1% improvement, respectively, was mediated by rectal bleeding remission, and 32.5% and 28.4%, respectively, mediated by stool frequency remission, noted May 8, 2023.",2 +CYTH,Niemann-Pick Disease Type C,Phase 1,10/18/22,"Phase 1 data showed that treatment overcomes the NPC1 defect by removing trapped cholesterol from cells both systemically and in the central nervous system (CNS), noted October 18, 2022.",2 +RHHBY,Diffuse large B-cell lymphoma (DLBCL),Approved,6/10/19,"FDA approval announced June 10, 2019.",2 +NBIX,Tourette syndrome - juvenile,Phase 2b,12/12/18,"Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.",0 +SXTP,COVID-19 patients with mild-moderate symptoms and low risk of disease progression,Phase 1a,9/18/23,"IND withdrawn, noted September 18, 2023",1 +NVS,Metastatic castration-resistant prostate cancer (mCRPC),Approved,3/23/22,"Approved March 23, 2022.",2 +SRPT,Duchenne Muscular Dystrophy,Approved,6/22/23,"FDA acelerated Approval on June 22, 2023.",2 +GSK,"Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients",CRL,10/26/17,"CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.",2 +OBSV,Uterine fibroids,Phase 3,10/20/21,"Phase 3 data reported once daily treatment without ABT reduced uterine volume by 39% after 24 weeks. However, co-administration of hormonal ABT after 24 weeks counteracted the uterine volume reducing effects at 52 weeks, noted October 20, 2021.",1 +GILD,Triple-negative breast cancer,Approved,4/22/20,"FDA Approval announced April 22, 2020.",2 +ARQT,Vitiligo,Phase 2b,7/1/21,"Phase 2a trial to be terminated - noted July 1, 2021.",0 +JNJ,Urothelial cancer,Approved,4/12/19,"FDA Approval announced April 12, 2019.",2 +RIGL,Acute myeloid leukemia,Approved,12/1/22,"Approved December 1, 2022.",2 AKRO,Nonalcoholic Steatohepatitis,Phase 2b,10/4/23,"Phase 2b results published at the Lancet Gastroenterology & Hepatology showed that both EFX doses achieved statistical significance on primary and secondary histopathology endpoints after 24 weeks, noted October 4, 2023.",2 -AZN,Refractory generalized myasthenia gravis (gMG),Approved,10/23/17,"Approval announced October 23, 2017.",2 -BCLI,Amytrophic lateral sclerosis (ALS),PDUFA,9/27/23,"Advisory Committee meeting voted 17-1 that NurOwn did not demonstrate substantial evidence of effectiveness for the treatment of mild to moderate ALS, noted September 27, 2023.",2 -RHHBY,SMA type 1/2/3 switching,Phase 2,6/11/21,"Phase 2 data reported a sustained >2-fold increase in median SMN protein levels versus baseline in all patients who received prior treatment, noted June 11, 2021.",2 -TNXP,fibromyalgia-type Long COVID,Phase 2,9/5/23,"Phase 2 topline data did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at Week 14, noted September 5, 2023.",2 -NOVN,Molluscum Contagiosum,Phase 3,9/23/21,"Phase 3 safety data showed TEAEs reported in greater than 5% of subjects in the SB206 treated groups were all at the application site (pain, erythema, pruritis, exfoliation, and dermatitis) with the high majority of these TEAEs being mild or moderate by severity, noted September 23, 2021.",2 -IOVA,anti-PD-1 therapy for advanced (unresectable or metastatic) Non-small Cell Lung Cancer (NSCLC),Phase 2,7/10/23,"Phase 2 preliminary data in the trial showed that the median duration of response wasn't reached. Treatrdent-emergent adverse events were consistent with the underlying disease and known adverse event profiles of non-myeloablative lymphodepletion and interleukin-2, noted July 10, 2023.",2 -LPTX,Esophagogastric adenocarcinoma,Phase 1/2,8/6/19,"Phase 1/2 data August 6, 2019 noted 50% ORR.",1 -GLPG,Idiopathic pulmonary fibrosis (IPF),Phase 2,11/30/20,"Phase 2 data released November 30, 2020 - forced vital capacity (FVC) decline of 42mL across treatment groups at 26 weeks. Phase 2b trial planned.",2 -EQ,Celiac disease,Phase 1,5/15/23,"Phase 1 data suggested that selective blockade of IL-15 and IL-21 inhibits the synergistic signaling that mediates NK and T cell responses in multiple immune disorders including celiac disease, noted May 15, 2023.",1 -CUE,Wilms' Tumor (WT1)-expressing cancers,Phase 1,11/3/23,"Phase 1 data presented at SITC demonstrated a 75%-80% DCR at the 4mg/kg and 2mg/kg doses respectively with two patients demonstrating tumor reductions of -30% and -29%, noted November 3, 2023.",2 -AMGN,Plaque psoriasis in pediatric patients,Phase 3,9/9/22,"Phase 3 primary endpoint was met, noted September 8, 2022.",1 -MRK,Pneumococcal Conjugate Vaccine,Phase 3,5/20/21,"Phase 3 trial met primary immunogenicity and safety endpoints - May 20, 2021.",2 -PHIO,Melanoma,Phase 1b,3/22/23,"Phase 1b safety data reported no dose-limiting toxicity, and no drug-related severe adverse events or serious adverse events, noted March 22, 2023.",1 -JNJ,Frontline multiple myeloma (non-transplant),Approved,5/7/18,"Approval announced May 7, 2018.",2 -TERN,Non-alcoholic steatohepatitis (NASH),Phase 1,11/4/22,"Phase 1 data reported that TERN-501 was generally well tolerated and exhibited dose-dependent pharmacokinetics with low variability, noted November 4, 2022",2 -ACIU,Alzheimer’s disease (AD),Phase 2,6/2/21,"Phase 2 interim analysis June 2, 2021. Good safety confirmed.",2 -BMY,Melanoma,Approved,3/18/22,"Approved March 18, 2022.",2 -AZN,B-cell non-Hodgkin lymphoma,Phase 1,12/12/22,"Phase 1 trial interim results presented at ASH reported that response-evaluable FL subjects treated at ≥ 800µg, the ORR was 88% (7/8 subjects); all responding subjects achieved a CR, noted December 12, 2022.",2 -ALNY,Primary Hyperoxaluria Type 1 (PH1),Approved,11/24/20,"FDA approval announced November 24, 2020.",2 -ALPMY,"Claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma",Phase 3,10/21/23,"Phase 3 data presented at ESMO reported that median PFS was 11.0 vs 8.9 mo and median OS was 18.2 vs 15.6 mo, noted October 21, 2023.",2 -VRCA,Molluscum contagiosum,Approved,7/21/23,"Approved July 21, 2023.",2 -BMY,Non-small-cell lung cancer (NSCLC) and solid tumors,Phase 1/2,4/12/22,"Phase 1/2 top-line data reported that in the ROS1-positive TKI-naïve advanced NSCLC population the cORR was 79%, with 4 patients receiving a complete response, and 52 having a partial response. With DOR ranging from 1.4+ to 35.1+ months and PFS ranging from 0+ to 40.4+ months, noted April 12, 2022.",1 -BPMC,CCNE-aberrant cancers,Phase 1/2,6/5/23,"Phase 1/2 data presented at ASCO reported a confirmed partial response, noted June 5, 2023.",2 -LGND,Pneumococcal Conjugate Vaccine,Phase 3,7/27/23,"Phase 3 trial met primary endpoints, noted July 27, 2023.",1 -CABA,Pemphigus vulgaris,Phase 1,5/18/23,"Phase 1 presented at ASGCT reported that no DLTs were observed and no clear pattern of changes in anti-DSG3 autoantibody levels across dosing cohorts were observed despite increased DSG3-CAART cell persistence, noted May 18, 2023.",2 -BLPH,Pulmonary Hypertension-Sarcoidosis (PH-Sarc),Phase 2,12/17/21,"Phase 2 top-line data reported that all 8 subjects demonstrated decreases in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). Treatment resulted in a median drop of 20% in PVR, compared to a median baseline PVR of 329 dyne/cm.sec-5; a reduction of 20% or more in PVR, noted December 17, 2021.",2 -SPPI,Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2,Phase 2,9/10/22,"Phase 2 cohorts 2 and 4 data presented at ESMO showed that 12/14 patients were evaluable and all had partial response, resulting in an ORR of 85.7% (95% CI, 57.2, 98.2) and a median DOR of 5.5 months . The ORR was 100% in the previously treated C2 patients, and 71.4% in the treatment naïve C4 patients. Median DOR was 5.3 months for the C2 patients and 8.9 months for those in C4, noted September 10, 2022.",2 -BMY,Melanoma,Phase 3,10/2/20,Statistically significant improvement in RFS in the all-comer (intent-to-treat) population failed to show.,0 -MDWD,Lower leg ulcers,Phase 2,4/12/22,"Phase 2 top-line data presented at the SAWC 2022 showed treatment to debride wounds and promote wound area reduction, while reducing biofilm and bacterial bioburden safely and effectively, noted April 12, 2022.",2 -EXEL,Thyroid Carcinoma,Phase 3,9/20/21,"Phase 3 data showed a median progression-free survival was 11.0 months for CABOMETYX compared with 1.9 months for placebo. Objective response rate (ORR) favored CABOMETYX at 11%, including one complete response, versus 0% for placebo. Median overall survival was 19.4 months, September 20, 2021.",2 -TBPH,Asthma,Phase 2,11/5/20,"Phase 2a trial did not meet primary endpoint - November 5, 2020.",0 -RARE,Glycogen Storage Disease Type Ia (GSDIa),Phase 1/2,5/19/22,"Phase 1/2 week 52 clinical efficacy and safety data reported that patients reached a mean total daily reduction of cornstarch intake of 70%, noted May 19, 2022.",2 -SNY,Atopic dermatitis 12-17 year-olds,Approved,3/11/19,"FDA approval announced March 11, 2019.",2 -GSK,HIV,Approved,1/21/21,"FDA approval announced January 21, 2021.",2 -BMEA,"Healthy volunteers, type 2 diabetes",Phase 2,6/24/23,"Additional Phase 2 data presented at ADA of eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B, measured during oral glucose tolerance testing (OGTT), supporting improved beta cell function for these patients, June 24, 2023.",2 -REGN,Prurigo nodularis (PN),Approved,9/28/22,"Approved September 28, 2022.",2 -IPSEY,Primary biliary cholangitis (PBC),Phase 3,6/30/23,"Phase 3 data reported that trial met primary endpoint, noted June 30, 2023.",1 -ASMB,Hepatitis B,Phase 1a,4/18/23,"Phase 1a clinical data for the remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and cccDNA formation, noted April 18, 2023.",2 -TVTX,IgA nephropathy (IgAN),Phase 3,11/3/23,"Additional Phase 3 data presented at ASN showed one of the slowest rates of kidney function decline in IgAN trials, consistent treatment effects across baseline eGFR and proteinuria, and higher rates of complete remission compared to maximally tolerated dose of irbesartan through 110 weeks of treatment, noted November 3, 2023.",2 -PFE,Gastric cancer,Phase 3,11/8/19,"Phase 3 endpoint not met - November 8, 2019.",0 -EXEL,First-line renal cell carcinoma,Phase 3,9/16/21,"Additional Phase 3 data presented at ESMO September 16, 2021. At a median follow-up of 23.5 months, progression free survival (PFS) and objective response rate (ORR) benefits were observed regardless of prior nephrectomy status. The magnitudes of PFS and ORR benefits were greater in the subgroup with prior nephrectomy.",2 -ALLK,Eosinophilic Gastritis and/or eosinophilic duodenitis (EoD),Phase 3,9/9/22,"Phase 3 24-week data showed that the company met its histologic co-primary endpoint but missed symptomatic co-primary endpoint, noted September 9, 2022.",2 -CRNX,Congenital adrenal hyperplasia and Cushing’s disease,Phase 1,5/25/22,"Data from MAD cohort results showed serum cortisol below normal levels and a marked reduction in 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations, noted May 25, 2022.",2 -CLNN,Amyotrophic Lateral Sclerosis,Phase 2,8/29/23,"Phase 2 OLE data reported a significant median survival benefit of 19.3 months using the rank-preserving structural failure time model (RPSFTM) and a significant 52% decreased risk of ALS clinical worsening events, noted August 29, 2023.",2 -FDMT,Choroideremia,Phase 1,10/25/21,"Phase 1 initial data from 6 patients enrolled in one of two dose cohorts: 3E11 vg/eye (cohort 1; n=3) and 1E12 vg/eye (cohort 2; n=3). The study showed that at the 3E11 vg/eye dose (Cohort 1), 4D-110 was well-tolerated with no dose-limiting toxicities or serious adverse events. At the 1E12 vg/eye dose, pigment dispersion (iris transillumination) was observed in 3 patients in the 1E12 vg/eye cohort ~7 to 9 months following treatment, 2 cases were asymptomatic and 1 patient reported mild glare.",1 -CYTK,Heart failure with reduced ejection fraction (HFrEF),Phase 3,4/3/22,"Phase 3 results reported that there was no change in pVO2 in patients treated with omecamtiv mecarbil versus placebo, noted April 3, 2022.",2 -ALNY,Alzheimer's Disease and Cerebral Amyloid Angiopathy,Phase 1,10/25/23,"Phase 1 achieve sustained pharmacodynamic activity up to 10 months after administration, noted October 25, 2023.",2 -DNLI,Hunter syndrome MPS II,Phase 1/2,8/30/23,"Additional data from SSIEM reported that data demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkers, noted August 30, 2023.",2 -GSK,Asthma,Approved,9/9/20,"FDA approval announced September 9, 2020.",2 -MRK,Untreated locally advanced or metastatic urothelial cancer (la/mUC),Phase 3,10/23/23,"Phase 3 data presented at ESMO reported a median OS of 31.5 months (95% CI: 25.4-NR) compared to 16.1 months in the chemotherapy arm, significantly prolonged OS, reducing the risk of death by 53% compared to treatment with chemotherapy, noted October 23, 2023.",2 -CPRX,MuSK-antibody positive myasthenia gravis (MuSK-MG),Phase 3,8/10/20,"Phase 3 trial did not meet primary endpoint - August 10, 2020.",0 -MRNS,Tuberous Sclerosis Complex,Phase 2,8/17/21,"Phase 2 top-line data released August 17, 2021. Primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline.",2 -UBX,Wet age-related macular degeneration (AMD),Phase 2,9/27/23,"Phase 2 patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease. 40% of UBX1325-treated patients did not require anti-VEGF treatment through 48 weeks and 64% achieved an anti-VEGF treatment-free interval of over 24 weeks, noted Septemeber 27, 2023.",2 -IMAB,Ulcerative colitis,Phase 2,4/26/21,Phase 2 trial met primary endpoint.,2 -ATHA,Alzheimer’s disease,Phase 3,10/17/22,"Phase 3 interim analysis reported that an additional enrollment of ~150 patients will be well powered for the primary endpoint analysis, noted October 17, 2022.",1 -MGNX,Solid tumors,Phase 1,2/14/23,"Phase 1 reported that nine of the 35 patients (25.7%) achieved confirmed partial responses (cPR), noted February 14, 2023.",2 -AZN,COPD,Phase 3,5/30/18,"Phase 3 data released May 30, 2018. Primary endpoint not met.",0 -JNJ,Psoriatic Arthritis in Pediatric Patients,Approved,8/1/22,"Approved August 1, 2022.",2 -ALEC,Frontotemporal Dementia,Phase 2,8/3/23,"Additional Phase 2 data considered to be uninformative regarding treatment effect, noted August 3, 2023.",2 -TBPH,Asthma,Approved,9/9/20,"FDA approval announced September 9, 2020.",2 -BIIB,Cognitive Impairment Associated With Schizophrenia (CIAS),Phase 2b,7/20/22,"Phase 2b trial did not meet its primary endpoint, and program will be discontinued, noted July 20, 2022.",2 -CRBU,B-Cell Non-Hodgkin Lymphoma,Phase 1,7/13/23,"Phase 1 update reported a 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010, with 24 months as the longer CR maintained to date, noted July 13, 2023.",1 -CALT,IgA Nephropathy,Phase 3,6/21/23,"Phase 3 data presented at ERA continue to show that study study met its primary endpoint with Nefecon demonstrating a highly statistically significant benefit over placebo. Additionally the company submitted its sNDA based on this results to the FDA, noted June 21, 2023.",2 -BGNE,Non-small cell lung cancer (NSCLC),Phase 3,4/12/21,"Phase 3 trial met primary endpoint of overall survival - November 17, 2020. Data presented at AACR meeting April 12, 2021. ORR 21.9% vs 7.0% for docetaxel; PFS 23.3% vs 5.7% in docetaxel arm; OS 17.2 months vs to 11.9 months in the docetaxel arm.",2 -ORIC,Multiple myeloma,Phase 1b,11/2/23,"Phase 1b data from ASH abstract reported that ORIC-533 was very well tolerated, with 5 patients experiencing a total of 10 treatment-related adverse events (TRAEs), noted November 2, 2023.",2 -GILD,Acute myeloid leukemia (AML),Phase 3,8/21/23,"Partial hold by the FDA on enrollment, noted August 21, 2023.",1 -GMAB,Follicular lymphoma (FL),Phase 1/2,6/28/23,"Phase 1/2 FL cohort data reported an overall response rate (ORR) of 82% and that the median duration of response (DOR) was not reached, noted June 28, 2023.",2 -XENE,Postherpetic neuralgia,Phase 2b,6/27/17,"Phase 2b data released June 27, 2017. Endpoints not met.",0 -ETNB,Severe hypertriglyceridemia,Phase 2,6/24/23,"Phase 2 data presented at EASL showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin's favorable safety and tolerability profile, noted June 24, 2023.",2 -BHVN,Multiple system atrophy (MSA),Phase 3,9/27/21,"Phase 3 trial did not met primary or secondary endpoints, noted September 27, 2021.",0 -SAGE,Major Depressive Disorder (MDD),Phase 3,12/5/19,"Phase 3 data did not meet primary endpoint - December 5, 2019.",0 -AMGN,Colorectal Cancer (CRC),Phase 1b,9/12/22,"Phase 1b data presented at ESMO showed that treatment achieved a 30% confirmed objective response rate in patients with KRAS G12C-mutated metastatic colorectal cancer. Treatment response rates can be as low as 2% in this patient population, and the current standard of care offers a median progression-free survival benefit of 2 months, noted September 12, 2022.",2 -FATE,Non Hodgkin Lymphoma,Phase 1,12/4/20,"Phase 1 interim data released December 4, 2020. 2/4 complete responses and one partial response.",1 -APRE,TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) - post transplant,Phase 2,12/13/21,"Phase 2 data from 33 patients enrolled demonstrated a 60% relapse free survival and 79% overall survival, both at 1 year post-transplant. Median overall survival was 20.6 months.",2 -LLY,Diabetes,Approved,6/15/20,"FDA Approval announced June 15, 2020.",2 -MRK,Non-muscle invasive bladder cancer (NMIBC),Phase 1,7/28/23,"Phase 1 dosing initiated, noted July 28, 2023.",1 -CUE,HPV16+ head and neck cancer,Phase 1,11/3/23,"Phase 1 data shared at SITC showed an overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) HNSCC patients treated with CUE-101 and pembrolizumab. ORR of 56% in patients with low expression of PD-L1 in the tumor, noted November 3, 2023.",2 -AZN,Anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG),Approved,4/28/22,"Approved April 28, 2022.",2 -SGEN,Acute myeloid leukemia (AML) - cancer,Phase 3,6/19/17,"Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.",0 -MEIP,B-Cell Malignancies or Acute Myeloid Leukemia (AML),Phase 1,11/2/23,"Phase 1 data from ASH abstract reported that at 200 mg, 5 of 10 AML pts (50%) had stable disease, noted November 2, 2023.",1 -HARP,Multiple myeloma,Phase 1,11/2/23,"Phase 1 data from ASH abstract reported that among the 12mg and 24mg cohorts, 55% (22/40) of efficacy-evaluable pts currently have had a confirmed response (PR or better) and among pts with a response, 73% (16/22) have had a confirmed response of VGPR or better, noted November 2, 2023.",2 -NVS,"Various blood cancers, rheumatoid arthritis.",CRL,5/2/18,"CRL issued May 2, 2018.",1 -KPRX,Rheumatoid Arthritis,Phase 1b,4/25/22,"Phase 1b results demonstrated safety and tolerability of treatment as well as statistically significant improvements in conjunctival hyperemia in the 0.15% arm compared to vehicle control, noted April 25, 2022.",2 -SNDX,"Recurrent non-small cell lung cancer (NSCLC), colorectal cancer",Phase 2,9/24/18,"Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.",0 -SQZ,Solid Tumors,Phase 1/2,12/9/21,"Phase 1/2 monotherapy data reported that of the five patients in this cohort, one patient showed a radiographic response and symptomatic improvement and reported a complete response, noted December 9, 2021.",1 -VRTX,Acute Pain following bunionectomy or abdominoplasty surgery,Phase 2,3/31/22,"Phase 2 trial met primary endpoint, noted March 31, 2022.",1 -MRSN,Non-small cell lung cancer (NSCLC) adenocarcinoma and ovarian cancer,Phase 1,8/6/21,Phase 1 top-line data due 4Q 2021.,1 -AADI,Soft Tissue Sarcoma,Phase 1,6/5/23,"Phase 1 data at ASCO reported that 3 of the 18 evaluable patients having achieved a partial response, and 13 achieving stable disease, noted June 5, 2023.",2 -INFI,Solid tumors,Phase 1,11/10/18,Further data due at SITC November 2018 noted 2/44 PRs.,1 -LLY,Systemic lupus erythematosus (SLE),Phase 2,4/27/23,"Phase 2 to be moved to from Lupus to Atopic dermatitis after disappointing results, noted April 27, 2023.",1 -HALO,Chronic inflammatory demyelinating polyneuropathy (CIDP),Phase 2,7/17/23,"Phase 2 trial met primary endpoints, noted July 17, 2023.",1 -GLUE,MYC-driven solid tumors,Phase 1/2,10/17/23,"Phase 1/2 initial data study demonstrated favorable tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in heavily pre-treated patients with lung and high-grade neuroendocrine cancers., noted October 17, 2023",2 -SRPT,Duchenne muscular dystrophy,Phase 2,5/3/21,"Phase 2 30 mg/kg arm data presented May 3, 2021 - mean exon skipping of 10.79% and mean dystrophin expression of 6.55%.",1 -PFE,Children - growth hormone deficiency,Approved,6/28/23,"FDA Approved on June 28, 2023.",2 -CLSD,Wet age-related macular degeneration,Phase 1/2,10/16/23,"Phase 1/2a results demonstrated the key benefits targeting the site of disease at the back of the eye, noted October 16, 2023.",2 -IXHL,Anxiety,Phase 2,3/15/23,"Phase 2 data reported that the company found that there is a high probability that the total study will show a statistically significant benefit for the psilocybin treatment arm over the placebo treatment arm. This projection is made by assuming the effect size observed in the interim analysis for 29 participants is representative of the effect size through the remaining 43 participants, noted March 15, 2023.",2 -ANAB,dMMR endometrial cancer,Approved,2/10/23,"Full approval granted February 10, 2023.",2 -CLDX,Metastatic triple negative breast cancers that overexpress gpNMB,Phase 2b,4/16/18,"Phase 2b data released April 16, 2018 - primary endpoint not met.",0 -SWTX,Neurofibromas,Phase 2b,2/25/21,Phase 2b interim data noted 10/20 Patients (50%) achieved an Objective Response,1 -TXMD,Moderate to severe vasomotor symptoms (VMS),Approved,10/29/18,"FDA approval announced October 29, 2018.",2 -ALT,Flu vaccine,Phase 2,3/19/19,"Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.",2 -EQ,Acute graft-versus-host disease,Phase 3,4/26/23,"Phase 3 results reported that response at Day 29 was associated with improved progression-free survival through 1 year, noted April 26, 2023.",2 -BBIO,Canavan Disease,Phase 1/2,5/22/23,"Phase 1/2 data presented at AGSCT reported percent decreases in NAA from baseline ranged between 70% and 95% in cerebrospinal fluid (CSF), 29% and 88% in urine, and 8% and 75% in brain, noted May 22, 2023.",2 -CORT,Antipsychotic-induced weight gain (APIWG),Phase 2,12/8/22,"Phase 2 data reported that AIWG did not reverse, noted December 8, 2022.",1 -MRK,"High-Risk, Early-Stage ER+/HER2- Breast Cancer",Phase 3,10/20/23,"Phase 3 data presented at ESMO reported that treatment significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy (24.3% vs. 15.6%, respectively), noted October 20, 2023.",2 -RVNC,Upper facial lines,Phase 2,12/17/20,Efficacy of none or mild wrinkle severity seen in greater than 92% of subjects after four weeks.,2 -IOVA,Solid Tumors,Phase 2,9/12/23,"Phase 2 data presented at WCLC reported that the ORR was 42.1%, noted September 12, 2023.",2 +ACRS,Rheumatoid arthritis (RA),Phase 2a,1/19/21,"Phase 2a 12-week data released January 19, 2021 - generally well tolerated.",2 +MACK,Cancer - Heregulin Positive Non-Small Cell Lung Cancer,Phase 2,10/19/18,"Phase 2 trial discontinued due to futility - noted October 19, 2018.",0 +MRNA,Seasonal influenza,Phase 3,9/13/23,"Phase 3 trial met all co-primary endpoints, noted September 13, 2023.",1 +CING,ADHD,Phase 3,9/9/23,"Phase 3 trial full results reported improvements on the PERMP scores with a trend towards statistical significance for PERMP ratings over the 16-hour period, noted September 9, 2023.",2 +MRNS,CDKL5 Deficiency Disorder (CDD),Approved,3/18/22,"Approved March 18, 2022.",2 +CYTO,COVID-19,Phase 1,1/24/23,"Phase 1 topline data reported that trial did not meet primary endpoint, noted January 24, 2023.",2 +MESO,"Inflammatory bowel disease (IBD), Ulcerative colitis or Crohn’s colitis",Phase 1/2,2/20/22,"Phase 1/2 interim analysis reported that all ulcerative colitis patients had improved clinical and endoscopy scores within two weeks, and all Crohn’s colitis patients showed treatment remissions or responses by three months, noted February 20, 2022.",2 +AGIO,Advanced hematologic malignancies with an IDH2 mutation,Approved,8/1/17,"Approval announced August 1, 2017.",2 +MRTX,Non-Small Cell Lung Cancer (NSCLC),Phase 2,10/20/23,"Phase 2 data presented at ESMO 2023 reported that in patients with PD-L1 TPS ≥50%, adagrasib + pembrolizumab demonstrated a higher response rate (63%) than expected with pembrolizumab monotherapy (39–45%3,4), noted October 20, 2023.",2 +MRUS,Solid Tumors,Phase 3,10/26/22,"Phase 1/2 update reported that treatment was well-tolerated, with 2 confirmed partial responses observed and 4 additional patients had >20% tumor shrinkage, noted October 26, 2022.",2 +NVS,Asthma,Phase 3,10/22/19,"Phase 3 data did not meet primary endpoint - noted October 22, 2019.",0 +ALPN,Advanced Malignancies,Phase 1,4/12/22,"Phase 1 dose escalation results across a range of dose regimens, tumor volume reduction was observed in 23% of evaluable participants despite heavily pretreated.",2 +ADMP,Emergency treatment of anaphylaxis,Approved,6/15/17,"CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.",2 +FUSN,Solid tumors,Phase 1,6/26/23,"Phase 1 pre-administration data reported a favorable gain in tumor lesion uptake versus normal tissue, noted June 14, 2022.",2 +RHHBY,Pemphigus vulgaris,Approved,6/7/18,"Approval announced June 7, 2018.",2 +GNPX,Non-small cell lung cancer (NSCLC),Phase 1,6/3/23,"Phase 1 data shared at ASCO reported that treatment was well tolerated, and there were no dose limiting toxicities, noted June 3, 2023.",2 +ASMB,Hepatitis B virus (HBV),Phase 2,11/1/22,"Phase 2 preliminary data from 65 patients randomized to receive AB-729+VBR+NA (n=32), AB-729+NA (n=17) or VBR+NA (n=16) for 48 weeks showed that adding VBR to AB-729+NA does not result in greater on-treatment improvements in markers of HBV infection as compared to AB-729+NA alone, noted November 1, 2022.",2 +BHVN,Spinocerebellar Ataxia (SCA),Phase 3,7/27/23,"The FDA informed Biohaven that it would not review the recently submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review. The communication from the FDA indicated that the Company may request a Type A meeting within 30 days, noted July 27, 2023.",2 +GRTS,1L Microsatellite-Stable Colorectal Cancer (MSS-CRC),Phase 1/2,1/13/22,"Phase 1/2 data demonstrated that patients who experienced a molecular response, continue to have an OS advantage compared to those patients who did not have a molecular response. All patients alive at the time of the ESMO 2021 data presentation remain alive after an additional 22 weeks of follow-up, noted January 13, 2021.",2 +GKOS,Glaucoma,Phase 3,9/7/22,"Phase 3 trials met primary endpoint, noted September 7, 2022.",1 +LLY,Severe hypoglycemia in people with diabetes,Approved,7/24/19,"FDA Approval announced July 24, 2019.",2 +BIIB,Chronic Kidney Disease,Phase 2,5/10/23,"Program discontinued, noted May 10, 2023.",0 +SNY,Hematological malignancies,Phase 1/2,10/16/23,"Phase 1/2 data from ESMO abstract reported that 3/8 patients achieved complete remission (CR), noted October 16, 2023.",2 +ATOS,Breast cancer,Phase 2,6/9/21,"Phase 2 final data presented June 9, 2021. Primary endpoint met.",2 +LCTX,Dry age-related macular degeneration (AMD),Phase 1/2,5/2/22,"Phase 1/2a full results presented at the Association for Research in Vision and Ophthalmology on May 2, 2022. All 24 treated patients reported at least one adverse event (AE) and at least one ocular AE. The majority of AEs reported with OpRegen were mild (Cohort 1-3, 87%; Cohort 4, 93%), and the immunosuppressive regimen was well tolerated. Preliminary evidence of improvement in visual function was observed in patients with GA and impaired vision at baseline (Cohort 4 [n=12]) Patients in Cohort 4 had an average 7.6 letter gain in visual acuity at 12 months in the study eye Three patients in Cohort 4 (25%) had a 15 letter or greater gain in visual acuity at 12 months in the study eye.",2 +TAK,Acute Graft-Versus-Host Disease (aGvHD) in patients allo-HSCT,Phase 3,2/18/23,"Phase 3 study met primary endpoint in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo, noted February 18, 2023.",1 +ATNXQ,Actinic keratosis,Approved,12/15/20,"FDA approval announced December 15, 2020.",2 +NBRV,Complicated urinary tract infections (cUTI),CRL,6/19/20,"CRL issued April 30, 2019. Further CRL received June 19, 2020.",1 +AKTX,Paroxysmal nocturnal hemoglobinuria (PNH),Phase 2/3,12/11/20,"Additional data from Phase 2 and 3 trials released December 11, 2020 - reduced transfusion dependence by 79% in the 14 formerly transfusion dependent patients.",2 +ISEE,Geographic atrophy,Phase 3,3/1/23,"Additional Phase 3 data reported that post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months, noted March 1, 2023.",2 +RDHL,IBS-D,Phase 2,10/3/17,"Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05.",2 +PFE,Squamous cell carcinoma of the head and neck (SCCHN),Phase 2,4/17/23,"Phase 2 interim results presented at AACR reported a confirmed ORR of 40%, with one complete response and 5 partial responses, noted April 17, 2023.",2 NVS,Acute postoperative pain,Approved,4/30/15,"Approved April 30, 2015.",2 -LPCN,Men with low testosterone (Low T),Approved,12/8/20,"FDA tentative approval announced December 8, 2020.",2 -NVO,Growth Hormone Deficiency (GHD),Approved,4/28/23,"Approved April 28, 2023.",2 -PLX,Fabry disease,Phase 3,5/31/22,"Phase 3 data reported that most treatment emergent adverse events were mild to moderate, noted May 31, 2022.",2 -AZN,HPV-associated squamous cell carcinoma of the head & neck (SCCHN),Phase 1,11/10/17,"Presentation at SITC Meeting - November 10, 2017.",1 -MRK,Endometrial carcinoma,Phase 3,3/23/23,"Additional Phase 3 data reported that KEYTRUDA plus chemotherapy reduced risk of disease progression or death by 46% in patients whose cancer was mismatch repair proficient (pMMR) and by 70% in patients whose cancer was mismatch repair deficient (dMMR), compared to chemotherapy alone, noted March 23, 2023.",2 -ETON,Pediatric adrenal insufficiency (AI),Approved,9/29/20,"FDA approval announced September 29, 2020.",2 -ADMA,Primary humoral immunodeficiency,Approved,12/13/22,FDA supplemental approval for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life.,2 -GILD,Cutaneous lupus erythematosus (CLE),Phase 2,10/24/19,Phase 2 trial did not meet primary endpoint.,0 -AZN,Anaemia in Chronic Kidney Disease,CRL,8/11/21,"CRL announced August 11, 2021.",1 -OTLK,Wet age-related macular degeneration (wet AMD),Phase 3,10/12/21,"Phase 3 safety data showed no intraocular inflammation or vasculitis, and the frequency and incidence of adverse events and ocular adverse events were low. The most common adverse event in the study eye conjunctival hemorrhage related to injection procedure, not to ONS-5010, and there were no additional serious adverse events associated with these injections, noted October 12, 2021.",2 -TYRA,Achondroplasia,Phase 2,8/1/23,"FDA Orphan drug designation (ODD) granted on August 1, 2023.",1 -RGLS,Autosomal dominant polycystic kidney disease (ADPKD),Phase 1b,10/12/21,"Termination of development in order to prioritize RGLS8429, noted October 12, 2021.",0 -EPZM,Epithelioid Sarcoma,Approved,1/23/20,"FDA approval announced January 23, 2020.",2 -OPTN,Nasal polyps,Approved,9/17/17,"Approval announced September 18, 2017 (prior to IPO).",2 -VSTM,KRAS mutant advanced solid tumors,Phase 1/2,9/28/23,"Phase 1/2 data reported an overall response rate (ORR) of 42% (11 of 26) in evaluable patients with low grade serous ovarian cancer (LGSOC), noted September 28, 2023.",2 -MRTX,MTAP-deleted cancers,Phase 1,8/8/23,"Phase 1 data reported a safety profile and early signs of clinical activity, noted August 8, 2023.",1 -AMGN,Thyroid Eye Disease (TED) - chronic,Phase 3,4/10/23,"Phase 4 topline data reported that treatment achieved a statistically significant reduction in proptosis from baseline compared to those receiving placebo, noted April 10, 2023.",2 -VNDA,Maintenance treatment of schizophrenia in adults,Approved,5/26/16,"Approved May 26, 2016.",2 -ONCT,Relapsed or refractory Ewing sarcoma,Phase 1/2,11/15/21,"Phase 1/2 interim data showed that the drug remains generally well tolerated. 2 CR in heavily pretreated patients. As of the October 1, 2021 data cutoff date, the most common drug-related adverse events included myelosuppression, fatigue, alopecia, nausea, pyrexia, and decreased appetite. No unexpected off-target toxicities have been observed, noted November 15, 2021.",1 -ELTX,Acute kidney injury (AKI) / Delayed Graft Function,Phase 3,10/26/21,"Phase 3 trial did not met the primary endpoint, noted October 26, 2021.",0 -ANVS,Alzheimer’s disease (AD),Phase 2/3,10/30/23,"Phase 2/3 trial DSMB feedback resulted in no drug-related SAEs, each AE < 5% and a very low dropout rate of 4.7%, noted October 30, 2023.",1 -AVDL,Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy,Approved,5/1/23,"Final approval granted by FDA on May 1, 2023.",2 -ARVN,Breast cancer,Phase 2,11/22/22,"Phase 2 data continued to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer, Median PFS of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant tumors support the initiation of two Phase 3 registrational trials, noted November 22, 2022. Phase 3 monotherapy trial enrollment to be completed by 2H 2024.",2 -ABBV,Relapsed or refractory multiple myeloma,Phase 3,9/29/23,"Phase 3 data reported that it showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone; however, the results did not reach statistical significance, noted September 29, 2023.",2 -GRTS,COVID-19 vaccine,Phase 1,10/11/23,"Phase 1 data reported that all doses were well tolerated in both HIV-negative participants and PLWH irrespective of SARS-CoV-2 serostatus at baseline, noted October 11, 2023.",2 -PFE,Non-small cell lung cancer (NSCLC),Phase 3,9/28/18,"FDA Approval announced September 27, 2018.",2 -AKBA,Anemia due to chronic kidney disease (CKD),NDA Filing,8/24/23,"NDA to be resubmitted, noted August 25, 2023. Upon acceptance of the NDA, Akebia expects the FDA to set a PDUFA date of six months from the date of submission.",1 -LQDA,Interstitial lung disease (PH-ILD),PDUFA,9/25/23,"FDA confirmed resubmission as Class II, PDUFA date assigned on January 24, 2024. Additionally, the FDA may not grant final approval of the PH-ILD indication until after the new clinical investigation exclusivity granted to Tyvaso expires on March 31, 2024, noted September 25, 2023.",2 -JNJ,Crohn's disease,Phase 3,10/16/23,"Phase 3 data reported that in the combination 54% of patients reached a clinical remission, noted October 16, 2023.",2 -AIM,Metastatic triple-negative breast cancer,Phase 1/2,4/11/22,"Phase 1 data presented at AACR reported that trial met primary endpoint, noted April 11, 2022.",2 -GSK,HIV,Approved,2/1/22,"Approved February 1, 2022.",2 -TVTX,Focal segmental glomerulosclerosis (FSGS),Phase 3,11/3/23,"Phase 3 presentations at ASN showed that sparsentan delivered a clinically meaningful benefit at 108 weeks with significant proteinuria reduction, higher rates of partial and complete remission, and lower rates of end-stage kidney disease, noted November 3, 2023.",2 -CRNX,Congenital hyperinsulinism (HI),Phase 1,9/15/21,"Phase 1 preliminary data demonstrated dose-dependent reductions in glucose-stimulated and sulfonylurea-induced Insulin secretion September 15, 2021.",2 -TOVX,Allogeneic hematopoietic cell transplantation (HCT) for the prevention of acute graft-versus-host-disease (aGVHD),Phase 1/2,2/16/23,"Phase 1b/2a data reported that no AEs or SAEs were determined to be related to study drug treatment by the investigators, noted February 16, 2023.",2 -DERM,Papulopustular rosacea,Phase 3,7/11/23,Phase 3 topline data achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues. NDA filing due in 2H 2023.,2 -HEPA,NASH and Liver Cancer,Phase 2a,1/8/22,"Phase 2a data reported that treatment was well-tolorated with ALT decreased in 50%, 67%, and 87% of the subjects in the placebo, 75 mg, and 225 mg cohorts, respectively, noted January 8, 2022.",2 -ETON,Injectable hospital product,Approved,6/15/21,"FDA approval announced June 15, 2021.",2 -MRK,Type 2 diabetes,Approved,12/20/17,"Approval announced December 20, 2017.",2 -MRNS,Refractory status epilepticus (RSE),Phase 2,9/26/19,"Phase 2 data met primary endpoint - September 26, 2019.",2 -GLYC,Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer,Phase 1/2,12/12/17,Phase 3 trial to be initiated mid-2018. Phase 1/2 data released at ASH 2017 showed clinical remission (CR+CRi) was 43%. Median overall survival was 9.4 months.,1 -ARQT,Seborrheic dermatitis,Phase 3,9/9/22,"Additional Phase 3 data presented at EADV reported that more than 60% of patients treated with roflumilast foam achieved an itch response at Week 8, noted September 9, 2022.",2 -MRK,Head and neck squamous cell carcinoma (HNSCC),Approved,6/11/19,"FDA Approval announced June 11, 2019.",2 -ADTX,Covid-19,Phase 3,11/12/21,"Phase 3 top-line data reported that the trial did not meet its primary endpoint, noted November 12, 2021.",0 -BPMC,PDGFRA exon 18 mutant Gastrointestinal stromal tumors (GIST),Approved,1/9/20,"FDA Approval announced January 9, 2020.",2 -TPTX,"Tumors harboring ALK, ROS1, or NTRK1-3 alterations",Phase 1/2,10/23/21,"Phase 1/2 early clinical data demonstrated confirmed responses in (3/4) TKI-naïve patients, noted October 23, 2021.",2 -AMGN,Sjögren’s syndrome,Phase 2,5/31/23,"Additional Phase 2 data reported that all ESSDAI responder analyses (pre-specified and post-hoc) favored dazodalibep over placebo, with greater numerical differences for the highest levels of response and patients treated with dazodalibep experienced numerically greater improvements in ESSPRI score and fatigue compared to those who received placebo at Day 169, noted May 31, 2023.",2 -SGEN,Cervical Cancer,Approved,9/20/21,"Approved September 20, 2021.",2 -IRWD,Gastroesophageal reflux disease (GERD),Phase 3,9/29/20,"Phase 3 trial did not meet primary endpoint - September 29, 2020.",0 -GLPG,Ankylosing spondylitis,Phase 2,9/5/18,"Phase 2 data released September 6, 2018. Primary endpoint met.",2 -ELEV,Solid tumors,Phase 1,6/3/23,"Phase 1 data presented at ASCO reported a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile, noted June 3, 2023.",2 -ARDX,Serum phosphorus - chronic kidney disease (CKD) on dialysis,Approved,10/17/23,"Approved October 17, 2023.",2 -LLY,Psoriatic Arthritis,Phase 3,12/17/18,Phase 3 trial met primary and key secondary endpoints.,2 -MNMD,Major Depressive Disorder (MDD),Phase 2,4/14/23,"Phase 2 topline data reported that trial met primary endpoint, noted April 14, 2023.",1 -ELOX,Alport syndrome,Phase 2,9/18/23,"Phase 2 additional independent confirmation reported that all three patients treated with ELX-02 showed a visual improvement in podocyte foot process effacement post-treatment in kidney biopsies demonstrating the disease modifying effect of ELX-02, noted September 18, 2023.",2 -MRTX,Colorectal Cancer,Phase 1/2,10/25/20,Phase 1/2 updated data noted (23/51) 45% ORR in NSCLC patients.,1 -NVCR,Recurrent glioblastoma,Phase 2,12/12/22,"Phase 2 trial data reported that median progression-free survival was 4.5 months compared to 2.2 months in the historical control, noted December 12, 2022.",1 -MNKKQ,Pain,CRL,12/12/18,"CRL issued December 12, 2018.",1 -VIGL,Healthy volunteers,Phase 1,10/17/23,"Phase 1 trial dosing initiated, noted October 17, 2023.",1 -OVID,Fragile X syndrome,Phase 2,4/19/21,"Development to be discontinued - April 19, 2021.",0 -JNJ,Treatment resistant depression,Approved,3/5/19,"FDA approval announced March 5, 2019.",2 +VRNA,COVID-19,Phase 2,4/23/21,"Phase 2 top-line data released April 23, 2021 - safe and well tolerated. One patient death was reported in the ensifentrine treatment group.",2 +VTVT,Type 2 Diabetes,Phase 2,12/14/16,"Phase 2 primary endpoint met - December 14, 2016.",2 +RCKT,Arrhythmogenic Cardiomyopathy,Phase 1,6/8/23,https://www.biopharmcatalyst.com/company/RCKT/news/140814,1 +ALT,Non-alcoholic fatty liver disease (NAFLD),Phase 2b,8/1/23,"Phase 2b IMPACT trial enrollment initiated, noted August 1, 2023.",1 +SESN,Non-muscle invasive bladder cancer (NMIBC),CRL,8/13/21,"CRL announced August 13, 2021.",1 +ANIP,Mycobacterium avium complex,Approved,12/21/21,"Approved December 21, 2021.",2 +ANAB,Palmo-plantar pustular psoriasis,Phase 2,3/8/21,"Phase 2 trial did not meet primary endpoint - March 8, 2021.",0 +ZYME,Solid Tumors,Phase 1,4/18/23,"Additional data reported that anti-tumor activity was observed in breast cancer and gastric cancer PDXs representing a range of HER2 expression, noted April 18, 2023.",2 +BGNE,Ovarian Cancers or Triple-Negative Breast Cancer,Phase 1/2,9/17/20,"Phase 1/2 data to be presented at ESMO September 2020. ORR 64.6% and 31.6% in cohorts 1 and 2, respectively.",1 +ALDX,Psoriasis / atopic asthma / COVID-19,Phase 2,3/29/22,"Phase 2 top-line data reported statistically significant improvements in all three indications with no serious adverse events, noted March 29, 2022.",2 +ICPT,NASH patients with compensated cirrhosis,Phase 3,8/2/23,"NASH Programs discontinued, noted August 2, 2023.",0 +TBPH,Ulcerative Colitis,Phase 2b,8/23/21,"Phase 2b data did not meet primary endpoint - August 23, 2021.",0 +IXHL,Anxiety,Phase 2,3/15/23,"Phase 2 data reported that the company found that there is a high probability that the total study will show a statistically significant benefit for the psilocybin treatment arm over the placebo treatment arm. This projection is made by assuming the effect size observed in the interim analysis for 29 participants is representative of the effect size through the remaining 43 participants, noted March 15, 2023.",2 PFE,Herceptin biosimilar,Approved,3/15/19,"FDA Approval March 11, 2019.",2 -JNJ,Multiple Myeloma,Approved,8/20/20,"FDA approval announced August 20, 2020.",2 -ABBV,Chronic Lymphocytic Leukemia,Approved,5/15/19,"FDA approval announced May 15, 2019.",2 -HALO,Testosterone deficiency,Approved,10/1/18,"FDA Approval announced October 1, 2018.",2 -LBPH,Developmental and epileptic encephalopathies (DEEs),Phase 1,12/5/22,"Phase 1 initial data reported favorable safety and tolerability results were observed in this study, with adverse events (AEs) generally consistent with previous clinical studies, noted December 5, 2022.",2 -AMGN,Biosimilar candidate to Avastin (bevacizumab),Approved,9/14/17,"Approved September 14, 2017.",2 -AMGN,Rheumatoid arthritis (RA),Approved,6/6/22,"Approved June 6, 2022.",2 -PFE,Acute treatment of migraine,Approved,2/27/20,"FDA Approval announced February 27, 2020.",2 -ASRT,Adrenocortical insufficiency screening,CRL,10/21/19,"CRL announced October 21, 2019.",1 -BMEA,Acute myeloid leukemia (AML) / acute lymphocytic leukemia (ALL) / Diffuse large B-cell lymphoma (DLBCL) / Multiple myeloma (MM),Phase 1,7/24/23,"Phase 1 clinical update of AML cohort revealed 2 complete responses (CRs) out of 5 relapsed/refractory AML patients carrying menin-dependent mutations treated at Dose Level 4, noted July 24, 2023.",2 -BMY,Kaposi’s sarcoma,Approved,5/15/20,"FDA Approval announced May 15, 2020.",2 -RYZB,Gastroenteropancreatic neuroendocrine tumors,Phase 1b,10/22/23,"Phase 1b data presented at ESMO reported that the confirmed ORR was 29.4%, with all five patients having a confirmed PR, noted October 22, 2023.",2 -AURA,Indeterminate lesions (ILs) and choroidal melanoma (CM),Phase 1/2,6/22/22,"Phase 1b/2 reported results from retrospective matched case control study, treatment achieved statistically significant vision preservation compared current standard of care, noted June 22, 2022.",2 -INZY,ABCC6 deficiency,Phase 1/2,10/13/23,"Phase 1/2 interim clinical data presented at ASBMR reported that treatment was generally well-tolerated on October 13, 2023.",2 -PRAX,Epilepsy,Phase 1,8/7/23,"Phase 1 study demonstrated pharmacodynamic activity across all dose levels for study subjects who received PRAX-628 at first administration as compared with subjects who received a placebo, noted August 7, 2023. Based on these studies and the preclinical results, Praxis intends to advance PRAX-628 into a Phase 2 study in focal epilepsy in the 1H 2024.",2 -MDWD,Severe burns - pediatric,Phase 3,7/20/21,"Phase 3 top-line data met primary endpoints - July 20, 2021.",2 -INCY,Steroid-refractory chronic GVHD (Graft versus host disease),Approved,9/22/21,"Approved September 22, 2021.",2 -SABS,COVID-19,Phase 3,4/26/23,"Phase 3 trial demonstrated benefit in sustained symptom resolution in study participants with COVID-19 caused by Omicron as compared to participants who received a monoclonal antibody combination, REGEN-COV. Specifically, 66% of participants treated with SAB-185 reached full symptom resolution for at least 4 consecutive days by Day 28, while only 50% of participants on REGEN-COV met this endpoint, and the median time to symptom resolution for at least 4 consecutive days was 7 days shorter for SAB-185, noted April 26, 2023.",2 -HALO,Amyloidosis,Approved,1/15/21,"FDA approval announced January 15, 2021.",2 -KYMR,"AML, Lymphomas, and Uveal melanoma",Phase 1,6/22/23,"FDA granted orphan drug designation on June 22, 2023.",1 -NVCR,Glioblastoma (GBM),Phase 2,3/24/22,"Phase 2 updated results reported a median progression-free survival was 12.1 months with median overall survival of 25.2 months, noted March 24, 2022.",1 -BBIO,"Venous, Lymphatic, and Venolymphatic Malformations",Phase 1/2,6/10/22,"Phase 1/2 preliminary results noted that treatment was generally well-tolerated with local self-limited rash was the only adverse experience reported, noted June 10, 2022.",2 +BMY,Myelofibrosis,Phase 1/2,12/12/22,"Phase 1/2 results presented at ASH reported that most TRAEs were grade 1/2 in severity, while grade 3 TRAEs were successfully managed with dose delays or modifications without leading to treatment discontinuation, noted December 12, 2022.",2 +ALXO,Head and Neck Squamous Cell Carcinoma,Phase 2,11/9/21,"Phase 2 clinical data showed that patients with ≥2L who have not received a prior checkpoint inhibitor (""CPI"") (n=10), long-term follow-up data shows that dosing demonstrates a 12-month OS rate of 80% with a mOS of 24.5 months, which compares favorably with standard pembrolizumab therapy in patients with 2L CPI, noted November 9, 2021.",2 +CRDF,KRAS-Mutated Colorectal Cancer,Phase 1/2,9/10/22,"Phase 1b/2 data presented at ESMO showed durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, noted September 10, 2022.",2 +CHRS,Esophageal Squamous Cell Carcinoma,Phase 3,9/17/21,"Phase 3 trial met the co-primary endpoints of progression free survival (PFS) and overall survival (OS) for patients treated with the toripalimab and chemotherapy combination compared to chemotherapy alone, September 17, 2021.",2 +REGN,Stage II to IV Cutaneous Squamous Cell Carcinoma (CSCC),Phase 2,10/16/23,"Phase 2 data from ESMO reported a median duration of follow-up was 18.7 months, and 1 of 10 pts with MPR experienced recurrence, noted October 16, 2023.",1 +CNTA,Kidney Disease,Phase 3,12/14/21,"Phase 3 data reported that ALT elevation peaked between 1.8x and 3.5x ULN and did not return to below ULN until 23 to 140 days after tolvaptan use was discontinued. Four patients were successfully titrated to a maintenance dose of lixivaptan of either 100 mg BID or 200 mg BID, noted December 14, 2021.",2 +BCYC,Solid tumors,Phase 1/2,2/14/23,"Phase 1/2 data reported a 50% ORR and 75% benefit rate, including one complete response, noted February 14, 2023.",1 +ITRM,Uncomplicated urinary tract infections (uUTI),CRL,7/26/21,"CRL announced July 26, 2021.",1 +ASRT,Postherpetic neuralgia - shingles,Approved,1/28/11,"Approved January 28, 2011.",2 +AZN,Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC),Approved,3/31/17,"Approval announced March 31, 2017.",2 +MOR,Myelofibrosis,Phase 2,6/10/22,"Phase 2 efficacy and safety data reported that over two-thirds of JAK inhibitor-naïve patients treated with the combination achieved at least a 35% reduction in spleen volume (SVR35) from baseline at week 24. Notably, 80% of patients achieved SVR35 at any time on study, noted June 10, 2022.",2 +PCSA,Gastroparesis,Phase 2a,5/6/23,"Phase 2a data reported at DDW noted that treatment improved both gastroparesis symptom scores and gastric emptying rate, noted May 6, 2023.",2 +GLTO,Liver cirrhosis,Phase 1/2,11/8/22,"Phase 1b/2a top-line data reported that data showed statistically significant reductions in the liver enzymes ALT, AST and GGT, with encouraging reductions for ALP , after 12 weeks of treatment, noted November 8, 2022.",2 +ASND,Mantle cell lymphoma (MCL),Phase 1,6/17/23,"Phase 1 data presented at ICML showed that 86.5% of patients in the relapsed or refractory mantle cell lymphoma cohort achieved a response, with 74.3% achieving a complete response, noted June 17, 2023.",2